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“Ideas won't keep; something must be done about them.” 
           Alfred North Whitehead  (1861 – 1947) 
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ATR   attenuated total reflection 
aq   aqueous 
B  base 
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brsm   based on recovered starting  
                          material 
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calcd  calculated 
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d  day(s) 
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TLC   thin layer chromatography 
TosMIC tosylmethyl isocyanide 
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A. Introduction 
G-protein coupled receptor 
The G-protein coupled receptors (GPCSs) are trans-membrane proteins and constitute the 
largest and most diverse family of cell surface signal-transducing proteins in mammals. The 
analysis of the human genome revealed that about 2% of the genes encode for 
approximately 800 GPCRs.1-4 GPCRs respond to a wide range of stimuli and transmit signals 
to the interior of the cell. About one half of the identified GPCRs respond to external signals 
such as light, pheromones, tastes and odors and are referred to as chemosensory receptors 
(csGPCRs). The other half (endoGPCRs) is addressed by endogenous ligands including 
biogenic amines, peptides, glycoproteins, lipids, nucleotides, ions and proteases.1,5 
Endogenous ligands are known for more than 260 endoGPCRs. For the remaining about 140 
receptors, ligands have not been identified yet and are termed orphan receptors.2,6 The 
important role of GPCRs in drug discovery is demonstrated by the fact that more than 30% 
of all marketed drugs target a GPCR.7  
A common structural feature of all GPCRs is the existence of seven transmembrane ?-helices 
connected by three intracellular and three extracellular loops with an intracellular C- and an 
extracellular N-terminus. Moreover, GPCRs interact with heterotrimeric guanine nucleotide-
binding (G) proteins inside the cell.7  
Classically, GPCRs were classified into six groups from A to F according to structural 
differences and functional properties.8 More recently, the classification system was 
developed further based on sequence comparison and comprises five classes.9 These classes 
are termed: Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2 and Secretin (shortened to the 
acronym GRAFS). The very large Rhodopsin family, also referred to as class A of GPCRs, is 
subdivided into ?, ?, ?, ?.  
In 2000, the first crystal structure of bovine rhodopsin was solved.10 Since then, a number of 
other GPCR crystal structures, including activated and agonist-bound GPCRs, could be 
elucidated.11-13 As  a  result,  more  detailed  information  of  the  spatial  orientation  of  the  
protein domains was available which helped to further analyze the exact mechanisms of 
GPCR signal transduction.  
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GPCR activation model and ligand classification 
Among many other different models, the cubic ternary model is regarded as the most 
adequate description of the interactions of the three component system, comprising a GPCR 
(R), a G-protein (G) and an agonist (A) (Figure 1).14-18 It incorporates the two-state model of 
GPCR activation which proposes the ability of the receptor to adopt an inactive 
conformation (R) and an active conformation (R*). These two states are in equilibrium, 
whereby the inactive state is prevailing in absence of an agonist. Due to the sufficient low 
energy barrier, spontaneous receptor activation by R to R* isomerization, independent from 
agonist  binding  is  possible  and  is  referred  to  as  constitutive activity,  which  is  a  common  
property of wild-type GPCRs.19 G-proteins couple especially to GPCRs in the active state, 
which induces GDP/GTP exchange at G-proteins enabling signal transduction and 
amplification. 
Figure 1. Two-state cubic ternary complex model of GPCR activation.14-18 
R R*
AR AR*
AR*G
R*G
ARG
RG
signal
transduction
 
R = inactive state of the receptor, R* = active state of the receptor, G = G-protein, A = agonist. 
 
On the basis of this model, ligands can be classified into full agonists, partial agonist, neutral 
antagonists, partial inverse agonists and full inverse agonists (Figure 2).20 Full agonists have a 
higher affinity for the R* state and stabilize the active conformation. As a consequence, 
basal G-protein activity is further increased. Full inverse agonists, on the opposite, decrease 
the functional response by interacting with the inactive conformation of the receptor and 
stabilize  the  R  state.  Partial  agonists  and  partial  inverse  agonists  show  a  lower  ability  to  
stabilize the respective states. The effect on the functional response is smaller in comparison 
with the full agonists and full inverse agonists. Neutral antagonists have the same binding 
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affinities for both conformations and have no influence on the R/R* equilibrium but they 
inhibit the effects of both agonists and invers agonists.20 In addition, Na+ stabilizes the 
inactive state in several constitutively active GPCRs, similar to inverse agonists.21 Based on 
the concept of constitutive activity, ligands acting at GPCRs and classified previously as 
antagonists have to be redefined as either neutral antagonists or inverse agonists.22  
Figure 2. Ligand classification. 
A)      B) 
  
 
A) Ligand classification according to their capability of shifting the equilibrium to either side of both states; R = inactive 
state of the receptor, R* = active state of the receptor; reproduced accoding to Seifert et al.19 B) dose response curves of 
full agonist, partial agonist, neutral antagonist, partial inverse agonist and full inverse agonist.  
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G-protein mediated signal transduction 
The heterotrimeric G-protein consists of a G?-subunit and a G??-heterodimer and is divided 
into four families based on similarities of the G? amino acid sequence and connected 
signaling pathways: Gs,  Gi/o,  Gq/11,  G12/13.23 When  the  GPCR  in  the  R*  state  (agonist  free  or  
agonist occupied) binds to the G-protein, a conformational change triggers the release of 
GDP from the G? binding site (Figure 3).24 In addition, the agonist affinity of the receptor is 
increased. The formed ternary complex is composed of the agonist, the receptor and the 
nucleotide-free G-protein. Subsequently, GTP binds to the G?-subunit, leading to separation 
of the GPCR from the G-protein. Furthermore, the heterotrimer dissociates into G?-GTP and 
G?? which activate or inhibit effector proteins, resulting in various cellular responses. This is 
accompanied by a decrease of agonist affinity of the receptor. The G?-subunit catalyzes the 
cleavage of GTP into GDP and phosphate, followed by reassociation of G?-GDP and the G?? 
complex. A family of proteins called regulators of G-protein signaling (RGS) is able to 
modulate the GTPase activity independent from GPCRs.25 
Figure 3. The G-protein cycle. Reproduced according to Igel.26 
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The G?-protein interacts with effector proteins to continue the signaling cascade.27 The G?s-
subunits activate adenylate cyclases which generate cAMP from ATP. The increased 
intracellular  cAMP  level,  in  turn,  effects  a  stimulation  of  cAMP-dependent  protein  kinases  
and subsequently cAMP-responsive-element-binding protein (CREB) to modulate gene 
transcription. In contrast, G?i mainly  inhibits  the  adenylate  cyclases.  A  decreased  cAMP  
production from ATP results in a decreased activity of protein kinases. G?q/11 stimulates 
membrane-bond phospholipase C (PLC?) which then hydrolyses phosphoinositol 
biphosphate (PIP2) to generate the second messenger inositol triphosphate (IP3) and 
diacylglycerol (DAG). IP3 promotes the release of Ca2+ from the endoplasmatic reticulum into 
the cytosol by binding to the IP3 receptor (Ca2+-ion channel). This results in an increased 
intracellular calcium level. Further modulation of cell processes is mediated by the activation 
of  protein  kinase  C  (PKC)  by  DAG.  G?12/13 regulates intracellular proteins function such as 
actin cytoskeletal transformation through the use of guanine nucleotide exchange 
factors.28,29 Besides  the  G?-subunits  also  the  G??-heterodimer can actively interact and 
activate effector molecules.30  
Although GPCR interaction with G-proteins accounts for the largest proportion of signal 
transduction from the extracellular to the intracellular region, recent work has 
demonstrated that GPCRs participates in further protein-protein interactions, which induces 
intracellular responses, in conjunction with G-proteins or even G-protein independently.31 
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Histamine, histamine receptors and histamine receptor ligands 
Histamine (1) consists of two basic centers, a primary aliphatic amine and an imidazole ring. 
At physiological pH the amino group (pKa =  9.4)  is  protonated  to  give  a  monocation  
predominantly and the heterocycle (pKa = 5.8), having one N-proton, equilibrates between 
its two tautomers N?-H-histamine (1A) and N?-H-histamine (1B) (Figure 4).32,33 
Figure 4. Tautomeric forms of histamine (1) at physiological pH. 
H
N
N
NH3 N
N
H
NH3
N
N N
N
N N
N -H-histamine (1A) N -H-histamine (1B)  
 
Three years after the first-time synthesis of histamine by Windaus und Vogt in 1907,34 Sir 
Dale and Barger,35 and independently Kutscher,36 succeeded in the isolation from ergot and 
observed first physiological effects.37 
Histamine  is  a  biogenic  amine  which  is  formed  from  the  amino  acid  L-histidine by 
decarboxylation catalyzed by the enzyme histidine decarboxylase.38 It  is  mainly  located  in  
mast cells, basophils, blood platelets, enterochromaffin-like (ECL) cells of the stomach, 
endothelial cells and also in neurons.39,40 It mediates multiple physiological effects through 
the interaction with four histamine receptor (HR) subtypes, termed H1,  H2,  H3 and  H4, all 
belonging to rhodopsin-like family A of G-protein-coupled receptors (GPCRs).41  
 
Histamine H1 receptor and its ligands 
In the beginning of the last century it became apparent that histamine plays an active role in 
allergy and anaphylaxis.38 This led to intensive efforts to search for compounds which inhibit 
these reactions. Since then, a plethora of so-called antihistamines have been developed and 
became blockbuster drugs for decades for the treatment of allergic disorders. Meanwhile, it 
is known that these classical antihistamines are inverse agonists at the H1R.22  
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The  H1R is mainly located in smooth muscle cells, endothelial cells, adrenal medulla, 
lymphocytes, heart and in the CNS and regulates smooth muscle contraction, stimulation of 
NO formation, endothelial cell contraction, vascular permeability, stimulation of hormone 
release and negative inotropism.39,42 Predominantly, the receptor signals through the G?q/11-
subunits resulting in calcium-mobilizing and activation of PKC.39 In 1991, the bovine H1 cDNA 
and two years later the human hH1R was cloned. 43,44 
Figure 5. H1 receptor antagonists. 
 
 
The first synthesized histamine receptor antagonists were brought to the market in the 
1940s.38 Phenbenzamine (AnterganTM)  (2) and the further developed mepyramine 
(NeoanterganTM)  (3) were the basis of numerous H1R antagonists for the treatment of 
allergic diseases (Figure 5). However, these fist-generation antihistamines cause sedation.45 
The reason is their capability to cross easily the blood-brain barrier due to their hydrophobic 
properties.  This  side-effect  was  exploited  for  example  for  the  treatment  of  motion  
sickness.38 Second-generation H1R antagonists such as cetirizine (4, ZyrtecTM) and loratidine 
(5, ClaritinTM) are almost devoid of CNS penetration and are less sedative which made them 
one of the most prescribed drugs against allergy.46  
For pharmacological studies mepyramine (3) represents the most relevant reference H1R 
antagonist and radioligand ([3H]mepyramine) for labeling H1 receptors in a variety of 
tissues.47 
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Figure 6. H1 receptor agonists. 
 
 
By contrast, H1R agonists as drugs for therapeutic applications are of much less significance 
than the antagonist counterparts. Only betahistine (6, AequamenTM) is used for the 
treatment of Menière’s disease (Figure 6).48 Further compounds, like 2-methylhistamine (7), 
revealed some selective H1R agonistic properties over H2R and were used as pharmacological 
tools to analyze receptor functions in biological systems.49 Later, it turned out that these 
compounds also showed H4R agonistic activity.50 High potencies and good subtype selectivity 
were found for histaprodifen (8)51 and especially for suprahistaprodifen (9).52 
 
Histamine H2 receptor and its ligands 
Since not all effects caused by histamine were inhibited by the antihistamines, the existence 
of different histamine targets was taken into considerations.53 In  1966,  Ash  and  Schield  
introduced the term H1 receptor to distinguish it from non-H1 receptors.54  
High expression levels for the H2R are found in gastric parietal cells and a variety of other 
tissues  including  leucocytes,  heart,  airways,  smooth  muscles  and  brain.42 This receptor 
subtype plays a crucial physiological role in stimulating gastric acid secretion. Additionally, it 
is associated with positive chronotropic and inotropic effects on atrial and ventricular 
tissues, it effects relaxation of airway, uterine and vascular smooth muscles and it inhibits a 
variety of functions within the immune system.39,42 The  H2R predominantly couples to the 
G?s-protein effecting a stimulation of adenylate cyclase to produce cAMP from ATP. cAMP, in 
turn, activates cAMP-dependent protein kinases.39 The cDNA of the H2R was cloned for the 
first time in 1991.55 
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Figure 7. H2 receptor antagonists. 
 
 
In 1972, burimamide (24, Figure 9, page 12) was the first compound which was termed H2R 
antagonist by Black.56 However, due to its insufficient bioavailability it was not considered as 
a drug candidate. A successive development gave rise to cimetidine (10, TagametTM) which 
was the first H2R antagonist brought to the market and became the most prescribed drug for 
several years (Figure 7).57 Fewer side effects were observed for ranitidine (11, ZanticTM) and 
famotidine (12, PepdulTM) which additionally showed that the imidazole function is not 
essential and can be displaced by different aromatic rings.42,53 Nowadays proton pump 
inhibitors like omeprazole are superior in treatment of acid-related gastrointestinal 
disorders.58 As  pharmacological  tools  further  potent  and  selective  H2R antagonists are 
established, e.g. tiotidine (13) and iodoaminopotentidine (14).42 Moreover, [3H]tiotidine and 
[125I]iodoaminopotentidine are the most important H2 radioligands at the present time.59,60 
Most  of  H2R antagonists are rather polar compounds and do not cross the blood-brain 
barrier. To investigate H2 receptor function in the CNS, zolantidine (15) was specifically 
designed capable of penetrating the brain.61 
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Figure 8. H2 receptor agonists. 
 
 
Numerous H2R agonists have been identified but are not routinely used in therapy so far. 
The first described agonist that discriminated between the H2 and  H1 receptor was 
5-methylhistamine (16, former nomenclature: 4-methylhistamine) (Figure 8). Meanwhile it 
turned out that it acts as a high-affinity full H4R agonist as well.49,62 Dimaprit (17), a further 
amine-type agonist, which is almost as active as histamine (1), shows good selectivity over 
the H1R and acts as a H3R antagonist but was also identified as a moderate H4R agonist.61,62 
Amthamine (18), a thiazole analogue of histamine and a cyclic analogue of dimaprit (17), is a 
full histamine H2R agonist and exhibits a slightly higher potency than histamine at the 
isolated guinea pig right atrium.63 Moreover, amthamine (18) is devoid of histamine H1R, H3R 
and H4R stimulatory activities at relevant concentrations.62 Guanidine-containing H2R 
agonists reveal much higher potencies compared to amino-type compounds. Impromidine 
(19) was the first H2R agonist which is more potent than histamine and was investigated for 
the treatment of severe catecholamine-insensitive congestive heart failure.64,65 Arpromidine 
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(20) shows up 400 times the potency of histamine at the guinea pig right atrium and is of 
therapeutic value as positive inotropic vasodilators.66 The pharmacokinetic drawbacks of low 
bioavailability  and  poor  CNS  penetration  of  these  compounds  caused  by  the  strong  basic  
guanidine  group  were  overcome  by  the  introduction  of  a  less  basic  acylguanidine  moiety  
resulting in NG-acylated imidazolylpropylguanidines like UR-AK24 (21).67 Although these 
compounds are very potent H2R agonists they also show considerable activity at the other 
HR  subtypes  especially  at  the  H3R  and  H4R. Selectivity was improved by bioisosteric 
replacement of the imidazole ring by a 2-amino-4-methylthiazol-5-yl moiety according to 
amthamine (18)  to form NG-acylated aminothiazolylpropylguanidines like UR-PG276 (22) as 
valuable pharmacological tools.68 Very recently, novel bivalent H2R agonists, like compound 
23, were synthesized. The combination of two pharmacophoric hetarylpropylguanidine 
moieties with octanedioyl or decanedioyl spacers led to the most potent agonists at the 
guinea pig right atrium known so far, exceeding up to 4000 times the activity of histamine in 
increasing heart rate.69 
 
Histamine H3 receptor and its ligands 
In the 1970s, it became apparent that histamine can inhibit its own release in the brain.70 
However, potent H1 and H2 antagonists were not able to reverse this effect. Those findings 
led to the assumption of a further histamine receptor subtype.38 The  H3R was 
pharmacologically characterized in 1983 by Arrang et al.71 The  H3R is mainly located on 
neurons, predominantly in the CNS and to a lesser extent in the peripheral nervous system.72 
It acts as a presynaptic autoreceptor that inhibits the synthesis and release of histamine 
from  histaminergic  neurons  and  as  a  heteroreceptor  it  controls  the  release  of  other  
neurotransmitters, e.g. acetylcholine, dopamine, noradrenaline, and serotonin.73 It regulates 
sleep/wakefulness, feeding and memory processes.74 Therefore, the H3R is considered a 
potential target for therapeutic applications against obesity, and a variety of CNS disorders 
such as Alzheimer’s disease, attention-deficit/hyperactivity disorder (ADHD), migraine, 
narcolepsy, schizophrenia, epilepsy, and depression.38,72 The cDNA encoding the human H3R 
was cloned by Lovenberg in 1999.75 The overall similarity between the human H3 receptor 
and the H1 and H2 receptors  is  very  low.  The  resemblance  amounts  to  22%  and  21%,  
12  
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respectively. The H3 receptor couples to G?i/o resulting in the inhibition of adenylate cyclase. 
Therefore H3 receptor activation lowers cAMP levels and reduces downstream events.76 
Figure 9. Imidazole-containing and imidazole-free H3 receptor antagonists. 
 
 
Originally developed as a H2R antagonist, burimamide (24) revealed a 100-flold higher 
affinity at the H3R (Figure 9).77 In 1987, the potent and highly selective H3R inverse agonist 
thioperamide (25) was designed which became the most important reference compound for 
many years and was applied in numerous preclinical studies.72,78 The potent H3R antagonists 
clobenpropit (26) and iodophenpropit (27),  which  is  derived  from  the  agonist  imetit  (33) 
(Figure 10), illustrates a trend that potent antagonists can be obtained from related agonists 
by attaching lipophilic chains and increasing the distance of the basic moieties.79 Researches 
tried to optimize the special arrangement of the ligands at the receptor binding site by 
introducing rigid structural motifs limiting the conformational freedom. This was realized in 
cipralisant (28), the first H3R antagonists that reached clinical phase II trials for the treatment 
of ADHD.80,81 Many of the discovered antagonists lacked of sufficient penetration of the 
blood-brain barrier because of the polar and hydrogen-bonding properties of the imidazole 
ring. In addition, imidazole-containing ligands interact with cytochrome P450 which is an 
unwanted property of drugs.82 Recent efforts of the academic and pharmaceutical industry 
research to develop imidazole-free H3R antagonists resulted in the syntheses of several 
potent and selective ligands, e.g. FUB-649 (29)83 and ABT-239 (30).84 Further advantages of 
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non-imidazole  compounds  are  lower  species  variations  in  the  receptor  affinity  and  better  
receptor-subtype selectivity.38 
Figure 10. H3 receptor agonists. 
 
Histamine  binds  with  high  affinity  to  the  H3R. As a consequence, only small structural 
differences for H3R agonists in comparison to histamine are tolerated and imidazole seems 
to be an essential pharmacophore.72 Methylation of the basic amine group gave rise to 
N?-methylhistamine (31), a high affinity H3R agonist which is about three times more active 
than histamine (Figure 10).85 The chiral (R)-?-methylhistamine (32) is another methyl 
derivative of histamine which was frequently used in pharmacological studies.78 However, 
high basicity, hydrophilicity and low bioavailability limited its use under in vivo conditions.72 
Imetit (33), the isothiourea analogue of histamine showed high selectivity over the H1R and 
H2R.79 Further  decrease  of  side-chain  flexibility  by  incorporation  of  the  basic  amino  group  
into a piperidine ring gave rise to immepip (34) which is also a potent H3R agonist with good 
brain penetration properties.86 After  discovering  the  H4 receptor it became apparent that 
many compounds like N?-methylhistamine (31), (R)-?-methylhistamine (32), imetit (33) and 
immepip (34), which were classified as H3R agonists, also act at the H4 receptor to a certain 
extent.87 Based on these findings the potent H3R agonist methimepip (35)  could  be  
developed which showed 2000-fold selectivity over the H4R.88  
The most frequently used H3R radioligands are [3H]N?-methylhistamine, [3H]R??-methyl-
histamine and [125I]iodophenpropit.89 
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Histamine H4 receptor and its ligands 
The H4R is the most recently discovered member of the family of histamine receptors and 
was identi?ed in 2000 and 2001, when several research groups cloned the gene encoding 
the hH4R.41 The  H4R couples to pertussis toxin-sensitive Gi/o proteins and thereby inhibits 
forskolin-induced cAMP production.90 It  is  mainly  expressed  in  mast  cells,  eosinophils,  
leukocytes, monocytes, CD8+T cells, basophils, dendritic cells, in the spleen and bone 
marrow and seems to play a crucial role in in?ammatory and immunological processes 
including asthma, atopic dermatitis, allergic rhinitis, pruritus, colitis, pain, cancer and 
autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.81 The rather high 
degree of homology with the hH3R (36% at the protein level, 58% within the transmembrane 
domains)  explains  the  high  af?nity  of  many  H3R ligands, in particular imidazole-containing 
compounds, for the H4R.91 In  contrast,  only  26%  and  27%  homology  within  the  
transmembrane regions was found with the H1R and H2R, respectively.92 
Figure 11. H4 receptor antagonists. 
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Thioperamide (25), for instance, previously considered as a selective H3R inverse agonist, 
turned out to act  at  the H4R as an inverse agonist as well with comparable affinities (pKi = 
6.9).62 Shortly afterwards, high-throughput screening by Johnson & Johnson led to the 
identification of the highly potent (pKi = 8.4) non-imidazole indole carboxamide JNJ-7777120 
(36)  which  behaves  as  a  neutral  antagonist  with  >1000-fold  selectivity  over  the  other  
receptor subtypes (Figure 11).93 It became the reference antagonist of choice to investigate 
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H4R function but short in vivo half-life makes it impractical for prolonged studies of chronic 
diseases.94 Further potent and selective indole and also benzimidazole derivatives such as 
VUF-6002 (37) (pKi = 7.6) and related compounds were synthesized.40 Quinoxaline turned 
out  to  be  a  further  promising  lead  structure  for  the  synthesis  of  potent  H4R antagonists. 
VUF-10214 (38) was identified as a potent H4R ligand with nanomolar affinities (pKi = 8.3) 
and showed significant anti-inflammatory properties in rat in vivo models.95 Compounds 
containing a 2-aminopyrimidine scaffold like compound 39 were found to possess potent 
antagonistic activity (pKb = 8.53) with good CNS penetration and were shown to be effective 
in inflammation and pain models.96 Some limitation of theses ligands like rapid 
metabolisation in vivo and rapid demethylation to metabolites with significant H4R activity 
could be improved by structural modifications. Additionally, selectivity over off-target sites 
was increased by annulation of the pyrimidine ring to furnish rotationally constrained 
antagonists like A-943931 (40) with high potencies and selectivity (> 190-fold) for the H4R 
across multiple species (pKb >  8).97 In this series of constrained 2-aminopyrmidines very 
recently JNJ-40279486 (41) was designed and also found to be a potent (pKi =  8.0)  and  
selective hH4R antagonist demonstrating acceptable pharmacokinetic pro?le in a mouse 
model of in?ammation.98 Meanwhile several H4R antagonists are announced as candidates 
for clinical trials. The first compound which finally entered clinical studies for the treatment 
of allergic respiratory diseases (completing the phase I ascending dose trial) and has been 
found to be safe and well tolerated is UR-63325 developed at Palau Pharma (undisclosed 
structure).99 
Several potent H1R, H2R and H3R ligands turned out to act as H4R agonists as well. Some even 
proved to be H4R selective. The first reported H4R agonist with moderate affinity and about 
40-fold selectivity over the H3R  was  OUP-16  (42) (Figure 12).100 Originally  developed  as  a  
selective H2R agonist, 5-methylhistamine (16) proved to be a potent human H4R full agonist 
with > 100-fold selectivity over the other hHR subtypes and has become the most frequently 
used hH4R agonist due to its easy accessibility.49,62,87 The antipsychotic drug clozapine turned 
out to moderately activate the H4R. Lead optimization by Smits et al. resulted in VUF-6884 
(43), a high affinity hH4R ligand (pKi = 7.6) with full agonistic activity (pEC50 = 7.7). It binds 
poorly  to the hH2R and hH3R (pKi > 5) but shows high affinity for the hH1R (pKi =  8.1)  with 
inverse agonistic activity.101 Based on the H2R agonist, H3 antagonist, and low affinity H4R  
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Figure 12. H4 receptor agonists. 
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partial agonist dimaprit (17) structure-activity relationship investigations revealed VUF-8430 
(44) as high affinity (pKi = 7.5) hH4R full agonist (pEC50 = 7.3) with 30-fold selectivity over the 
hH3R with negligible affinity for the hH1R and hH2R.102,103 Derived from the originally 
developed H2R agonistic NG-acylated imidazoylpropylguanidines, cyanoguanidino compound 
UR-PI376 (45) was designed and identified as a potent hH4R agonist (pEC50 = 7.5) devoid of 
any agonistic activity at the other three hHR subtypes which makes it superior to other 
selective hH4R agonists.104 It shows negligible hH1R and hH2R affinities and 25-fold selectivity 
over the hH3R. A drawback, however, are species-dependent discrepancies.87 In the course 
of the development of new H4R antagonists on the basis of 2-arylbenzimidazoles by Johnson 
& Johnson a number of compounds were synthesized revealing full agonistic activity at the 
hH4R.105 These include 46 which is one of the most potent hH4R agonist known so far having 
sub-nanomolar affinity. In addition, it shows negligible affinity at the hH1R (pKi > 5), > 600-
fold selectivity over the hH2R (pKi = 6.9) and > 1700-fold selectivity over the hH3R (pKi = 6.4).  
[125I]Iodophenpropit (27), tritiated histamine (1), JNJ-7777120 (36), and the recently 
developed acylguanidine UR-PI294 (47) were used as radioligands in binding studies.81 
Despite  the  lack  of  selectivity  of  UR-PI294  (47) and other ligands to the hH3R they can be 
used for pharmacological experiments on the H4R in native or recombinant systems devoid 
of hH3Rs.  
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Stereochemical diversity-oriented conformational restricted ligands  
Frequently, endogenous ligands such as histamine (1) possess flexible structures owing to 
rotations around single bonds and can adopt a variety of conformations. At different 
receptor subtypes distinct conformations are preferred which have lower affinities at the 
respective other subtypes.106 A reasonable strategy to improve affinity  and selectivity  is  to 
create analogues with a conformational restricted linker which only allows a concrete spatial 
arrangement of the functional groups that are essential for receptor binding.107-109               
To acquire potent and selective histamine receptor ligands, the imidazole ring and the basic 
nitrogen must have a defined orientation that superimpose the bioactive conformation in 
which these pharmacophoric elements effectively interact with certain amino acid residues 
in the binding pocket of the receptor. Due to the difficulties with the structural analysis of 
membrane-bound proteins the bioactive conformation of the natural ligand is usually not 
known with precision. To investigate the bioactive conformation and to refine the models of 
interaction a stereochemical diversity-oriented conformational restriction strategy proved to 
be  a  valuable  method.  In  most  cases  restriction  of  the  flexible  linker  is  achieved  by  a  
displacement with rigid carbo- and heterocycles. 
 
Cyclopropane-based conformationally restricted HR ligands 
The above mentioned approach was successfully applied by Kazuta et al. to  identify  novel  
H3R agonists.110 From a series of cyclopropane-based conformationally restricted histamine 
analogues 48 with divers stereochemistry the “folded” cis-analogue AEIC revealed to be the 
most potent agonist at the hH3R (Ki = 1.3 nM, EC50 = 10 nM) which had virtually no effect on 
the H4R subtype (Figure 13). 
Figure 13. Cyclopropane-based conformationally restricted histamine analogues. 
 
AEIC: (1R,2S)-48, n = 2; 49: R = 4-chlorobenzyl, cyclohexylmethyl. 
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The same concept was followed by Watanabe et al. for  the  search  of  H3R and H4R 
antagonists.111 By attaching hydrophobic side-chains at the amino group of the 
cyclopropane-based conformationally restricted histamine 48,  both  selective  H3R  and  H4R 
antagonists  were  obtained  (Figure  13).  Among  them,  the  (1R,2S)-trans-isomer of 49 
(R = 4-chlorobenzyl, n = 1) was found to be a potent H4R  antagonist  (Ki = 118 nM) with 
> 8.5-fold selectivity over the H3R. 
 
Cyclohexane-based conformationally restricted HR ligands 
Based on the selective H4R agonist UR-PI376 (45), Geyer and Buschauer explored structural 
rigidified analogues having the flexible tetramethylene chain replaced by conformationally 
constrained spacers.112 While phenyl linker yielded only the very weakly active compounds 
50 and 51 at both hH3R and hH4R, less rigid 1,4-cyclohexylene linker exhibited cis- and trans-
configured molecules 52 revealing EC50 or KB values ? 110 nM at the hH3R and hH4R (Figure 
14). Cis-con?gurated diastereomers prefer the hH4R and are partial agonists, whereas trans-
isomers are antagonists at the hH4R. At the hH3R the trans-diastereomers are superior to the 
cis-isomers by a factor of 10. It was suggested that an appropriate balance between 
constraint and flexibility is important to further elucidate the requirements of high hH4R 
affinity and selectivity. 
Figure 14. Cyclohexane-based conformationally restricted HR ligands. 
 
R1 = -CH3, -cPr, -CH2CH(CH3)2, -(CH2)3-Ph, -(CH2)2-S-Ph; R
2 = -CH3, -(CH2)2-S-Ph. 
 
  
Introduction 
19 
 
Tetrahydrofuran-based conformationally restricted HR ligands 
In 2003, Hashimoto et al. synthesized a series of tetrahydrofuranylimidazoles and examined 
the binding affinity and functional activity for the human H3 and  H4 receptors by in vitro 
studies (Figure 15).100,113,114 In  general  the  amino  compounds  –  imifuramine  (53a)  and  its  
stereoisomers 53b, 53c, 53d – behaved as partial to full agonists at the hH3R and hH4R with 
selectivity  for  the  hH3R. When the amino group was replaced with a less basic 
cyanoguanidine  moiety  (42a, 42b, 42c, 42d) agonistic activity at the hH3R decreased. In 
contrast,  the  potencies  and  intrinsic  activities  increased  at  the  hH4R for most isomers. 
Especially imifuramine (53a) and its enantiomer 53b showed full agonistic activities (0.9 < ? 
<  1.0)  at  the  hH3R with EC50 values of 45 and 105 nM and had 45- and 300-fold higher 
potency than at the hH4R, respectively. The cyanoguanidine analogue of imifuramine, 
(2R,5R)-configured compound OUP-16 (42a), exhibited the highest agonistic activity with a 
EC50 value of 77 nM at the hH4R with 41-fold selectivity over the hH3R. 45-fold selectivity for 
the hH4R was observed for  (2R,5S)-isomer 42d.  Until  that  time,  42a and 42d were the first 
described selective H4R agonists. These findings imply the usefulness of stereoselective 
syntheses to develop selective HR ligands. (Ki, EC50 and ? values of all compounds: page 73) 
Figure 15. Tetrahydrofuran-based conformationally restricted H3R and H4R ligands.100 
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Aim of this work 
There is still a need for the development of selective ligands targeting histamine receptors, 
especially the H4R, in order to further elucidate its biological roles which would offer new 
opportunities for the therapy of several diseases. Based on the work of Hashimoto et al. this 
work aims at the enantioselective synthesis and pharmacological evaluation of potential 
histamine receptor ligands containing a modified tetrahydrofuran-spacer with a 
conformational restricted structure (Scheme 1).  
Scheme 1. Retrosynthesis of the target compounds. 
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For that reason, the core structure consists of a fused ring system and is formed by an 
asymmetric cyclopropanation reaction, established in our group, which gives rise to the 
bicyclic building block 59.115 The formation of the imidazole moiety represents a key step in 
the synthetic route and is realized by conversion of aldehyde 58 by  means  of  a  TosMIC  
strategy.116-119 Finally, the amino group of 55 and the cyanoguanidino group of 54 are 
introduced by further functional group interconversions including a Mitsunobu-type Gabriel 
reaction.120 In parallel, analogues 57 and 58 with an oxazole moiety as a potential bioisoster 
are synthesized and pharmacologically characterized. All target compounds are accessible as 
both enantiomers depending on the choice of the respective chiral ligand in the asymmetric 
cyclopropanation step. 
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B. Main Part 
Cyclopropanation 
Cyclopropane rings are encountered in a multitude of natural products and due to its 
chemical properties employed as versatile building blocks in synthetic applications.121,122 A 
well-documented method of the cyclopropanation arsenal is the transition metal-catalyzed 
decomposition of diazo alkanes 61 (Scheme 2).123 This includes diazo compounds bearing an 
electron-withdrawing group especially diazo esters which reacts with electron-rich alkenes 
60 catalyzed by metals such as Rh, Ru, Co and Cu. In this process, under release of nitrogen, 
a metal carbene complex is generated which undergoes a [2+1]-cycloaddition to an olefin 
(transition state 62). The formation of two C-C bonds creates up to three new stereogenic 
centers (compound 63). A controlled introduction of stereochemistry is achieved using chiral 
transition metal complexes (MLn*). A large number of ligands have been developed for that 
reason. The complex of copper(I) and a bidentate bis(oxazoline) ligand, disclosed by Evans 
and coworkers, has become a standard for asymmetric cyclopropanation reactions.124,125  
Scheme 2. Cyclopropanation by transition metal-catalyzed decomposition of diazo alkanes. 
 
 
Based  on  a  racemic  cyclopropanation  of  2-furoic  methyl  ester  (73) with ethyl diazoacetate 
(75) using Rh2(OAc)4 as a catalyst reported by Wenkert et al.126 Reiser et al. developed a 
copper(I)-catalyzed asymmetric cyclopropanation of the same furan 73. This was achieved by 
using ethyl diazoacetate (75) in the presence of (S,S)-isopropyl bis(oxazoline) (71) as a chiral 
ligand showing high enantio- and diastereoselectivity (Scheme 4, page 23).115  
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The bicyclic building block 59 or its enantiomer ent-59, which are used in the following for 
the preparation of the desired target molecules, were already successfully employed for 
total syntheses of several natural products such as paraconic acids 64 and 65127,128 or 
ArglabinTM (66) (Figure 16).129 Recently, (-)-Paeonilide (67) was synthesized starting from the 
3-substituted analogue of 59.130 
Figure 16. Natural products synthesized from cyclopropanation adducts by Reiser et al. 
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64a: R = n-C13H27: (-)-Roccellaric acid; 4b: R = n-C11H23: (+)-Nephrosteranic acid; 65a: R = n-C12H24CO2H: 
(-)-Protopraesorediosic acid; 65b: R = n-C13H27: (-)-Protolichesterinic acid; 65c:  R  =  n-C5H11: (-)-Methylenolactocin; 
66: ArglabinTM; 67: (-)-Paeonilide. 
  
The bis(oxazoline) ligand 71 for the cyclopropanation reaction was accessible via a two-step 
synthesis starting from 2,2-dimethylpropanedioyl dichloride (68) and L-valinol (69) forming 
the diamide intermediate 70 (Scheme 3). Subsequent cyclisation afforded ligand 71.131 Using 
D-valinol gave rise to the enantiomer ent-71. 
Scheme 3. Preparation of bis(oxazoline) ligand 71.131 
 
Reagents and conditions: a) L-valinol (2 equiv), NEt3 (5  equiv),  DCM,  0  °C  to  rt,  70  min,  84%;  b)  DMAP  (0.1  equiv),  
NEt3 (4 equiv), TsCl (2 equiv), DCM, rt, 27 h, 83%. 
 
The substrate for the cyclopropanation, 2-furoic methyl ester (73), was prepared from 
commercially available furan carboxylic acid 72 by a sulfuric acid catalyzed esterification in 
89% yield (Scheme 4). Ethyl diazoacetate (75) was obtained from glycine ethyl ester 
hydrochloride (74) via diazotization in 95% yield as a solution in DCM (9 - 12 wt%).132  
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The bicyclic building block 59 was obtained by the above mentioned copper(I)-catalyzed 
asymmetric cyclopropanation of 2-furoic methyl ester (73) using ethyl diazoacetate (75) in 
the presence of (S,S)-isopropyl bis(oxazoline) (71) (Scheme 4). The active copper(I) complex 
was generated in situ by reduction of copper(II) triflate with phenylhydrazine. The reaction 
was accomplished with high regio- and diastereoselectivity: preferentially, the less 
substituted and more electron-rich double bond was cyclopropanated and only the exo 
isomer with the ester functionality oriented on the convex face of the bicyclic framework 
was  observed.  The  enantiopurity  was  improved  from  85  -  90%  to  >99%  ee by  a  single  
recrystallization.  On a 50 g scale an isolated yield of  37% (brsm 62%) of  compound 59 was 
achieved. 
Scheme 4. Preparation of starting materials and cyclopropanation. 
 
Reagents and conditions: a) H2SO4 (cat.), MeOH, ?, 20 h, 89%; b) NaNO2 (1.3 equiv), H2SO4 (cat.), DCM/H2O, - 20 °C to 0 °C, 
95%; c)  i.  71 (1.0 mol%), Cu(OTf)2 (0.75 mol%),  PhNHNH2 (0.9 mol%), DCM, 0 °C, 7 d, 54%, 85-90% ee; ii. recrystallization 
(DCM, n-pentane), 37%, > 99% ee. 
 
The following mechanistic aspects deduced from Pfaltz133 and Andersson134 provide an 
explanation for the stereochemical results of the asymmetric cyclopropanation of 2-furoic 
methyl ester (73)  (Scheme  5).  First  the  bis(oxazoline)  copper(I)  complex  reacts  with  ethyl  
diazoacetate (75) to afford a metal carbene complex 76 under release of nitrogen. The ligand 
forms a plane which is perpendicular to the plane formed by the trigonal copper carbenoid. 
Due to the C2-symmetry of the ligand, two opposite quadrants are sterically blocked by the 
bulky isopropyl substituents. Therefore, trajectory A and C are unfavored. 2-Furoic methyl 
ester (73) attacks the carbenoid center with its less substituted and more electron-rich 
double bond. This causes a change of the hybridization of the carbenoid carbon to sp3 
arranging it in a tetrahedral geometry. In consequence, trajectory B is also not favored 
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because the approach of 2-furoic methyl ester (73) increases the repulsive steric interaction 
between the ester function at the former carbenoid center and the isopropyl group of the 
oxazoline ring. By contrast, the steric interaction between the ethyl ester group and the 
oxazoline  hydrogen  atom  of  the  ligand  is  much  smaller.  In  summary,  this  results  in  a  
preference for trajectory D. Moreover, the high enatioselectivity results also from the 
structural properties of the olefin: (1) the double bond approaches via trajectory D with the 
methyl ester group pointing away from the ligand framework, (2) the approach of the 
substrate to the reaction center via trajectory D is directed due to an attractive interaction 
of the endocyclic oxygen atom of 73 and the metal atom. 
Scheme 5. Mechanistic aspects of the asymmetric cyclopropanation reaction. 
 
 ?
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Route I - Introduction of an aldehyde functionality 
On  the  basis  of  the  bicyclic  building  block  59 the synthesis of the target compounds is 
divided into two parts: The functional group interconversion of the methyl ester group to 
the imidazole moiety and the transformation of the ethyl ester function to the amino and 
cyanoguanidino  group,  respectively.  A  key  step  in  the  synthesis  is  the  preparation  of  the  
imidazole moiety. The imidazole ring is incorporated in countless natural products and is 
part of many pharmaceutical drugs and compounds with industrial and technological 
importance.135-137 Therefore numerous methods for the construction of the imidazole ring 
were developed since its first synthesis from glyoxal and ammonia by Debus more than 150 
years ago.138,139 A convenient way for the de novo synthesis of 4(5)-monosubstituted and 
1,4- or 1,5-disubstituted imidazole compounds is the application of tosylmethyl isocyanide 
(TosMIC) chemistry which was initially described by van Leusen.116 Some related 
methodologies have been developed which all have an aldehyde as the starting material in 
common.117-119 Therefore, generation of an aldehyde function was the next task in the 
reaction route. 
Having the bicyclic building block 59 in hand a sequence of double bond hydrogenation, 
methyl ester saponification and carboxylic acid reduction was contemplated in order to 
realize a chemoselective reduction of the CO2Me group (Scheme 6).  
Scheme 6. Preparation of alcohol 79. 
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Reagents and conditions: a)  i)  Pd/C  (10%),  EA,  H2 (balloon), rt, 1.5 h, ii) recrystallization (DCM, n-pentane) 73%;                    
b) LiOH (1.2 equiv), THF/H2O, rt,  1 h,  92%; c)  LiOH (1.1 equiv),  THF/H2O, rt,  1 h,  94%; d)  Pd/C (10%),  EA,  H2 (balloon), rt, 
1.5 h, 70%; e) BH3•DMS (1.5 equiv), THF, 0 °C to rt, 4 h, 77%; f) LAH (0.6 equiv), THF, 45 min, 87% 79, 5% 80. 
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The double bond was hydrogenated according to Weisser et al. using palladium on charcoal 
in EA.140 The hydrogenation proceeded via syn-addition exclusively from the less hindered 
convex face of the bicyclic framework to form 78 as a single stereoisomer in 73% yield after 
recrystallization. The choice of mild conditions by employing a small stoichiometric excess of 
LiOH in aqueous THF effected selective saponification of the methyl ester group to yield 82 
in 92%.141 The reverse reaction order, first saponification to 81, then hydrogenation, 
afforded 82 in comparable yields as well but separation of unreacted 81 from 82 proved to 
be difficult.141  
Subsequently, the reducing agent borane dimethyl sulfide complex, which enables 
chemoselective reduction of carboxylic acids to alcohols without affecting ester functions, 
was successfully applied to obtain alcohol 79 in 77% yield.142  
It is assumed that the selectivity in the LiOH-mediated saponification reaction is also 
attributed to a chelation of the lithium ion by the methyl ester carbonyl oxygen atom and 
the endocyclic oxygen atom that activates the methyl ester group for nucleophilic attack. In 
consequence, it was expected that the strong reducing agent LAH behaves in a similar way 
so that the hydride ion reduces the methyl ester faster than the ethyl ester. Indeed, by an 
accurate addition of two reduction equivalents a selective reduction of compound 59 to 
alcohol 79 was accomplished in 87% yield. The instable dihydroxyl product 80 was obtained 
in 5% yield and characterized as its diprotected derivative 115 (page 36). 
To oxidize alcohol 79 to the corresponding aldehyde 83 two standard procedures were 
examined (Scheme 7). Swern oxidation, using oxalyl chloride, DMSO and NEt3 afforded 83 in 
65% yield.143 Oxidation mediated by Dess-Martin periodinane, which was prepared in two 
steps from 2-iodobenzoic acid,144 furnished 83 in 88% yield. In addition to the improved yield 
Dess-Martin oxidation exhibited a shorter reaction time and was more convenient to 
perform. 
Scheme 7. Preparation of aldehyde 83. 
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Reagents and conditions: a) (COCl)2 (1.5 equiv), DMSO (2.5 equiv), NEt3 (5 equiv), DCM, -78 °C, 1.5 h, 65%; b) Dess-Martin 
periodinane (1.05 equiv), DCM, rt, 1 h, 88%. 
  
Main Part 
27 
 
Route I - Introduction of the imidazole ring 
TosMIC (84), introduced by van Leusen, is a versatile synthon in organic chemistry.145 Among 
the synthetically useful applications are: the conversion of aldehydes and ketones to 
homologous nitriles146 and carboxylic acids147 and the synthesis of ketones,148??-diketones149 
and azoles150,151 such as oxazoles, pyrroles, 1,2,4-triazoles, thiazoles and imidazoles. TosMIC 
accommodates a reactive isocyanide carbon and a methylene group which is activated by a 
tosyl group (Scheme 8). Bases induce a [3+2] anionic cycloaddition of the C–N=C moiety with 
polarized double bonds to give five-membered heterocycles 85. 
Scheme 8. Cycloaddition reaction of TosMIC (84). 
 
The  first  reported  synthesis  of  imidazole  derivatives  using  TosMIC  proceeds  through  a  
cycloaddition with N-protected aldimines 88 derived from corresponding aldehydes 86 
(Scheme 9).116 The intermediate 4-tosyl-2-imidazoline 89 eliminates p-toluenesulfinic acid 
(TsH) resulting in the formation of 1,5-disubstituted imidazoles 90. Complete transformation 
in a  single operation is  effected by using K2CO3 as a base in a mixture of MeOH and DME. 
Alternatively, amine 87 can be applied which corresponds to the aldimine, to prevent amine 
exchange. 
Scheme 9. TosMIC-mediated method (A) for the preparation of imidazoles.116,119 
 
R1 = alkyl, alkenyl, aryl; R2 = alkyl, aryl, tosyl. 
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According  to  ten  Have  et al., 4(5)-monosubstituted imidazoles are obtained when the 
reaction is carried out with p-toluenesulfonamide (87,  R2 = tosyl) to form an activated 
imine 88 possessing an electron withdrawing tosyl group.119 The initially formed 
1-tosylimidazole 90 (Scheme 9, R2 = tosyl) spontaneously splits off the tosyl group. 
In  the  presence  of  a  catalytic  amount  of  a  weak  base  such  as  NaCN  or  K2CO3 in a protic 
solvent like EtOH the [3+2] cycloaddition of TosMIC and aldehyde 86 affords isolable trans-
configured 4-tosyloxazolines 91 (Scheme 10).152 4(5)-monosubstituted or 1,4-disubstituted 
imidazoles 92 can be obtained when those oxazolines 91 are heated with a saturated 
solution of ammonia in methanol or monoalkylamines in benzene or xylene at 90 - 110 °C in 
a sealable pressure tube.117 
Scheme 10. TosMIC-mediated method (B) for the preparation of imidazoles.117 
 
R1 = alkyl, alkenyl, aryl; R2 = H, alkyl. 
 
In  an  aprotic  solvent  such  as  DME  and  with  tBuOK  as  a  strong  base  the  cycloadduct  of  
aldehyde 86 and TosMIC undergoes ring opening to provide N-(1-tosyl-1-alkenyl)formamide 
93 (Scheme 11) which is the acyclic isomer of oxazoline 91 (Scheme 10).118 Two sets of 
signals were frequently observered in NMR spectra which were assumed in many scientific 
publications to arise from E/Z-isomers at the newly formed C=C bond although van Leusen et 
al. attributed this fact to restricted rotation around the amide bond based on temperature 
dependent 1H-NMR analysis. Subsequent dehydration with POCl3 give  rise  to  ???-
unsaturated sulfonyl isocyanides 94. Treating with a primary aliphatic amine or ammonia 
affords the formation of 1,5-disubstituted or 4(5)-monosubstituted imidazoles 95.  
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Scheme 11. TosMIC-mediated method (C) for the preparation of imidazoles.118 
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R1 = alkyl, alkenyl, aryl; R2 = H, alkyl. 
 
 
Formation of the imidazole ring via method (A) 
To obtain 4(5)-monosubstituted imidazole 97 via method (A) first N-tosylaldimine 96 was 
intended to prepare (Scheme 12). Due to the limited nucleophilicity of N-sulfonamides 
toward aldehydes harsh reaction conditions are generally required for their direct 
condensation like the use of strong Lewis and Brønsted acids to eliminate water, high 
temperature and long reaction times. Additionally, enolizable aldehydes are known to suffer 
from side reactions. As a result, various direct and indirect condensation methods have been 
developed for the preparation of N-sulfonylimines since they are versatile intermediates in 
organic synthesis.153-165  
Scheme 12. Envisaged TosMIC-mediated method (A) for the preparation of imidazole 97.119  
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When aldehyde 83 was conducted with p-toluenesulfonamide in anhydrous DCM in the 
presence of MgSO4 under reflux conditions crude NMR showed full conversion of the 
aldehyde and indicated, among other undefined side products, the formation of a small 
amount of the desired imine 96 which was confirmed by mass spectroscopy. However, the 
isolation was not feasible owing to the sensibility of the imine toward hydrolytic cleavage. It 
was tried to improve the outcome of the reaction by addition of p-toluenesulfonic acid as a 
Brønsted acid or AlCl3 as  a  Lewis  acid.  Both resulted in an acceleration of  the formation of  
unwanted side products.  
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In the following experiments, procedures were applied which are known to manage the 
conversion of enolizable aldehydes.  
Fan et al. reported a method which enables the direct condensation of enolizable aldehydes 
with p-toluenesulfonamide through a Barbier-type reaction using benzyl bromide and zinc 
dust.162 However, the desired product 96 could not be detected by NMR, only 
p-toluenesulfonamide was isolable.  
Chemla et al. published a two-step procedure for the formation of N-sulfonyl aldimines using 
p-toluenesulfonamide in the presence of sodium benzenesulfinate in formic acid and water 
to produce an intermediate that was treated with NaHCO3.158 But in the present case the 
reaction  again  did  not  afford  the  desired  imine  96.  Most  of  the  employed  
p-toluenesulfonamide was recovered.  
Another mild, indirect method is known as the Kresze reaction.153 N-sulfinyl 
p-toluenesulfonamide166 is  used  instead  of  p-toluenesulfonamide to generate the product 
via a [2+2] cycloaddition and extrusion of sulfur dioxide in the presence of the Lewis acid 
trifluoride etherate.154 In the crude NMR spectrum of this reaction with aldehyde 83 small 
amounts of the desired imine 96, unreacted aldehyde and a multiple amount of 
p-toluenesulfonamide could be identified. N-tosylaldimine 96 seemed to be unstable under 
these conditions and prone to hydrolysis after its formation.  
The Kresze reaction had been engaged also for the in situ generation of sulfonylaldimines 
which had been further converted directly. Therefore, it was tried to perform a Kresze 
reaction with aldehyde 83 which  was  immediately  treated  with  TosMIC  and  K2CO3 to 
accomplish imidazole 97 directly in a one-pot two-step synthesis. A complex product mixture 
was obtained with no indication of desired imidazole 97. 
Due  to  the  problems  associated  with  enolizable  aldehydes  it  was  decided  to  skip  the  
hydrogenation step in the reaction sequence (Scheme 6) to retain the double bond in the 
molecule resulting in the ???-unsaturated aldehyde 99 that has no acidic ?-hydrogen atom. 
As illustrated in Scheme 13 compound 59 was first selectively reduced with LAH to afford 
allyl alcohol 98 in 79% yield. Subsequently, Dess-Martin oxidation accomplished the 
preparation of aldehyde 99 in 49% yield. Both 98 and 99 proved to be slightly unstable when 
subjected  to  column  chromatography  and  upon  storing  at  room  temperature  for  a  
prolonged period.  
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Scheme 13. Preparation of ???-unsaturated aldehyde 99. 
 
 
Reagents and conditions: a)  LAH  (0.6  equiv),  THF,  0  °C,  1  h,  79%;   b)  Dess-Martin  periodinane  (1.06  equiv),  DCM,  rt,            
1.5 h, 49%. 
 
Aldehyde 99 was reacted with p-toluenesulfonamide in the presence of the dehydration 
agent TiCl4 and  NEt3 in  DCM  at  0  °C.155 Conversion of the aldehyde and formation of new 
products was indicated by TLC but crude NMR did not show evidence for the formation of 
imine 100 (Scheme 14). Column chromatography could not reveal any characterizable 
compounds apart from the starting material p-toluenesulfonamide. Comparable results were 
obtained applying the above mentioned Barbier-type and Kresze methods.154,162  
Scheme 14. Envisaged TosMIC-mediated method (A) for the preparation of imidazole 101.119  
 
 
The  installation  of  the  1,5-distubstituted  imidazole  ring  was  investigated  next.  For  this  
reason, it was considered to use benzylamine to prepare a N-benzyl imine which is then 
subjected to a cycloaddition with TosMIC under van Leusen conditions.116 The resulting N-
protected imidazole is cleavable by hydrogenation in a subsequent operation.167 Formation 
of N-benzyl imine 102 was achieved quantitatively by treating aldehyde 83 with benzylamine 
in  DCM  in  the  presence  of  MgSO4 (Scheme 15). Attempts of purification by column 
chromatography led to hydrolysis of the imine. The crude product was applied in a van 
Leusen reaction using TosMIC and K2CO3 or benzylamine as a base in MeOH or a mixture of 
DME and MeOH. No conversion was observed at room temperature. Nor could higher 
temperatures and longer reaction times promote the generation of imidazole 103.  
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Scheme 15. Envisaged TosMIC-mediated method (A) for the preparation of imidazole 103.116 
 
Reagents and conditions: a) benzylamine (1.0 equiv), MgSO4, DCM, reflux, 1.5 h, quant.; b) TosMIC (1.5 equiv), K2CO3 
(2.0 equiv), MeOH/DME (2:1), rt - reflux, 1 - 17 h; c) TosMIC (2.0 equiv), benzylamine (2.0 equiv), MeOH, rt - reflux, 6 - 18 h. 
 
In parallel, the analogous ???-unsaturated N-benzyl imine 104 was prepared from aldehyde 
99 and used in the next step without purification (Scheme 16). Again, it was not possible to 
convert imine 104 to  the  desired  imidazole  105 under van Leusen conditions with TosMIC 
and K2CO3 in  a  DME/MeOH  mixture.  Using  benzylamine  instead  of  K2CO3 remained 
unsuccessful as well. Also the initial reaction of the reported two-step procedure employing 
NaH in DME did not provide the expected intermediate, not even at elevated temperature.   
Scheme 16. Envisaged TosMIC-mediated method (A) for the preparation of imidazole 105.116 
 
Reagents and conditions: a) benzylamine (1.1 equiv), MgSO4, DCM, reflux, 1.5 h, quant.; b) TosMIC (1.5 equiv), K2CO3 
(2.0 equiv), MeOH/DME (2:1), rt to reflux, 3 - 20 h; c) TosMIC (2.0 equiv), benzylamine (2.0 equiv), MeOH, rt to reflux, 20 h;  
d) TosMIC (1.1 equiv), NaH (2.4 equiv), DME, -20 °C to rt, 2 h. 
 
Obviously, electrophilicity of the N-alkylated imines 102 and 104 is drastically reduced, thus 
TosMIC is not reactive enough to cycloadd to the C=N bond of those imines.  
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Formation of the imidazole ring via method (B) 
Following method (B), the aldehyde 83 was allowed to react with TosMIC in the presence of 
NaCN in EtOH to yield 4-tosyloxazoline 106 in  70%  as  a  2:1  mixture  of  presumably  trans-
configured diastereomers (Scheme 17). Aiming at the formation of an unprotected 
monosubstituted imidazole ring, oxazoline 106 was heated in a saturated solution of 
ammonia in MeOH or EtOH at various temperatures from 80 to 110 °C and various reaction 
times from 0.5 h to 20 h in a sealable pressure tube. It was considered that these conditions 
might allow tansesterification or amide formation at the ethyl ester group as known from 
literature precedents.168 However, none of the expected imidazole containing compounds 
107 could be identified from the reaction mixture by NMR and mass analysis.   
Scheme 17. Envisaged TosMIC-mediated method (B) for the preparation of imidazole 107.117 
 
 
Reagents and conditions: a) TosMIC (1.1 equiv), NaCN (0.18 equiv), EtOH, rt, 1 h 70%; b) saturated NH3 in MeOH or EtOH, 
80 to 110°C, 0.5 - 20 h; R = Et, Me, NH2. 
 
 
Two test reactions were carried out in order to exclude any unexpected side reactions of the 
bicyclic core such as ring opening of the cyclopropane moiety. Additionally, information 
about the behavior of the ethyl ester group should be gained when treated with ammonia at 
elevated temperature and pressure (Scheme 18). Reaction of diester 78 with a saturated 
solution  of  ammonia  in  MeOH  at  95  °C  in  a  sealable  pressure  tube  for  17  h  gave  rise  to  a  
transesterification of the ethyl ester group and amide formation at the methyl ester function 
to furnish compound 108 in 28% yield. Compound 109, bearing two amide functions, was 
isolated in 67% yield. When TBS-protected compound 110 was employed, analogous 
reactions to methylester 111 and amide 112 were performed. 
Neither the bicyclic scaffold was affected under these conditions nor was any other 
transformations observed. 
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Scheme 18. Test reactions with ammonia.  
 
 
Reagents and conditions: a) saturated NH3 in MeOH (100 equiv), 95 °C, 17 h, 28% 108, 67% 109; b) saturated NH3 in MeOH 
(100 equiv), 80 °C, 16 h, 38% 111, 55% 112. 
 
Formation of the imidazole ring via method (C) 
Method (C) seemed to be promising for the formation of the desired heterocycle since the 
imidazole forming step requires less drastic conditions in comparison to method (B). 
Treating aldehyde 83 with tBuOK in DME at -35 °C afforded the acyclic N-(1-tosyl-1-
alkenyl)formamide 113 in 54% yield (Scheme 19). Two sets of signals were observed in NMR 
spectra as explained above (page 28). The following dehydration with POCl3 in DME gave rise 
to sulfonyl isocyanides 114, proved by NMR, IR and mass analysis. However, compound 114 
turned out to be unstable on silica gel. Therefore, the crude reaction mixture was treated 
without further purification with 2 - 300 equivalents of ammonia saturated in MeOH at room 
temperature but did not show any conversion to the desired product. Higher temperature, 
however, provided a complex mixture of substances. None of the expected imidazole-
containing compounds 107 could be identified by NMR or mass analysis. 
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Scheme 19. Envisaged TosMIC-mediated method (C) for the preparation of imidazole 107.118 
 
 
Reagents and conditions: a) tBuOK (1.3 equiv), TosMIC (1.0 equiv), DME, -35 °C, 0.5 h, 54%; b) NEt3 (4.7  equiv),  POCl3 
(1.5 equiv), DME, rt, 0.5 h; c) saturated NH3 in MeOH (2 -300 equiv), rt to 90 °C, 6 h; R = Et, Me, NH2. 
 
 
To summarize, starting from aldehyde 83 the introduction of the imidazole moiety by 
different methods using TosMIC chemistry failed. Preparation via tosylimines from 
enolazible and non-enolizable aldehydes suffered from hydrolysis of the generated imine 
and formation of side products. A benzyl substituent led to deactivation of the imino group 
whereby TosMIC was not able to form 1,5-disubstituted imidazoles by cycloaddition. Finally, 
tosyloxazoline 106 and tosylisocanide 114 did not react with ammonia in the expected way 
to accomplish 4(5)-monosubstituted imidazoles 107. Although it was shown that harsh 
ammoniacal conditions had no influence on the core structure, it remained unclear, whether 
the amide functionality, whose formation was confirmed by test reactions, might interfere 
with the imidazole forming step in the latter two cases.  
For that reason, it was considered to displace the ethyl ester moiety by a protection group 
which is inert toward ammonia.  
 
 ?
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Synthesis of imidazole-containing ligands - Route II 
To circumvent the difficulties associated with the imidazole forming step in the previous 
section it was decided to reduce the ethyl ester function to the corresponding hydroxyl 
group which is then converted to a base-resistant benzyl ether protection group.  
For this purpose, alcohol 79 was protected almost quantitatively as silyl ether 110 by using 
TBSCl under basic conditions with DMAP as a catalyst (Scheme 20). 110 was also obtained in 
comparable yields from diester 78 in two steps without purification of the crude 
intermediate by column chromatography. In this case diprotected compound 115 was 
isolated in up to 5% yield resulting from dialcohol 80 (Scheme 6). Subsequently, reduction of 
the ethyl ester moiety using an excess of LAH afforded alcohol 116 in almost quantitative 
yield as well.  
Scheme 20. Preparation of alcohol 116. 
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Reagents and conditions: a) NEt3 (1.5 equiv), TBSCl (1.2 equiv), DMAP (0.05 equiv), DCM, rt, 18 h, 95%; b) LAH (0.8 equiv), 
THF, 0 °C, 45 min, 95%. 
 
The protection of alcohol 116 succeeded in 85% yield by employing benzyl bromide under 
basic conditions in DMF to give compound 117 (Scheme 21). The cleavage of the siliylether 
was accomplished by the use of TBAF in THF excellent yield. The resulting alcohol 118 
represents the benzyl ether analogue of compound 79.  
Scheme 21. Preparation of alcohol 118. 
 
Reagents and conditions: a) NaH (2.0 equiv), BnBr (2.0 equiv), DMF, 0 °C to rt, 2 h, 85%; b) TBAF•3H2O (1.5 equiv), THF, rt, 
13 h, 95%. 
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In analogy with the reactions depicted in Scheme 7 and Scheme 17 oxidation of alcohol 118 
was performed by Dess-Martin reagent in 90% yield to give aldehyde 119. This compound 
underwent a [3+2] anionic cycloaddition with TosMIC under basic conditions to form 
4-tosyloxazoline 120 as a mixture of presumably trans-configured isomers in 77% yield and a 
diastereomeric ratio of 3:2 (Scheme 22). 
Scheme 22. Preparation of tosyloxazolin 120. 
 
Reagents and conditions: a)  Dess-Martin  periodinane  (1.1  equiv),  DCM,  rt,  2  h,  90%,  b)  TosMIC  (1.1  equiv),  NaCN  
(0.22 equiv), EtOH, rt, 2 h, 77%. 
 
In the following key step oxazoline 120 was treated with a solution of ammonia in MeOH 
under elevated temperature in a sealable pressure tube (Table 1). The desired imidazole 
formation was achieved in up to 68% yield. Beside the formation of the expected imidazole 
121a the corresponding epimer 121b was identified as well. Several experiments confirmed 
the dependence of the combined yield and the ratio of both isomers on the reaction 
temperature. Heating to 100 °C afforded almost equal amounts of the isomers (entry 2) 
while lower temperatures encouraged the formation of 121a with unchanged configuration 
of the relevant stereogenic center (entry 1).  
Table 1. Preparation of imidazole 121. 
 
 
entry NH3 (equiv)[a] t (h) T (°C) yield (%)  dr (121a : 121b)[b] 
1 70 16 95 68 84 : 16 
2 70 16 100 49 53 : 47 
[a] saturated in MeOH. 
[b] determined by 1H-NMR. 
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The epimerisation in the present case can be explained by the following proposed 
mechanism according to Horne et al. (Scheme 23).117 Initially, aminooxazoline 123 is 
generated  by  the  attack  of  ammonia  on  the  immino  function  of  tosyloxazoline  122 under 
release of sulfinic acid. Addition of a second molecule of ammonia and heating effects 
fragmentation of intermediate 124 to  formamidine  (125) and iminoalcohol 126 which 
isomerizes to ?-amino ketone 127. Finally, 4(5)-monosubstituted imidazole 130 is formed by 
a sequence of intermolecular condensation and intramolecular cyclization which is related to 
the well documented imidazole syntheses with ?-halogen ketones and amidines169 and the 
Bredereck synthesis of ?-hydroxy, ?-halogen and ?-amino ketones with formamide.170 It  is  
suspected that intermediate 128, possessing a delocalized ?-system, comprises an ?-acidic 
proton at the adjacent carbon. Proton abstraction by suitable bases such as the 
intermediately generated formamidine (125) causes the observed equilibration of the 
stereogenic center. 
Scheme 23. Proposed mechanism for imidazole formation.117 
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Separation of the two isomers by column chromatography was not possible at this stage. 
Referring to a concept of Harusawa et al. protection of the imidazole ring should facilitate 
the separation of the isomers at a later stage of the synthetic route.171 Ethyl chloroformate 
was employed to convert imidazole 121 to its base-sensitive carbamate-protected derivative 
131 in 73% yield (Scheme 24). Cleavage of the benzylether was realized by hydrogenolysis 
under catalytic transfer hydrogenation using palladium hydroxide on carbon and 
cyclohexene as the hydrogen donor to give alcohol 132 in 73% yield.172 
Scheme 24. Preparation of alcohol 132. 
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Reagents and conditions: a) ethyl chloroformate (1.9 equiv), pyridine (1.9 equiv), DMAP (0.16 equiv), benzene, 50 °C, 
10 min, 73%; b) Pd(OH)2/C, cyclohexene (40 equiv), EtOH, reflux, 1 h, 73%. 
 
At this point separation of the isomers became necessary since the next step provided 
several side-products which were otherwise tedious to separate and to characterize. Partial 
separation of the less polar alcohol 132a from the isomeric mixture could be achieved by a 
single column chromatographical run. On the other hand, several purification steps were 
required to achieve an analytically pure sample of isomer 132b.  
To  displace  the  hydroxyl  group  of  the  3R-isomer 132a with  an  amino  moiety  a  
phthaloylimination under Mitsunobu conditions and subsequent hydrazinolysis was 
performed.120 By treating 132a with phthalimide in the presence of PPh3 and DIAD, desired 
phthalimide 133 was obtained in low yields of 29% (Table 2). In addition, further ring-
opening compounds were formed. Phthalimides 135a and the corresponding epimer 135b 
could be isolated in 51% and 10% yield, respectively. Diene 134 was  observed  as  well  but  
was not separable from the triphenylphosphine oxide byproduct.  
In order to optimize the conditions for the preparation of the desired phthalimide 133 
several test reactions using model compound 116 were carried out, presented in section 
Mitsunobu reaction (page 48). A mechanistic view on the formation of these side products is 
also given there.  
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Table 2. Mitsunobu-type Gabriel reaction. 
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PPh3     phthalimide DIAD 
yield (%) 
133 134 135a 135b 
1.5 equiv 1.5 equiv 1.5 equiv 29 nd 51 10 
Conditions: THF, rt, 18 h. 
 
 
Cleavage of the phthalimide moiety of compound 133 by means of hydrazinolysis proceeded 
smoothly with simultaneous removal of the base-sensitive carbamate protection group at 
the imidazole ring to give the desired target compound aminoimidazole 55a in  77%  yield  
(Scheme 25).120  
Scheme 25. Preparation of aminoimidazole 55a. 
 
Reagents and conditions: a) hydrazine hydrate (5.4 equiv), EtOH, reflux, 1 h, 77%. 
 
The conversion to the analogous cyanoguanidine-containing compound 54a required two 
additional steps (Scheme 26). First, aminoimidazole 55a was treated with an excess of 
dimethyl N-cyanodithioiminocarbonate ((MeS)2C=N-CN) in MeOH to furnish isothiourea 136 
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which was then directly converted without purification to the desired 
cyanoguanidinoimidazole 54a by adding an ethanolic solution of MeNH2.  
Scheme 26. Preparation of cyanoguanidinoimidazole 54a. 
 
Reagents and conditions: a) dimethyl N-cyanodithioiminocarbonate (2.4 equiv), MeOH, rt, 18 h; b) MeNH2 in EtOH 
(150 equiv), rt, 18 h, 69% over two steps. 
 
The respective 3S-configured target compounds, aminoimidazole 55c and 
cyanoguanidinioimidazole 54c, were derived from the corresponding 3S-configured alcohol 
132b running through an analogous synthetic pathway via phthalimide 137 (Scheme 27).  
Scheme 27. Preparation of aminoimidazole 55c and cyanoguanidinoimidazole 54c. 
 
Reagents and conditions: a) PPh3 (1.5 equiv), phthalimide (1.5 equiv), DIAD (1.5 equiv), rt, 18 h, 27%; b) hydrazine hydrate 
(5.4 equiv), EtOH, reflux, 1.5 h, 68%; c) i) dimethyl N-cyanodithioiminocarbonate (3.0 equiv), MeOH, rt, 18 h; ii) MeNH2 in 
EtOH (150 equiv), rt, 18 h, 64%. 
 
Consequently, the target molecules, aminoimidazoles 55a and 55c and 
cyanoguanidinoimidazoles 54a and 54c were synthesized in 15 and 17 steps, respectively 
from commercially available 2-furan carboxylic acid (72). By employing (R,R)-isopropyl 
bis(oxazoline) ligand ent-71 in the asymmetric cyclopropanation reaction (Scheme 4), 
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additionally, the respective enantiomers, aminoimidazoles 55b and 55d and 
cyanoguanidinoimidazoles 54b and 54d, were accessible as well (Figure 17). 
Figure 17. Synthesized imidazole-containing target compounds. 
 
 
 ?
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Synthesis toward imidazole- containing ligands - Route III 
To shorten the synthetic route of the target compounds depicted in Figure 17 by three steps 
an alternative pathway was conceived circumventing some protecting-deprotecting 
reactions. Starting from alcohol 116 it was intended to avoid an O-benzylation of the 
hydroxyl group, as described in the previous section, and to prepone the phthaloylimination 
step. The phthalimide moiety itself acts then as a protecting group which was expected to be 
cleaved simultaneous with the imidazole formation step.  
Scheme 28. Alternative synthetic pathway.  
 
 
Reagents and conditions: a) PPh3 (1.5 equiv), DIAD (1.5 equiv), phthalimide (1.5 equiv), THF, 50 °C, 1 h, 31%; b) TBAF•3H2O 
(1.5 equiv), THF, 0 °C to rt, 1.5 h, 70%; c) NaHCO3 (2.0  equiv),  Dess-Martin  periodinane  (1.7  equiv),  DCM,  rt,  5  h,  79%;           
d) TosMIC (1.1 equiv), NaCN (0.18 equiv), EtOH/DCM, rt, 1 h, 81%; e) NH3 in MeOH, 100 °C, 20h. 
 
Mitsunobu-type Gabriel reaction (see section Mitsunobu reaction, page 48) afforded 
phthalimide 138 in 31% yield (Scheme 28). The subsequent deprotection of the silylether 
gave rise to alcohol 139 in 70% yield which turned out to be acid-sensitive. For that reason, 
addition of NaHCO3 was vital for the Dess-Martin oxidation in the following step to obtain 
aldehyde 140 in 79% yield. Base-induced [3+2] cycloaddition with TosMIC furnished 
tosyloxazoline 141 as a 1:1 mixture of diastereomers. However, treatment with a saturated 
solution of ammonia in MeOH in a sealable pressure tube under elevated temperature did 
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not form the desired aminoimidazole 54a. Only a mixture of inseparable polar compounds 
was detected.  
 
 ?
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Synthesis of oxazole-containing ligands 
In  the  course  of  developing  potent  histamine  receptor  ligands,  which  show  selectivity  for  
certain subtypes, the search for appropriate bioisosteres, besides altering the spacer 
properties between the pharmacophores, has become a common method (see 
Introduction).68,173 Especially, the imidazole ring has been successfully modified by 
introducing various substitution patterns or was replaced by different kinds of heterocycles 
such  as  thiazoles.  It  was  decided  to  exchange  the  imidazole  ring  of  the  above  described  
amino-  and  cyanoguanidinoimidazoles  (Figure  17)  by  an  oxazole  ring  as  an  isostere.  The  
effects of these replacements were then analyzed by determining the functional activities on 
the H3R and H4R subtypes. 
Since 5-substituted oxazole derivatives are accessible in a similar way than the 
corresponding imidazole analogues via the TosMIC strategy developed by van Leusen a 
previous synthetic approach was adjusted.152 Starting from tosyloxazoline 106, which was 
originally envisaged for the formation of the imidazole ring, elimination of sulfinic acid 
afforded oxazole 142 in 31% yield (Scheme 29).  
Scheme 29. Preparation of oxazole 142.152 
 
Reagents and conditions: a) K2CO3 (2.0 equiv), MeOH, reflux, 0.5 h, 31%. 
 
The subsequent transformations of the ethyl ester moiety were in line with parts of the 
reaction sequence of section Synthesis of imidazole-containing ligands - Route II. The 
reduction of the ethyl ester group with an excess of LAH first gave rise to the expected 
alcohol 143 in only moderate yield (Table 3). The unstable diol 80 was identified as a side 
product. By decreasing the amount of LAH to a slight excess the yield of alcohol 143 could be 
increased to 71%.  
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Table 3. Ester reduction to alcohol 143. 
 
  entry[a] LAH (equiv) 
yield (%) 
142 143 80 
1 1.5 - 44   56[b] 
2 0.6  12[b]       71 (81)[b]   6[b] 
[a] LAH, 0 °C, 0.5 h. 
[b] determined by 1H-NMR. 
 
Mitsunobu-type Gabriel reaction afforded phthalimide 144 (Scheme 30). The expected ring-
opening side products were again observed but the yield of the relevant phthalimide 144 
was significantly higher (55%) compared to the analogous Mitsunobu reactions that 
furnished compound 133 in 29% (Table 2, page 40) and compound 138 in 31% yield (Scheme 
32, page 49). Cleavage of the phthalimide moiety revealed 57a in 72% yield. The conversion 
with dimethyl N-cyanodithioiminocarbonate to isothiourea 145 proceeded quantitatively. 
Subsequent treatment with a solution of MeNH2 in EtOH finally gave rise to cyanoguanidine 
56a in 90% yield.  
Scheme 30. Preparation of aminooxazole 57a and cyanoguanidinooxazole 56a. 
 
 
Reagents and conditions: a) PPh3 (1.5 equiv), phthalimide (1.5 equiv), DIAD (1.5 equiv), THF, 0 °C, 0.5 h, 55%; b) hydrazine 
hydrate (5.0 equiv), EtOH, reflux, 1.5 h, 72%; c) dimethyl N-cyanodithioiminocarbonate (2.0 equiv), EtOH, rt, 18 h, quant.;  
d) MeNH2 in EtOH, rt, 18 h, 90%. 
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By  following  this  reaction  sequence  the  target  molecules,  aminooxazole  57a and 
cyanoguanidinooxazole 56a were synthesized in 10 and 12 steps, respectively, from 
commercially available 2-furan carboxylic acid (72). Enantiomer 57b and 56b were obtained 
using  the  (R,R)-isopropyl bis(oxazoline) ligand 71 in the asymmetric cyclopropanation 
reaction. Unlike the imidazole analogues no epimerization emerged in the course of the 
oxazole formation. As a result only 3,6-trans-configured compounds were accessible (Figure 
18).  
Figure 18. Synthesized oxazole-containing target compounds. 
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Mitsunobu reaction 
The Mitsunobu reaction, discovered in 1967,174 is a valuable method to convert hydroxyl 
groups into a wide range of different functional groups, like esters, azides, cyanides, imides, 
amines, ethers, or thioesters.175,176 This formal condensation reaction of a primary or 
secondary alcohol 146 and a suitable nucleophile precursor 147 (pKa <  11)  is  driven  by  a  
redox process where a trialkylphosphine 148 is oxidized to trialkylphosphine oxide 151 and a 
diazo compound 149 is reduced to the corresponding hydrazine compound 152 (Scheme 31). 
A  big  advantage  of  the  Mitsunobu  reaction  is  its  stereospecifity  in  the  case  of  secondary  
alcohols. The transformation proceeds with inversion of the stereogenic center. Therefore, it 
has become a widespread tool in natural product syntheses.176  
Scheme 31. Mitsunobu reaction. 
 
R1 = alkyl, R2 = H, alkyl, R3 = aryl, alkyl, R4 = alkyl. 
 
Mitsunobu-type Gabriel reaction 
In 1972, the method was expanded to phthalimide as the nucleophile precursor which 
opened up a mild two-step methodology to convert a hydroxyl into an amine group.120 The 
Mitsunobu-type Gabriel reaction, followed by hydrazinolysis of the alkylated phthalimide 
reveals the corresponding amine.  
The Mitsunobu reaction of compound 132 in  section  Synthesis of imidazole-containing 
ligands - Route II (Table 2, page 40) was investigated more closely on the model compound 
116 and is described in the following.  
When alcohol 116 was converted under standard Mitsunobu reaction conditions, using 
1.5 equivalents each of triphenylphosphine, diisopropyl azodicarboxylate (DIAD) and 
phthalimide in THF at 0 °C, the desired product 138 was isolated in only 30% yield (Table 4, 
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entry 1, page 52). Beside the formation of the desired phthalimide 138, three compounds 
were encountered additionally: diene 153, phthalimide 154a and the corresponding 
epimer 154b (Scheme 32).  
Scheme 32. Mitsunobu-type Gabriel reaction. 
 
Reagents and conditions: a) PPh3 (1.5 equiv), DIAD (1.5 equiv), phthalimide (1.5 equiv), THF, 0 °C, 6 h, 30% 138. 
 
These side products have a ring-opening of the cyclopropyl moiety in common. The following 
mechanistic considerations explain the formation of all products in detail: In the irreversible 
first step triphenylphosphine (155) attacks one of the diazo-nitrogen atoms of DIAD (156) to 
create a betaine intermediate 157 (Scheme 33). A pKa value of 8.3177 for phthalimide (158) 
enables the betaine 157 to abstract the acidic proton, leading to the formation of ion pair 
159. This sequence proceeds within seconds as evidenced by the decolorization of DIAD 
upon addition.178 Reaction with alcohol 116 under release of hydrazine 160 gives rise to the 
key alkoxyphosphonium salt 161, which is in equilibrium with other species (not shown in 
the scheme).179,180 This equilibrium depends on the pKa value of the acidic compound and on 
the polarity of the solvent. Up to now, it is still under discussion whether such species play a 
role in the Mitsunobu reaction or whether they are present just as spectators. In the further 
course different pathways are possible. As a good leaving group, triphenylphosphine oxid 
(163) is displaced by the deprotonated phthalimide (162) through nucleophilic attack to form 
the desired product 138. 
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Scheme 33. Mitsunobu reaction – mechanism I. 
 
 
R = TBS, phth = phthalimide. 
 
In parallel with such a SN2-type reaction a cyclopropylcarbinyl-homoallylic rearrangement 
takes place due to the stabilization of the emerging positive charge by the endocyclic oxygen 
atom (Scheme 34). Such kind of ring opening reactions of similar cyclopropylcarbinols was 
reported previously in the fields of terpene and sugar chemistry.181-183 The carbenium ion 
can be trapped by the phthalimide nucleophile 162 from two sides resulting in a pair of 
stereoisomers, phthalimide 154a and its epimer 154b. In this regard, the formation of 154a 
is preferred due to the steric hindrance of the two substituents on the heterocycle. The 
diastereomers 154a and 154b were isolated in a 4:1 ratio. In competition with this SN1-type 
mechanism  an  E1  elimination  takes  place.  The  proton  is  abstracted  by  a  base  to  give  
oxacyclic diene 153. 
 
  
Main Part 
51 
 
Scheme 34. Mitsunobu reaction – mechanism II.  
 
R = TBS, Nu = nucleophile, B = base. 
 
In order to improve the yield of phthalimide 138 different reaction conditions were 
investigated (Table 4). Initially, diethyl azodicarboxylate (DEAD), which is also a common 
reagent for this reaction, was used instead of DIAD under the same conditions but only slight 
differences  in  product  distribution  were  observed  (entry  2).  The  addition  order  of  the  
reagents has a strong influence on the product distribution in certain cases.184 Commonly, 
DEAD  or  DIAD  is  added  to  a  solution  of  alcohol,  PPh3 and the acidic compound (Table 4, 
method A). Alternatively, PPh3 and the azodicarboxylate are premixed and nucleophile and 
alcohol are added successively (method B). However, altering the order of addition did not 
show any effects (entry 3). A reaction temperature of -40 °C caused a slight increase of yield 
for  the  products  which  arise  after  ring  opening  whereas  the  yield  of  phthalimide  138 
remained at the same level (entry 4). Nevertheless, further decrease of the reaction 
temperature to -78 °C resulted in an incomplete conversion of the starting material (entry 5). 
As a consequence, the isolated yields of all products dropped but the product ratio shifted in 
favor of compounds 154a, 154b and 153 and in disfavor of phthalimide 138. Higher amounts 
of the reagents gave rise to larger quantities of triphenylphosphine oxide (163) and 
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Table 4. Optimization of the reaction conditions. 
entry method[a] PPh3, DIAD (equiv) 
phthalimide 
(equiv) T (°C) solvent
[b] 
yield (%) 
138 154[c] 153 
1 A 1.5 1.5 0 THF 30 45 7 
2 A  1.5[d] 1.5 0 THF 29 42 8 
3 B 1.5 1.5 0 THF 30 45 10 
4 B 1.5 1.5 -40 THF 30 52 12 
   5[e] B 1.5 1.5 -78 THF 14 37 7 
6 A 6.0 6.0 0 THF nd 52 nd 
7 A 1.5 3.0 0 THF 26 46 13 
   8[e] A 1.5 3.0 0 MeCN 20 20 9 
9 A 1.5 3.0 0 toluene 23 52 15 
10 A 1.5 1.5 50 THF 31 39 23 
   11[f] A 1.5 1.5 50 MeCN 16 48 13 
[a] addition order: A) 1. 116, 2. PPh3, 3. phthalimide, 4. DIAD; B) 1. PPh3, 2. DIAD, 3. phthalimide, 4. 116.   
[b] c = 0.05 mol/L.            
[c] combined yield of 154a and 154b.           
[d] DEAD instead of DIAD.             
[e] unreacted starting material 116 recovered.          
[f] 17% yield 165.   
 
 
hydrazine byproducts, which strongly hampered the isolation of both diene 153 and 
phthalimide 138 (entry 6). However, the combined yield of compounds 154a and 154b 
amounted to 52% which suggests that a substantial improvement for product 138 was not 
achieved. The mechanistic studies of the Mitsunobu esterification reaction by Hughes et al. 
revealed that the nucleophilicity in the SN2 reaction step is influenced by hydrogen 
bonding.178 In principal, this effect should also exist for the corresponding phthalimidation 
reaction and is explained as follows. When equimolar amounts of PPh3,  DIAD  and  
phthalimide are employed in the reaction, complete protonation of betaine 159 occurs 
(Scheme 33). When 2 equivalents of phthalimide are used, 1 equivalent is deprotonated and 
1 equivalent remains unreacted to give a hydrogen bonded species consisting of both. As a 
consequence, the activity of the nucleophile is reduced. The resulting lowered reaction rate 
for  the  SN2 reaction should be reflected in a lower yield for phthalimide 138 and higher 
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yields for the ring-opening products. These assumptions are confirmed by the experimental 
data, but only to a rather small extend (entry 7). Further experiments were carried out, in 
order  to  investigate  solvent  effects.  It  was  assumed,  that  a  much  more  polar  solvent,  like  
acetonitrile, is capable of breaking up the tight ion pair 159 making the phthalimide anion 
more easily accessible to the SN2 displacement. But again a considerable amount of starting 
material was recovered (entry 8). Nevertheless, a shift in the product distribution in favor of 
phthalimide 138 was observed. Moreover, when E1 and SN1 mechanisms are in competition, 
the elimination is supported by more polar solvents. The product ratio of the SN1 products 
154a and 154b to E1 product 153 decreased from 3.5 (entry 7) to 2.2 (entry 8). The opposite 
case, when less polar toluene was used, the ratio of the ring-opening products to 
phthalimide 138 increased  from  2.3  (entry  7)  to  2.9  (entry  9).  Since  low  temperature  
promotes the formation of ring-opening products, running the reaction at elevated 
temperatures should display the contrary effect. This was partly confirmed as shown in 
entry 10. The absolute yield of phthalimide 138 was slightly improved to 31% but the yield of 
the ring-opening products rose as well (entry 10) which gives an even higher product ratio of 
2.0 compared to 1.7 (entry 1). As expected, the elimination product 153 profited from the 
elevated reaction temperature against the SN1  products,  resulting  in  a  product  ratio  of  
phthalimides 154a and 154b to diene 153 of 1.7. To combine all the putative positive effects 
for the formation of phthalimide 138,  the  reaction  was  performed  in  acetonitrile  at  50  °C  
and 1.5 equivalents of each reagent. Interestingly, the yield of phthalimide 138 was  not  
enhanced, but further side products encountered in 17% combined yield, which turned out 
to be the self-condensation product 165a and epimer 165b of alcohol 116 (Figure 19). 
Figure 19. Condensation product 165. 
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In parallel, the ???-unsaturated analogue 167 was also investigated in the Mitsunobu 
reaction. It was synthesized from alcohol 98 in 2 steps via a  hydroxyl-protection  and  an  
ester-reduction reaction (Scheme 35). The treatment of alcohol 98 with PPh3, phthalimide 
and DIAD afforded the SN2-type product, phthalimide 169,  in  low  38%  yield.  Even  in  this  
case, ring-opening predominated. However, unlike when saturated alcohol 116 was 
employed, not the C-C bond of alcohol 167, which is referred to as ?, was broken but the 
cyclopropane C-C bond termed ? was cleaved. This reaction is promoted by rearomatization 
and gave rise to vinylfuran 168 in 54% yield.  
Scheme 35. Preparation of alcohol 167 and Mitsunobu reaction. 
 
 
Reagents and conditions: a) NEt3 (1.5 equiv), TBSCl (1.2 equiv), DMAP (0.05 equiv), DCM, rt, 4 h, 99%; b) LAH (0.85 equiv), 
THF, 0 °C, 1 h, 88%; c) PPh3 (1.5 equiv), DIAD (1.5 equiv), phthalimide (1.5 equiv), THF, 0 °C, 2 h, 54% 168, 38% 169. 
 
Additional products were not observed. This indicates that the release of triphenylphosphine 
oxide and proton abstraction proceeded in a concerted manner (Figure 20). Therefore, a 
positively charged intermediate was not generated which could be traped by a phthalimide 
nucleophile in a SN1-type reaction. 
Figure 20. Ring-opening of intermediate 170. 
 
 
  
Main Part 
55 
 
Conversion of alcohols to azides 
A further convenient two-step method to convert alcohols into the corresponding amines is 
via a Mitsunobu-mediated displacement of the hydroxyl by an azide group185 and a 
subsequent reduction of the latter.186 Apart from hydrazoic acid, appropriate azide sources 
are  diphenyl  phosphoryl  azide  (DPPA),  trimethylsilyl  azide,  sodium  azide,  zinc  azide  or  
nicotinoyl azide.176 The reduction to the amine is effected by various reagents, including 
lithium aluminium hydride, sodium borohydride and catalytic hydrogenation.187 A very mild 
and selective way to reduce the azide group comprises the Staudinger reaction188-190 where 
triphenylphosphine (155) and azide 171 form a phosphazide 172. Cyclization and release of 
molecular nitrogen result in an iminophosphorane 173 which after hydrolysis gives the 
desired amine 174 (Scheme 36). 
Scheme 36. Staudinger reaction and hydrolysis. 
 
 
It was contemplated that an azide anion might act as a better nucleophile than the 
phthalimide anion in the Mitsunobu reaction. This is tantamount to a higher reaction rate of 
the  SN2 displacement contributing to a product distribution with smaller amounts of ring-
opening compounds. The attempt to perform the Mitsunobu-mediated azide formation 
using hydrazoic acid as the azide source failed (Table 5, entry 1). Conversion of alcohol 116 
was not discernible. The same was observed applying sodium azide in DMF (entry 2).191 
Using modified Bose conditions192,  DIAD  was  added  to  a  THF  solution  of  alcohol  116, 
triphenylphosphine and DPPA at 0 °C (entry 3) which afforded a product pattern in analogy 
to the Gabriel reaction. The desired SN2 substitution product azide 175 was obtained in poor 
yield. This was again due to the competing ring opening which resulted in the formation of 
azide 176a, its epimer 176b and oxacyclic diene 153.  A  smaller  value  of  2  for  the  
diastereomeric ratio of azide 176a and 176b compared to the ratio of phthalimides 154a and 
154b under similar conditions is due to a smaller size of the azide anion, facilitating the 
attack of the occurring carbenium ion from the shielded face.  
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Table 5. Conversion of alcohol 116 into azide 175. 
 
entry reagents and conditions 
yield (%) 
175 176 [a] 153 
1 PPh3 (1.5 equiv), DIAD (1.5 equiv), HN3 in toluene (3 equiv), THF, 0 °C to rt, 18 h. no conversion 
2 PPh3 (1.5 equiv), DIAD (1.5 equiv), NaN3 (3 equiv), DMF, rt, 18 h. no conversion 
3 PPh3 (2 equiv), DIAD (2 equiv), DPPA (2 equiv), THF, 0 °C, 0.5 h. 21 52 5 
4 DPPA (2 equiv), DBU (2 equiv),  toluene/DMF 9:1, 50 °C,     1 h. 12 60 5 
[a] combined yield of 177a and 177b. 
 
Thompson et al. developed an alternative method for the direct conversion of activated 
alcohols to azides.193 The alcohol 177 was allowed to react with a combination of DPPA (178) 
and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, 179) in toluene or DMF to give the azide 
product 18 (Scheme 37). Mechanistically, in the first step phosphate 180 and the DBU salt of 
hydrazoic acid (181) are formed. Subsequently, the in situ generated azide anion displaces 
the leaving group. The resulting DBU salt of diphenyl phosphate (183)  is  water soluble and 
can be removed by aqueous workup, facilitating the purification of the product compared to 
Mitsunobu  procedures.  Apart  from  this  operational  simplicity,  the  authors  emphasize  the  
improved yields, formation of fewer byproducts and enhancement of integrity of the desired 
SN2 displacement. This method activates the alcohol by creating a phosphate intermediate 
instead of a triphenylphosphonium ion in the Mitsunobu reaction with potentially different 
leaving  group  properties.  Hence,  it  was  conceivable  that  it  has  a  beneficial  effect  on  SN2 
product formation in the present case. The reaction was carried out using Danishefsky 
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conditions (Table 5, entry 4).194 Once again, the ring-opening products predominated and 
the yield of desired azide 175 was even lower than in the Mitsunobu-type reaction. A 
diastereomeric ratio of azide 176a to 176b of 1.0 is attributed to the elevated reaction 
temperature. 
Scheme 37. Azide formation according to Thompson.193  
 
R1 = alkyl, R2 = H, alkyl. 
 
The traditional route to prepare azides from alcohols requires an additional step to convert 
the hydroxyl group into a sulfonate which can be displaced subsequently by an azide 
anion.187 The most commonly employed leaving groups are the methanesulfonate (mesyl) 
and p-toluenesulfonate (tosyl) moieties. However, it was known that the preparation of 
sulfonates from alcohols is prone to alkene formation and rearrangements in certain cases. 
In consequence, it was obvious that the reaction of alcohol 116 with p-toluenesulfonyl 
chloride in presence of triethylamine and DMAP as a catalyst afforded mainly ring-opening 
products, indicated by TLC and crude NMR measurements.  
To conclude, the direct conversion of alcohol 116 to phthalimide 138 by Mitsunobu-type 
Gabriel reaction was accomplished in poor yield due to ring-opening side reactions. 
Attempts to increase the yield by changing reagents, addition order, concentrations, solvent 
and reaction temperature were not successful. Reaction of ???-unsaturated alcohol 167 also 
showed a preference for ring-opening. However, the formation of vinylfuran 168 as the only 
ring-opening product discloses a different mechanism for the ring-opening. Switching to the 
azide methodology showed similar results for the Mitsunobu reaction as well as the 
Thompson variant. To afford the desired azide by an indirect way via tosylation  of  the  
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alcohol again caused ring opening. Obviously, all strategies, which include activation of the 
alcohol to enable its displacement, are facing the problem of ring opening side reactions due 
to the stabilizing effect of the oxacyclic oxygen atom.  
To overcome this difficulty a different synthetic strategy, starting from the cyclopropyl ester, 
formation of the primary amide and reduction to the desired amine might be a viable 
alternative. 
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Dehydration of alcohol to diene 
The oxacyclic diene 153, encountered in the Mitsunobu reaction of alcohol 116, represents 
an interesting building block for Diels-Alder reactions to synthesize polycyclic scaffolds. For 
this reason, it was tried to find conditions and alternative procedures providing the desired 
diene in higher yields. 
Table 6. Mitsunobu dehydration reaction.  
 
entry PPh3/DIAD (equiv) T (°C) solvent 
yield (%) 
 116[a] 165[b] 153 184[c] 185 
1 2 0 THF 32 - 38 27 - 
2 3 0 THF - - 9 54 32 
3 4 0 THF - - 12 51 35 
4 2 0 MeCN <5 16 16 47 <5 
5 2 50 THF - - 8 45 45 
[a] recovered unreacted starting material; [b] combined yield of 165a and 165b; [c] combined yield of 184a and 184b. 
As shown in Table 4, the maximum yield of diene 153 was  23%.  This  is  due  to  the  
nucleophilic substitution reactions trapping the intermediate carbocations before a proton is 
abstracted to form the C-C double bond (Scheme 34). In order to prevent nucleophilic side 
reactions the nucleophile source should be omitted. Several precedents in the literature 
show promising examples for such kind of Mitsunobu dehydration reactions.176 When the 
reaction was performed with alcohol 116, however, separation of the product mixture 
revealed new compounds in addition to diene 153, identified as hydrazine 184a, its epimer 
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184b and 185 (Table 6). According to literature precedents176 the alcohol itself can react with 
the hydrazine intermediates if the betaine is not able to abstract the proton of the 
nucleophile  precursor  or  a  nucleophile  is  not  available.  The  use  of  2  equivalents  of  each  
reagent in THF at  0 °C afforded diene 153 in 38% yield which was a small improvement to 
previous Mitsunobu reactions (Table 6, entry 1). Additionally, hydrazine products 184a and 
184b were isolated in 27% combined yield and 32% of the starting alcohol was recovered. 
Therefore the amount of the reagents was increased to 3 and 4 equivalents, respectively 
(entry 2 and 3). Although the conversion was complete, the yield of diene 153 decreased in 
favor of the formation of hydrazine 184a, 184b and 185.  Performing  the  reaction  in  
acetonitrile did not result in an improvement with regard to diene 153 but the self-
condensation products 165a and 165b encountered in 16% combined yield (entry 4). An 
elevated reaction temperature of 50 °C did not contribute to a higher yield for diene 153 as 
well but promoted in particular the formation of the SN2 product 185 (entry 5).  
Scheme 38. Dehydration reaction of alcohol XXX.183 
 
Reagents and conditions: a) PO(OPh)2Cl (2.7 equiv), pyridine (1.3 equiv), DCM, rt, 83%. 
 
During the course of synthesizing potential inhibitors of glycosyl hydrolases Stick and Stubbs 
observed the transformation of alcohol 186 to diene 188 in 83% yield (Scheme 38).183 
Alcohol 186 was allowed to react with diphenyl chlorophosphonate and pyridine in DCM. 
Formation of phosphate 187 immediately initiated ring-opening caused by the ability of the 
endocyclic oxygen atom to stabilize the positive charge of the generated carbenium ion 
intermediate. Subsequent elimination afforded oxacyclic diene 188. These results prompted 
to employ the same conditions for the reaction with alcohol 116. However, reaction control 
by TLC and characteristic signals in crude NMR spectrum indicated the formation of the SN1 
and SN2 side products. These side products were not isolated and characterized but the yield 
of diene 153 did not exceed 10%. Using phosphoryl chloride195 instead of diphenyl 
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chlorophosphonate in combination with pyridine or DBU showed similar unsatisfactory 
results. 
Classical dehydration catalysts include protic acids like sulfuric acid and phosphoric acid. 
They enable elimination reactions of primary, secondary and tertiary alcohols through E1 or 
E2 pathways by protonating the hydroxyl group and making it a good leaving group. Adding a 
dilute solution of sulfuric acid or phosphoric acid in anhydrous toluene to a solution of 
alcohol 116 in toluene in one portion at ambient temperature only gave a black insoluble tar. 
Therefore, the alcoholic solution was cooled to -78 °C before adding the precooled acid 
solution in the presence of molecular sieves dropwise. Subsequently, the reaction mixture 
was allowed to warm to room temperature. Reaction control by TLC indicated complete 
conversion of starting material after 4 h and showed the formation of several side products. 
The desired diene 153 was only generated in trace amounts. Similar observations were made 
for applying phosphoric acid and tosylic acid. It is assumed, that an acid catalyzed 
deprotection of the silylether takes place to reveal another free hydroxyl group, interfering 
with the expected reaction pathway. 
Copper(II)  triflate  was  found  to  be  an  efficient  catalyst  for  the  dehydration  of  a  variety  of  
tertiary, secondary and primary alcohols.196 The proposed mechanism starts with an 
interaction of the alcohol and the electron deficient copper(II) triflate. Two proposed 
pathways result in the formation of a carbocation which upon deprotonation generates the 
olefin.  
Scheme 39. Self-condensation of alcohol 116. 
 
Reagents and conditions: a) Cu(OTf)2 (0.18 equiv), benzene, rt, 1 h, 95%. 
 
When  this  method  was  employed  to  alcohol  116 only a diastereomeric mixture of the 
asymmetric dimer 165 could be identified (Scheme 39). A value of 95 % yield was calculated 
based on 1H-NMR measurement by means of 1,2,4,5-tetrachlorobenzene as an internal 
standard. However, formation of diene 153 was not observed. 
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Scheme 40. Reaction of alcohol 116 with oxalyl chloride. 
 
Reagents and conditions: a) (COCl)2 (1.5 equiv), NEt3 (3 equiv), DCM, 0 °C, 0.5 h, 86%. 
 
Oxalyl chloride was used to effect the dehydration of serine containing peptides.197 This is 
explained by the fragmentation of an initially formed Ser-O-oxalyl chloride. When 
alcohol 116 was  treated  with  oxalyl  chloride  in  the  presents  of  triethylamine  in  DCM  only  
oxalic ester 190 could be isolated in 86% yield (Scheme 40). Obviously, the intermediate 189 
is stable enough not to decompose but to react with a second molecule of 116. 
It was not possible to obtain distinct products when oxalyl chloride was exchanged by 
thionyl chloride which was supposed to effect a related reaction.  
Goodall and Parsons developed a method to dehydrate hydroxyamino acids by the reaction 
of dichloroacetyl chloride in presence of triethylamine or DBU.198 They were able to isolate 
the formed dichloroesters or to effect subsequent elimination of dichloroacetic acid upon 
employing a further equivalent of base. Alcohol 116 reacted to the corresponding 
dichloroester 191 with 2.2 equivalents of each reagent and base but did not proceed to 
eliminate, not even when a further equivalent of base was added and the reaction mixture 
was heated (Scheme 41).  
Scheme 41. Reaction of alcohol 116 with dichloroacetyl chloride. 
 
Reagents and conditions: a) ClCOCHCl2 (2.2 equiv), NEt3 (2.2 equiv), DCM, rt, 1.5 h, 94 %. 
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Dicyclohexyl- or diisopropylcarbodiimide in combination with copper(I) chloride were found 
to be efficient dehydrating agents for ?-hydroxycarbonyl compounds,199 nitrated alcohols200 
and amino acids.201 This methodology could be improved by employing 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) and copper(II) chloride.202,203 These ?-elimination 
reactions proceed by generating an O-alkylisourea intermediate. A six-membered transition 
state effects cycloelimination under release of urea. In the case of alcohol 116 the 
elimination does not take place via a six-membered but a seven-membered transition state.  
Table 7. Reaction of alcohol 120 with EDC. 
 
entry EDC (equiv) CuCl2 (equiv) T (°C) solvent yield (%)[a] 
1 2.0 1.1  80 toluene  49 
2 2.0 1.1 80 MeCN 62 
[a] determined by 1H-NMR with 1,2,4,5-tetrachlorbenzene as internal standard. 
 
Treatment of alcohol 116 with EDC and copper(II) chloride in toluene at 80 °C afforded diene 
153 in 49% yield (Table 7, entry 1). In acetonitrile, an aprotic polar solvent which promotes 
elimination reactions, the yield could be increased to 62% (entry 2).  
To summarize, different procedures and dehydrating agents were examined to achieve 
diene 153. Mitsunobu dehydration suffered from the formation of hydrazine side products. 
Phosphorous based dehydrating agents could not avoid undesired SN displacement 
reactions. Cu(OTf)2 as a Lewis acid only afforded self-condensation products. Oxalyl chloride 
gave the corresponding oxalic ester. Reaction with dichloroacetyl chloride stopped at the 
stage of the dichloroester, subsequent elimination did not occur. Finally, application of EDC 
and CuCl2 improved the outcome and yielded diene 153 in 62%.  
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Furanyldiene in Diels-Alder Reaction 
The Diels-Alder reaction is considered as a very powerful tool for stereospecific carbon-
carbon bond formation.204 Chiral oxacyclic dienes with five or six membered rings, such as 
those depicted in Figure 21, constitute valuable building blocks for the formation of 
enantiopure polycyclic furanyl and pyranyl derivatives via Diels-Alder reactions, which are 
encountered in many natural products. Preparation of theses oxacyclic moieties comprises 
enyne metathesis using Grubbs catalyst (193a,205 193c,206 194c206), isomerization of 2-
vinylidene furans (193b207)  and  pyrans  (194b208), Wittig alkenylation (193b,209 194a210), 
[3+2] cycloaddition of propargyltungsten compounds and aldehydes (193a,211-213 193c,214 
194a211,213), cyclopropylcarbinyl-homoallyl rearrangement (194a183) and addition of vinyl 
Grignard reagent to 2-oxo, 3-oxo and 4-oxo pyrans with subsequent dehydration (194b,215 
194a,216 194d217). 
Figure 21. Furanyl (193a-c) and pyranyl dienes (194a-d). 
 
 
By means of a tungsten-mediated [3+2] cycloalkenation Liu and coworkers synthesized a 
furanyl diene of type 193a211-213 which distinguishes from diene 153 by a chiral 1,3-dioxolane 
moiety instead of a methoxysilane group (Scheme 42). To introduce the dioxolane group at 
C2 of the heterocycle they started the sequence from L(+)-diethyl tartrate (195).  In  the  
keystep  the  chiral  tungsten  alkynol  196 was treated with acetaldehyde in the presence of 
BF3•Et2O giving rise to an oxacarbenium salt 197 which was deprotonated to afford tungsten 
furanyl diene 198. Subsequent hydrodemetalation with Me3NO in acetonitrile provided the 
desired chiral oxacyclic diene 199.  
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Scheme 42. Synthesis of furanyl diene 199 according to Liu et al.211-213 
 
 
Reagents and conditions: a) i) MeCHO (4 equiv), BF3•Et2O (1.2 equiv), Et2O, -78 °C, 5 h; ii) NEt3 (4.5 equiv), DCM, rt, 0.5 h, 
64%; b) Me3NO (5.2 equiv), MeCN, rt, 4 h, 60%; W* = CpW(CO)3. 
 
The electron rich oxacyclic diene 199 was subjected to a number of Diels-Alder reactions 
with electron deficient dienophiles under ambient conditions (Scheme 43). The [4+2] 
cycloadducts were obtained in good yields and with high diastereoselectivity. The latter is 
attributed to endo-facial cycloaddition and the steric effect of the chiral dioxolane moiety. 
Scheme 43. Diels-Alder reactions of furanyl diene 199. 
 
Reagents and conditions: a) DCM or toluene, rt, 12 h, 84 - 87%, dr > 20. 
 
For reasons of  clarity  the (S)-configured oxacyclic diene ent-153 was used in the following. 
The Diels-Alder reaction of diene ent-153 and N-phenyl maleimide (202)  in  DCM  at  room  
temperature was accomplished in comparable 83% yield (Scheme 44) but was less selective 
than the reaction of diene 199. Cycloadducts 206a and 206b were produced in 70% and 13% 
yield  which  amounts  to  a  diastereomeric  ratio  of  5.4.  The  structural  elucidation  relies  on  
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COSY and NOESY spectra. Dienophile 202 approaches diene ent-153 from the face opposite 
to the methoxysilane substituent in an endo mode to form the major product 206a. The 
minor product 206b possesses an endo-configuration as well and emerges from the attack at 
the more shielded face. The conceivable exo cycloadducts were not observed. As a result, 
the dioxolane moiety in diene 199 is more capable of shielding one face than the 
methoxysilane substituent in diene ent-153.  
Scheme 44. Diels-Alder reaction of oxacyclic diene ent-153 and N-phenyl maleimide (202). 
 
Reagents and conditions: a) DCM, rt, 16 h, 83%, dr = 5.4. 
 
In conclusion, oxacyclic diene ent-153 was successfully applied in a [4+2] cycloaddition 
reaction with electron deficient N-phenyl maleimide (202) to give the tricyclic compounds 
206a and 206b. Enantiopure diene ent-153 was obtained in 7 steps from commercially 
available 2-furan carboxylic acid (72) with an overall yield of 23%. The cycloaddition reaction 
of diene ent-153 showed  a  strong  endo/exo-selectivity but the shielding ability of the 
methoxysilane substituent was not sufficient to avoid formation of a second stereoisomer in 
considerable yields. However, introduction of a bulkier group enables enhancement of 
stereoselectivity as it was shown for diene 199. 
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C. Pharmacological results and discussion 
Pharmacological testing was performed at the Institute of Pharmacy in the group of Prof. 
Buschauer, University of Regensburg.  
The binding affinity of the synthesized imidazole compounds (Figure 17, page 42) using [3H]-
N?-methylhistamine and [3H]histamine as radio ligands for the human H3R subtype and 
[3H]histamine for the human H4R subtype was evaluated.  
The compounds, having submicromolar Ki values  were  investigated  for  agonism  or  
antagonism at hH3R and hH4R subtypes in [35S]GTP?S binding assays using membrane 
preparations of Sf9 insect cells co-expressing the hH3R plus G?i2 plus G?1?2 or co-expressing 
the hH4R plus G?i2 plus  G?1?2. In the following agonistic potencies are expressed as EC50 
values. Intrinsic activities (?) refer to the maximal response induced by the standard agonist 
histamine. Compounds identified to be inactive as agonists (? < 0.1 or negative values, 
respectively, determined in the agonist mode) were investigated in the antagonist mode. 
The corresponding KB values of neutral antagonists and inverse agonists were determined 
from the concentration-dependent inhibition of the histamine-induced increase in 
[35S]GTP?S binding. The results are shown in Table 8.  
As expected from the findings of Hashimoto et al. the aminoimidazoles 55a-d exhibited 
significantly stronger binding affinities at the hH3R than at the hH4R. At the hH3R the (6R)-
configured eutomers 55a and 55c showed submicromolar Ki values. Both compounds were 
about  10-fold  more  potent  than  its  (6S)-configured distomers 55b and 55d. At the hH4R 
aminoimidazoles 55a and 55d, having the (3R)-configuration, exhibited weak binding 
affinities with low micromolar Ki values. In contrast to this, the respective (3S)-configured 
epimers 55b and 55c were inactive at this receptor subtype. An unambiguous preference for 
either the folded isomers ((3R,6R)-cis-55a and (3S,6S)-cis-55b) or the extended analogues 
((3S,6R)-trans-55c and (3R,6S)-trans-55d) was not observed at both receptor subtypes. As a 
result, binding affinity at the hH3R were 25, >4, >34 and 3-fold higher for aminoimidazoles 
55a, 55b, 55c and 55d than at the hH4R subtype, respectively. 55a and 55c were investigated 
for their functional activity at the hH3R. In opposite to the aminoimidazoles 53a-d, reported 
by Hashimoto, which all act as full agonists at the receptor subtype, 55a and 55c turned out 
to be almost neutral antagonists with KB values of 181 and 32 nM.   
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The elongated spacer length between the pharmacophoric elements and their different 
spatial arrangement to each other was tolerated to certain extent for the aminoimidazole 
compounds compared to Hashimoto’s THF-based ligands. At both receptor subtypes 
comparable Ki values were observed, especially at the hH3R but the quality of action differs. 
In contrast, the cyanoguanidinoimidazoles 54a-d turned out to be inactive at both the H3R 
and the H4R. In this case, the orientation of the pharmacophoric elements, provided by the 
bicyclic core, was detrimental for receptor binding. An improvement of hH4R affinity by 
displacement of the amino group with a cyanoguanidino moiety - as in the case of 
Hashimoto’s THF-based compounds - was not achieved. (Ki, EC50 and  ? values  of  all  
tetrahydrofuranylimidazoles according to Hashimoto et al., see page 73) 
The synthesized oxazole compounds 56a, 56b, 57a and 57b were investigated in [35S]GTP?S 
functional binding assays but did not reveal any activity at both receptor subtypes. Since 
even oxazole 57a, whose imidazole analogue 55a exhibited submicromolar affinities at the 
hH3R,  was  not  active  at  the  hH3R it can be concluded independently from the other 
structural modifications that an oxazole ring is not a suitable imidazole-bioisoster to improve 
potency and selectivity at the HR subtypes. 
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Figure 22. Overview of all synthesized and pharmacologically tested target molecules. 
Table 8. Potencies, efficacies and affinities of the synthesized amino- and cyanoguanidinoimidazoles and amino- and cyanoguanidinooxazoles at 
the hH3R and hH4R subtypes in the [35S]GTP?S assay[a] or in radioligand binding experiments.[b] 
compound configuration 
hH3R hH4R 
Ki (nM) N KB (nM) ? N  Ki (nM) N KB (nM) ? N 
histamine -  10[c] - - 1 -   16[c] - - 1 - 
55a 3R,6R 231 ± 106 3 181 ± 119 -0.10 2 5787 ± 853 2 nd nd - 
55b 3S,6S 2326 ± 982 2 nd nd - >10000 2 nd nd - 
55c 3S,6R 295 ± 154 2 32 ± 17 -0.12 2 >10000 2 nd nd - 
55d 3R,6S 2818 ± 1823 2 nd nd - 8415 ± 417 2 nd nd - 
54a 3R,6R >10000 2 nd nd - >10000 2 nd nd - 
54b 3S,6S >10000 2 nd nd - >10000 2 nd nd - 
54c 3S,6R >10000 2 nd nd - >10000 2 nd nd - 
54d 3R,6S >10000 2 nd nd - >10000 2 nd nd - 
57a 3R,6R nd - >10000 -0.08 2 nd - >10000   0.02 2 
57b 3S,6S nd - >10000 -0.06 2 nd - >10000   0.13 2 
56a 3R,6R nd - >10000   0.07 2 nd - >10000 -0.03 2 
56b 3S,6S nd - >10000 -0.07 2 nd - >10000 -0.06 2 
[a] [35S]GTP?S functional binding assays with membrane preparations of Sf9 cells expressing the hH3R + G?i2 + G?1?2 or  the  hH4R  +  G?i2 + G?1?2 were performed as described in section 
Pharmacological methods. [b] Displacement of [3H]N?-methylhistamine (3 nM) or [3H]histamine (15 nM) from Sf9 cell membranes expressing the hH3R + G?i2 + G?1?2 or the hH4R + G?i2 + G?1?2 
was determined as described in section Pharmacological methods. [a][b] Reaction mixtures contained ligands at a concentration from 1 nM to 1 mM as appropriate to generate saturated 
concentration/response curves. N gives the number of independent experiments performed in triplicate each. The intrinsic activity (?) of histamine was set to 1.00 and ? values of other 
compounds were referred to this value. The ? values of neutral antagonists and inverse agonists were determined at a concentration of 10 ?M. The KB values of neutral antagonists and inverse 
agonists were determined in the antagonist mode versus histamine (100 nM) as the agonist. [c] Ki values for hH3R and hH4R taken from Smits et al.
218 
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Pharmacological data of imifuamine based compounds 
 
Figure 23. Tetrahydrofuranylimidazoles according to Hashimoto et al.100 
 
Table 9. EC50 values and affinity values of tetrahydrofuranylimidazoles for the hH3R and hH4R according to Hashimoto et al.[a], 100 
compound configuration 
hH3R hH4R 
Ki (nM) EC50 (nM) ? Ki (nM) EC50 (nM) ? 
histamine - 34 4.1 1 - 21 1 
(R)-?-methyl-
histamine - - 0.12 0.85 - 550 1.01 
(imifuramine) 53a  2R,5R 229 45 1.04 891 1995 0.70 
53b 2S,5S 219 105 0.91 12882 30903 0.60 
53c 2S,5R 1698 813 0.95 6457 7585 1.02 
53d 2R,5S 2041 776 1.06 2512 5495 0.88 
(OUP-16) 42a 2R,5R 2188 3162 0.79 126 77 0.99 
42b 2S,5S 18620 >10000 - 20417 21380 1.06 
42c 2S,5R 8128 - <0.1 8128 7586 1.07 
42d 2R,5S 7079 10233 0.43 224 224 1.01 
[a] Ki and EC50 values calculated from the respective pKi and pEC50 values; the EC50 values were determined by the inhibition of the forskolin-stimulated (1 µM) cAMP production, expressing the 
human H3 or H4 receptor. H3-receptor competition binding was performed using [
3H]N?-methylhistamine (1 nM), H4-receptor competition binding was performed using [
3H]histamine (10 nM). 
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D. Summary 
Based on the results of Hashimoto et al.,100 who synthesized imifuramine analogues and 
examined these molecules at the human H3 and H4 receptor, and following the concept of 
stereochemical diversity-oriented conformational restriction the aim of this work was to 
synthesize and investigate related amino- and cyanoguanidinoimidazole compounds 
containing a modified bicyclic core. The preparation of the aminoimidazole compounds 55a 
and 55b and their corresponding epimers 55c and 55d was realized in 15 steps starting from 
commercially available 2-furan carboxylic acid (72). The cyanoguanidino analogues 54a and 
54b and the corresponding epimers 54c and 54d were accomplished in 17 steps (Scheme 
45). The reaction sequence comprised the following key steps: A copper-catalyzed 
asymmetric cyclopropanation furnished both enantiomers of compound 59 depending on 
the stereochemistry of the employed bis(oxazoline) ligand. The imidazole ring was 
introduced by conversion of aldehyde 119 applying TosMIC chemistry. This included partial 
epimerization to result both isomers 121a and 121b. A Mitsunobu-type Gabriel reaction 
afforded phthalimides 133 and 137 which were subsequently cleaved to give the target 
aminoimidazoles 55a-d. The corresponding cyanoguanidines 54a-d were obtained after two 
additional steps. 
Scheme 45. Synthetic route toward imidazole-containing target compounds. 
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Radioligand displacement studies revealed a preference of the aminoimidazole compounds 
for  the  hH3R subtype. Among them, 55a and 55c, having the (6R)-configation, exhibited 
submicromolar Ki values at the hH3R with 10-fold higher affinities than their (6S)-enatiomers 
and 25 and >34-fold selectivity over the hH4R, respectively. Both act as neutral antagonists at 
the hH3R with KB values of 181 and 32 nM, respectively. The cyanoguanidinoimidazole 
analogues 54a-d turned out to be inactive at both the hH3R and the hH4R. 
In  addition,  it  was  aimed  to  synthesize  oxazole  analogues  as  potential  bioisosteres  and  to  
investigate their pharmacological properties at the H3R and H4R subtypes. The preparation of 
aminooxazole 57 succeeded in 10 steps, the cyanoguanidine derivative 56 was performed in 
12  steps  starting  from  2-furan  carboxylic  acid  (72)  (Scheme  46).  The  oxazole  ring  was  
prepared by transforming aldehyde 83 into compound 142 using  TosMIC  chemistry.  As  
expected, epimerisation was not observed under these conditions giving rise to the trans-
configured target molecules exclusively.  
Scheme 46. Synthetic route toward oxazole-containing target compounds. 
  
All four synthezised oxazole-containing target molecules were inactive at both the hH3R and 
hH4R  in  [35S]GTP?S functional binding assays. Hence, discplacement of imidazole with an 
oxazole moiety could not contribute to an improvement of potency and selectivity at the 
histamine receptor subtypes. 
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The Mitsunobu-type Gabriel reaction was part of a number of different reaction sequences 
within this work introducing a phthalimide function as shown exemplarily for alcohol 116 in 
Scheme  47.  Apart  from  the  desired  SN2-product 138 additional ring-opening structures 
emerged as a result of a cyclopropylcarbinyl-homoallylic rearrangement. 
Scheme 47. Mitsunobu-type Gabriel reaction. 
 
 
The chiral oxacyclic diene 153 was regarded as a valuable substrate for Diels-Alder reactions 
to build up polycyclic scaffolds. For that reason, several procedures were tested to enhance 
the dehydration of alcohol 116. Best results were obtained by a cycloelimination reaction 
using EDC and CuCl2 in MeCN (Scheme 48). 
Scheme 48. Dehydration of alcohol 116 to diene 153. 
O H
H
TBSO OH
O
TBSO
116 153
EDC (2 equiv)
CuCl2 (2 equiv)
MeCN, rt, 0.5 h
62%
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Furanyldiene ent-153 was applied to a Diels-Alder reaction with N-phenyl maleimide (202) to 
accomplish the tricyclic compounds 206a and 206b in  good  combined  yield  (Scheme  49).  
However, the shielding ability of the methoxysilane substituent was less effective compared 
to a dioxolane group reported in the literature resulting in a moderate selectivity for endo-
cycloadduct 206a. 
Scheme 49. Diels-Alder reaction of diene 153. 
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E. Experimental 
General 
All reactions were carried out in oven dried glassware under atmospheric conditions unless 
otherwise stated. Commercially available chemicals were used as received, without any 
further purification. The following solvents and reagents were purified prior to use: 
Dichloromethane (DCM) was distilled from CaCl2 and stored over molecular sieves (4 Å). 
Ethanol  (EtOH)  and  methanol  (MeOH)  were  distilled  from  magnesium  and  stored  over  
molecular sieves (3 Å). 1,2-Dimethoxyethane (DME) and tetrahydrofuran (THF) were distilled 
from sodium wire. Benzene and toluene were dried with CaH2, distilled and stored over 
sodium wire. Dimethylformamide (DMF) and dimethyl sulfoxide (DMSO) were dried with 
CaH2, distilled and stored over molecular sieves (4 Å). Ethyl acetate (EA) and hexanes (PE) for 
chromatographic separations were distilled prior to use. Millipore water was used 
throughout for the preparation of buffers and HPLC eluents. Benzyl bromide, ethyl 
chloroformate, oxalyl chloride, cyclohexen, benzylamine and dichloroacetyl chloride were 
distilled prior to use. Triethylamine and pyridine were distilled from KOH.  
Chromatography 
Analytical thin layer chromatography was performed on Merck TLC aluminium sheets silica 
gel 60 F254. Visualization was accomplished with UV light (? = 254 nm). Vaniline, ninhydrin, 
mostain and permanganate solutions followed by heating or iodine were used for staining. 
Liquid chromatography was performed using Merck silica gel 60 (0.063 - 0.200 mm) and flash 
silica gel 60 (0.040 - 0.063 mm). 
NMR-Spectroscopy  
1H- and 13C-NMR spectra were recorded on a Bruker Avance 300 (300 MHz for 1H, 75 MHz 
for 13C), Bruker Avance III 400 “Nanobay” (400 MHz for 1H, 101 MHz for 13C) or Avance III 600 
(600 MHz for 1H, 151 MHz for 13C) FT-NMR-Spectrometer at ambient temperature. Data are 
given  as follows for 1H-NMR: Chemical shift in ppm from internal CHCl3 (7.27 ppm) or CH3OH 
(3.31 ppm) as standard on the ? scale,  multiplicity  (br  = broad,  s  =  singlet,  d  = doublet,  t  =  
triplet, q = quartet, dd = doublet of doublet, ddd = doublet of doublet of doublet, dt = 
doublet of triplet, qd = quartet of doublet, sept = septet and m = multiplet), integration and 
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coupling constant (Hz). Data are as follows for 13C-NMR: Chemical shift in ppm from internal 
CHCl3 (77 ppm) or CH3OH (49 ppm) as standard on the ? scale. The 13C signals were assigned 
with DEPT-135: “+” (primary or tertiary carbon, positive intensity in DEPT-135), 
“-“ (secondary carbon, negative intensity in DEPT-135), “Cq” (quaternary carbon, zero 
intensity in DEPT-135). 
Mass spectrometry 
Mass spectrometry was performed using Varian MAT 311A, Finnigan MAT 95, Thermoquest 
Finnigan  TSQ  7000  or  Agilent  Technologies  6540  UHD  Accurate-Mass  Q-TOF  LC/MS  at  the  
analytical department of the University of Regensburg. The percentage set in brackets gives 
the peak intensity related to the basic peak (I = 100%). High resolution mass spectrometry 
(HRMS): The molecular formula was proven by the calculated precise mass. 
IR spectroscopy 
ATR-IR spectroscopy was carried out on a Biorad Excalibur FTS 3000 spectrometer, equipped 
with a Specac Golden Gate Diamond Single Reflection ATR-System. 
Optical rotation 
Optical rotations were measured on a P8000T polarimeter (Kruess) at a wavelength of 
589 nm in a 5 cm cell of 0.7 mL volume in the specified solvent. Concentrations are indicated 
in [g/100 mL] 
Elemental analysis 
Elemental  analysis  was  performed  by  the  analytical  department  of  the  University  of  
Regensburg using a Vario EL III or Mikro Rapid CHN (Heraeus). 
Melting points 
The melting points were measured on a Büchi SMP-20 apparatus in a silicon oil bath. Values 
thus obtained were not corrected. 
Lyophilisation 
Lyophilisation was done with a Christ alpha 2-4 LD equipped with a vacuubrand RZ 6 rotary 
vane vacuum pump. 
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HPLC 
Preparative HPLC was performed at room temperature with a system from Knauer (Berlin, 
Germany) consisting of two K-1800 pumps, a K-2001 detector (UV detection at 220 nm) and 
a RP-column (VP Nucleodur 100-5 C18 ec, 250 x 21 mm, 5 ?m, Macherey Nagel, Düren, 
Germany) at a flow rate of 15 mL/min or a RP-column (YMC-Triat C18, 150 x 20.0 m, 5 µm, 
YMC Europe GmbH Dinslaken, Germany) at a flow rate of 10 mL/min. Mixtures of 
acetonitrile and 0.1% aq. TFA were used as mobile phase in case of the Nucleodur column 
and  mixtures  of  acetonitrile  and  0.1%  aq.  NH3 were  used  as  mobile  phase  in  case  of  the  
YMC-Triat column. Acetonitrile was removed from the eluates under reduced pressure (final 
pressure: 90 mbar) at 45 °C prior to lyophilization. 
Analytical HPLC analysis was performed with a system from Merck (Darmstadt, Germany), 
composed of a L-5000 controller, a 655A-12 pump, a 655A-40 autosampler and a L-4250 UV-
VIS detector on a Eurospher-100 C18 column (250 × 4 mm, 5 ?m, Knauer, Berlin, Germany) 
at  a  flow  rate  of  0.8  mL/min.  Mixtures  of  acetonitrile  and  0.05  %  aq.  TFA  were  used  as  
mobile phase. Helium degassing was used throughout. 
Compound purities were calculated as the percentage peak area of the analyzed compound 
by  UV  detection  at  210  nm.  HPLC  conditions,  retention  times  (tR), capacity factors 
(k’ = (tR - t0)/t0) and purities of the synthesized compounds are listed in the appendix. 
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Syntheses of literature-known compounds and reagents 
2,2-Dimethylmalonyl dichloride (68),219 (S)-2-amino-3-methylbutan-1-ol  (69),219 N1,N3-
bis((S)-1-hydroxy-3-methylbutan-2-yl)-2,2-dimethylmalonamide (70),131 (4S,4'S)-2,2'-
(propane-2,2-diyl)bis(4-isopropyl-4,5-dihydrooxazole)   (71),131 ethyl 2-diazoacetate (75),132 
(1S,5S,6S)-6-ethyl 3-methyl 2-oxabicyclo[3.1.0]hex-3-ene-3,6-dicarboxylate (59),115,128 
(1S,3R,5S,6S)-6-ethyl 3-methyl 2-oxabicyclo[3.1.0]hexane-3,6-dicarboxylate (78),140 
(1S,3R,5S,6S)-6-(ethoxycarbonyl)-2-oxabicyclo[3.1.0]hexane-3-carboxylic acid (82),141 
(1S,5S,6S)-6-(ethoxycarbonyl)-2-oxabicyclo[3.1.0]hex-3-ene-3-carboxylic acid (81),141 Dess-
Martin periodinane,144 N-sulfinyl p-toluenesulfonamide.166 
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Syntheses 
1-(((1S,3R,5S,6R)-3-(1H-imidazol-5-yl)-2-oxabicyclo[3.1.0]hexan-6-yl)methyl)-2-cyano-3-
methylguanidine (54a) 
 
 
 
A solution of compound 55a (5.0  mg,  0.028  mmol)  and  dimethyl  
N-cyanodithioiminocarbonate (9.9 mg, 0.067 mmol, 2.4 equiv) in anhydrous MeOH (0.55 mL) 
was stirred at room temperature for 18 h. Then a 33% solution of MeNH2 in EtOH (0.52 mL) 
was added and stirred for 18 h at room temperature. The solvent was evaporated to give a 
residual oil that was purified by column chromatography (EA/MeOH 4:1) to give compound 
54a (5.0 mg, 0.019 mmol, 69%) as a colorless oil. For pharmacological testing the product 
was further purified by preparative HPLC (YMC-Triat column, mobile phase: MeCN, 0.1% aq. 
NH3). 
Rf = 0.19 (EA/MeOH 4:1); [?]??? = + 18.2 (MeOH, c = 0.2); 1H-NMR (300 MHz, MeOD): ?H = 
7.62 (d, J = 1.0 Hz, 1H), 6.96 (s, 1H), 5.38 (t, J = 7.9 Hz, 1H), 3.89 (dd, J = 6.4, 1.1 Hz, 1H), 3.05 
(dd, J = 14.3, 6.9 Hz, 1H), 2.91 (dd, J = 14.3, 7.9 Hz, 1H), 2.79 (s, 3H), 2.55 (dt, J = 12.8, 7.4 Hz, 
1H), 2.06 (ddd, J = 12.8, 8.1, 1.9 Hz, 1H), 1.74 - 1.63 (m, 1H), 1.46 - 1.36 (m, 1H); 13C-NMR 
(75 MHz, MeOD): ?C = 161.96 (Cq), 140.02 (Cq), 136.79 (+), 120.08 (Cq), 117.42 (+), 83.90 (+), 
65.43 (+), 42.58 (-), 36.41 (-), 33.19 (+), 28.67 (+), 24.09 (+); IR (ATR): ? (cm-1) = 3268 (br), 
2928, 2160, 1729, 1575, 1485, 1448, 1404, 1369, 1247, 1174, 1097, 1066, 1030, 988, 838, 
752, 716, 618, 570; MS (ESI): m/z (%) = 163.1 [M+?C3H5N4] (60), 261.1 [MH+] (100); 
HRMS (ESI): calcd for C12H17N6O [MH+] 261.1458, found 261.1458. 
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1-(((1S,3S,5S,6R)-3-(1H-imidazol-5-yl)-2-oxabicyclo[3.1.0]hexan-6-yl)methyl)-2-cyano-3-
methylguanidine (54c) 
 
 
 
A solution of compound 55c (3.0  mg,  0.017  mmol)  and  dimethyl  
N-cyanodithioiminocarbonate (8.2 mg, 0.05 mmol, 3.0 equiv) in anhydrous MeOH (0.34 mL) 
was stirred at room temperature for 18 h. Then a 33% solution of MeNH2 in EtOH (0.31 mL) 
was added. The resulting mixture was stirred for 18 h at room temperature. The solvent was 
evaporated to give a residual oil that was purified by column chromatography (EA/MeOH 
4:1) to give compound 55c (2.8 mg, 0.011 mmol, 64%) as a colorless oil. For pharmacological 
testing the product was further purified by preparative HPLC (YMC-Triat column, mobile 
phase: MeCN, 0.1% aq. NH3). 
Rf = 0.20 (MeOH/saturated NH3 in MeOH 95:5); [?]??? =  +  36.7  (MeOH,  c  =  0.1);  1H-NMR 
(600 MHz, MeOD): ?H = 7.62 (s, 1H), 7.00 (s, 1H), 4.76 (dd, J = 8.7, 7.7 Hz, 1H), 3.94 (dd, J = 
5.7, 1.1 Hz, 1H), 3.07 (dd, J = 14.3, 6.9 Hz, 1H), 2.97 (dd, J = 14.3, 7.7 Hz, 1H), 2.81 (s, 3H), 
2.29 (dd, J = 12.4, 7.1 Hz, 1H), 2.25 - 2.19 (m, 1H), 1.62 - 1.59 (m, 1H), 1.59 - 1.54 (m, 1H); 
13C-NMR (151 MHz, MeOD): ?C = 162.01 (Cq), 136.88 (+), 120.08 (Cq), 63.74 (+), 49.57 (+), 
42.71 (-), 35.51 (-), 28.69 (+), 22.28 (+), 21.94 (+), Im-C5 and Im-C4 signals  too weak to be 
observed; IR (ATR): ? (cm-1) = 2934 (br), 2163, 1582, 1486, 1410, 1372, 1322, 1175, 1121, 
1100, 922, 892, 833, 689, 617; MS (ESI): m/z (%) = 261.1 [MH+] (100), 521.2 [2MH+] (15); 
HRMS (ESI): calcd for C12H17N6O [MH+] 261.1458, found 261.1457.  
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((1S,3R,5S,6R)-3-(1H-imidazol-5-yl)-2-oxabicyclo[3.1.0]hexan-6-yl)methanamine (55a) 
 
 
 
A solution of phthalimide 133 (30  mg,  0.079  mmol)  and  hydrazine  hydrate  (21  µL,  
0.43  mmol,  5.4  equiv)  in  anhydrous  EtOH  (1.6  mL)  was  refluxed  for  1  h.  The  solvent  was  
removed under reduced pressure and the residue was purified by column chromatography 
(MeOH/saturated NH3 in MeOH 95:5) to afford compound 55a (11 mg, 0.061 mmol, 77%) as 
a colorless amorphous solid. For pharmacological testing the product was further purified by 
preparative HPLC (Nucleodur column, mobile phase: MeCN, 0.1% aq. TFA). 
Rf = 0.20 (MeOH/saturated NH3 in MeOH 95:5); [?]??? =  +  36.4  (MeOH,  c  =  0.5);  1H-NMR 
(300 MHz, MeOD): ?H = 7.61 (d, J = 1.0 Hz, 1H), 6.95 (s, 1H), 5.38 (t, J = 7.9 Hz, 1H), 3.82 (dd, 
J = 6.4, 1.2 Hz, 1H), 2.63 - 2.49 (m, 1H), 2.38 (d, J = 7.3 Hz, 2H), 2.04 (ddd, J = 12.7, 8.0, 1.9 Hz, 
1H), 1.61 (tdd, J = 6.2, 3.9, 1.9 Hz, 1H), 1.26 (tdd, J = 7.4, 4.0, 1.1 Hz, 1H); 13C-NMR (75 MHz, 
MeOD): ?C = 136.71 (+), 117.55 (+), 83.87 (+), 65.46 (+), 42.61 (-), 36.63 (-), 36.07 (+), 23.99 
(+), Im-Cq-signal too weak to be observed; IR (ATR): ? (cm-1) = 3094 (br), 2937, 2869, 2625, 
1573, 1454, 1414, 1361, 1306, 1177, 1098, 1067, 1028, 980, 912, 841, 632, 540, 497; 
MS (ESI): m/z (%) = 163.1 (100) [MH+?NH3], 180.1 (19) [MH+], 359.2 (11) [2MH+]; HRMS (ESI): 
calcd for C9H14N3O [MH+] 180.1131, found 180.1130. 
55a•2TFA: 1H-NMR (600 MHz, MeOD): ?H = 8.83 (d, J = 1.0 Hz, 1H), 7.45 (s, 1H), 5.51 (t, J = 
7.4 Hz, 1H), 4.10 (dd, J = 6.3, 0.7 Hz, 1H), 2.90 - 2.63 (m, 3H), 2.14 (ddd, J = 13.1, 7.0, 1.5 Hz, 
1H), 1.92 - 1.87 (m, 1H), 1.31 - 1.26 (m, 1H); 13C-NMR (151 MHz, MeOD): ?C = 163.10 (Cq, 
TFA), 162.87 (Cq, TFA), 136.63 (+), 135.90 (Cq), 119.17 (+, TFA), 117.23 (+, TFA), 116.76 (+), 
79.55 (+), 65.65 (+), 40.61 (-), 35.88 (-), 29.34 (+), 24.45 (+). 
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((1S,3S,5S,6R)-3-(1H-imidazol-5-yl)-2-oxabicyclo[3.1.0]hexan-6-yl)methanamine (55c) 
 
O H
H
NH2
NH
N
 
 
A solution of phthalimide 137 (16  mg,  0.042  mmol)  and  hydrazine  hydrate  (11  µL,  
0.23 mmol, 5.4 equiv) in anhydrous EtOH (0.85 mL) was refluxed for 1.5 h. The solvent was 
removed under reduced pressure and the residue was purified by column chromatography 
(MeOH/saturated NH3 in MeOH 97:3) to afford compound 55c (5.1 mg, 0.028 mmol, 68%) as 
a colorless amorphous solid. For pharmacological testing the product was further purified by 
preparative HPLC (Nucleodur column, mobile phase: MeCN, 0.1% aq. TFA). 
55c•2TFA: Rf =  0.20  (MeOH/saturated  NH3 in MeOH 95:5); [?]??? =  +  5.5  (DCM,  c  =  0.2);  
1H-NMR (600 MHz, MeOD): ?H = 8.88 (d, J = 1.3 Hz, 1H), 7.50 (d, J = 0.9 Hz, 1H), 4.94 (dd, J = 
8.9, 7.5 Hz, 1H), 4.14 (dd, J = 5.8, 1.2 Hz, 1H), 2.82 (dd, J = 13.4, 8.0 Hz, 1H), 2.77 (dd, J = 13.4, 
7.8 Hz, 1H), 2.51 (dd, J = 12.7, 7.4 Hz, 1H), 2.22 (ddd, J = 12.8, 9.1, 5.6 Hz, 1H), 1.83 - 1.79 (m, 
1H), 1.56 (tdd, J = 7.9, 3.9, 1.1 Hz, 1H).13C-NMR (151 MHz, MeOD): ?C = 162.80 (Cq, TFA), 
162.56 (Cq, TFA), 136.08 (Cq), 134.59 (+), 119.04 (+, TFA), 117.45 (+), 117.11 (+, TFA), 72.81 
(+), 64.08 (+), 40.76 (-), 35.51 (-), 22.52 (+), 20.51 (+); IR (ATR): ? (cm-1) = 3240 (br), 2935, 
2873, 2627, 1580, 1492, 1420, 1372, 1312, 1180, 1101, 899, 840, 630, 540; MS (ESI): 
m/z (%) = 180.0 (100) [MH+], 359.2 (20) [2MH+];  HRMS  (ESI):  calcd  for  C9H14N3O [MH+] 
180.1131, found 180.1133. 
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2-cyano-1-methyl-3-(((1S,3R,5S,6R)-3-(oxazol-5-yl)-2-oxabicyclo[3.1.0]hexan-6-yl)methyl) 
guanidine (56a) 
 
 
 
Compound 145 (26 mg, 0.09 mmol) was dissolved in a 33% solution of MeNH2 in EtOH (2 ml) 
and stirred for 18 h at room temperature. The solvent was evaporated under reduced 
pressure. Purification by column chromatography (DCM then DCM/MeOH 9:1) afforded 
compound 56a (22 mg, 0.08 mmol, 90%) as a colorless oil. 
Rf = 0.32 (DCM/MeOH 9:1); [?]????= + 18.9 (DCM, c = 1.0); 1H-NMR (400 MHz,  CDCl3): ?H = 
7.84 (s, 1H), 6.96 (s, 1H), 5.64 (s, 1H), 5.43 (dd, J = 8.3, 7.4 Hz, 1H), 5.20 (s, 1H), 3.95 (dd, J = 
6.3, 1.0 Hz, 1H), 3.24 - 3.13 (m, 1H), 2.95 - 2.86 (m, 1H), 2.85 (d, J = 4.9 Hz, 3H), 2.62 (ddd, J = 
13.1, 8.6, 7.0 Hz, 1H), 2.14 (ddd, J = 13.1, 7.0, 1.4 Hz, 1H), 1.73 - 1.67 (m, 1H), 1.37 (tdd, J = 
8.0, 4.0, 1.0 Hz, 1H); 13C-NMR (101 MHz, CDCl3): ?C = 160.65 (Cq), 151.72 (Cq), 151.44 (+), 
124.01 (+), 118.53 (Cq), 78.46 (+), 65.08 (+), 42.03 (-), 33.91 (-), 30.74 (+), 28.57 (+), 23.15 (+); 
IR (ATR): ? (cm-1) = 3292 (br), 2954, 2929, 2165, 1583, 1507, 1453, 1409 1370, 1174, 1103, 
1028, 963, 838, 717; MS (ESI): m/z (%) = 262.1 (25) [MH+], 523.2 (100) [2MH+]; HRMS (EI): 
calcd for C12H15N5O2 [M+•] 261.1226, found 261.1222.  
 
((1S,3R,5S,6R)-3-(oxazol-5-yl)-2-oxabicyclo[3.1.0]hexan-6-yl)methanamine (57a) 
 
 
 
A solution of phthalimide 144 (60 mg, 1.19 mmol) and hydrazine hydrate (48 mg, 0.97 mmol, 
5  equiv)  in  EtOH  (4  mL)  was  refluxed  for  1.5  h  and  then  cooled  in  an  ice  bath.  The  white  
precipitate was removed by filtration through a Celite pad. The filtrate was concentrated in 
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vacuo. Column chromatography (DCM/saturated NH3 in MeOH 20:1) afforded compound 
57a (25 mg, 0.10 mmol, 72%) as a colorless solid.  
mp = 51 °C; Rf =  0.32  (DCM/saturated  NH3 in MeOH 9:1); [?]??? =  +  36.2  (DCM,  c  =  1.0);  
1H-NMR (400 MHz, CDCl3): ?H = 7.80 (s, 1H), 6.93 (s, 1H), 5.41 (dd, J = 8.1, 7.4 Hz, 1H), 3.82 
(dd, J = 6.3, 1.2 Hz, 1H), 2.58 (ddd, J = 12.9, 8.6, 7.0 Hz, 1H), 2.51 - 2.39 (m, 2H), 2.11 (ddd, J = 
12.9, 6.9, 1.5 Hz, 1H), 1.59 - 1.51 (m, 1H), 1.28 - 1.22 (m, 1H), 1.25 (br s, 2H); 13C-NMR (75 
MHz, CDCl3): ?C = 152.16 (Cq), 151.25 (+), 123.68 (+), 78.37 (+), 65.19 (+), 42.33 (-), 34.78 (-), 
34.12 (+), 22.68 (+); IR (ATR): ? (cm-1) = 3356 (br), 3127, 2949, 1636, 1567, 1508, 1482, 1427, 
1377, 1318, 1380, 1103, 1027, 980, 955, 849, 723, 646, 610; MS (ESI): m/z (%) = 181.0 (7) 
[MH+], 222.0 (100) [MH+MeCN]; HRMS (ESI): calcd for C9H13N2O2 [MH+] 181.0972, found 
181.0969. 
 
(1S,3R,5S,6S)-ethyl 3-(hydroxymethyl)-2-oxabicyclo[3.1.0]hexane-6-carboxylate (79) 
(1S,3R,5S,6R)-2-oxabicyclo[3.1.0]hexane-3,6-diyldimethanol (80) 
 
 
 
Method A: To a stirred ice-cooled solution of compound 82 (2.25 g, 11.3 mmol) in anhydrous 
THF (110 mL) under a nitrogen atmosphere borane-dimethyl sulfide complex (1.7 mL, 10 M 
in DMS, 17 mmol, 1.5 equiv) was added dropwise. Hydrogen evolved during the course of 
addition.  The  resulting  solution  was  stirred  for  4  h  and  allowed  to  warm  to  room  
temperature. The solution was quenched with MeOH (5 mL) and stirred overnight. After 
solvent  evaporation  the  mixture  was  treated  with  MeOH  (5  mL)  and  the  solvent  was  
evaporated once again. Purification of the crude product by column chromatography 
(PE/EA 1:1) afforded compound 79 (1.62 g, 8.72mmol, 77%) as a colorless oil. 
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Method B: To a stirred ice-cooled solution of 78 (2.45 mg, 11.4 mmol) in anhydrous THF 
(45 mL) under a nitrogen atmosphere, a suspension of LAH (260 mg, 6.87 mmol, 0.6 equiv) in 
anhydrous THF (5 mL) was added dropwise within 10 min. The reaction mixture was stirred 
for  45  min  at  0  °C.  After  dropwise  addition  of  water  (260  µL)  the  mixture  was  stirred  for  
another 30 min. Then a 15% NaOH solution (260 µL) was added followed by water (780 µL). 
The mixture was warmed to room temperature, treated with MgSO4 and filtered through a 
Celite pad. The solvent was evaporated under reduced pressure. The crude product was 
purified by chromatography (PE/EA 1:1) to obtain compound 79 (1.85 g, 9.94 mmol, 87%) 
and compound 80 (82 mg, 0.57 mmol, 5%) as colorless oils. 
79: Rf = 0.34 (PE/EA 1:1), 0.49 (EA); [?]??? = + 63.7 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): 
?H = 4.60 - 4.50 (m, 1H), 4.18 (d, J = 5.9 Hz, 1H), 4.07 (q, J = 7.1 Hz, 2H), 3.58 (ddd, J = 11.9, 
6.0, 3.2 Hz, 1H), 3.41 - 3.31 (m, 1H), 2.37 (ddd, J = 13.1, 8.8, 7.0 Hz, 1H), 2.26 - 2.11 (m, 1H), 
2.14 (br s, 1H), 1.81 (ddd, J = 13.1, 7.7, 1.1 Hz, 1H), 1.72 (dd, J = 3.8, 0.8 Hz, 1H), 1.22 (t, J = 
7.1 Hz, 3H).; 13C-NMR (75 MHz, CDCl3): ?C = 170.50 (Cq), 87.00 (+), 67.37 (+), 64.91 (-), 60.59 
(-), 33.39 (+), 30.31 (-), 27.56 (+), 14.33 (+); IR (ATR): ? (cm-1) = 3460 (br), 2978, 2939, 2880, 
1713, 1454, 1407, 1386, 1309, 1269, 1175, 1111, 1074, 1048, 980, 878, 851, 808, 712; MS 
(ESI): m/z (%) = 186.9 (40) [MH+], 228.0 (100) [MH+MeCN], 373.1 (40) [2MH+], 390.0 (30) 
[2MNH4+]; HRMS (ESI): calcd for C9H15O4 [MH+] 187.0965, found 187.0966. 
Labile 80 was analytically characterized as diprotected compound 115 (see page 99).  
 
(1S,3R,5S,6S)-ethyl 3-formyl-2-oxabicyclo[3.1.0]hexane-6-carboxylate (83) 
 
 
 
Method A: To a stirred solution of oxalyl chloride (746 µL, 8.70 mmol, 1.5 equiv) in 
anhydrous DCM (17 mL) under a nitrogen atmosphere at -78 °C a solution of DMSO (1.03 mL, 
14.5  mmol,  2.5  equiv)  in  anhydrous  DCM  (7  mL)  was  added.  After  15  min,  a  solution  of  
alcohol 79 (1.08 mg, 5.80 mmol) in anhydrous DCM (34 mL) was added dropwise over a 
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period of  20 min at.  After  stirring for  15 min at  -78 °C,  NEt3 (4.02 mL, 29.0 mmol, 5 equiv) 
was  added  and  further  stirred  for  10  min  at  -78  °C.  The  reaction  mixture  was  warmed  to  
room temperature and stirred for another 30 min. Water (50 mL) was added to quench the 
reaction, the layers were separated and the aqueous phase was extracted with DCM 
(1 x 25 mL). The organic phases were washed with brine, 1% aqueous H2SO4 solution, water 
and 5% aqueous NaHCO3 solution (1 x 50 mL each) and dried over MgSO4. The solvent was 
evaporated in vacuo. Purification by column chromatography (PE/EA 1:1) afforded 
compound 83 (694 mg, 3.77 mmol, 65%) as a yellowish oil. 
Method B: Dess-Martin periodinane (4.24 g, 10.0 mmol, 1.05 equiv) was added to a solution 
of alcohol 79 (1.77 g, 9.52 mmol) in DCM (95 mL) at room temperature and stirred for 1 h. 
After completion the reaction was quenched with a mixture of saturated aqueous Na2S2O3 
solution (50 mL) and saturated aqueous NaHCO3 solution (50 mL). The mixture was stirred 
for 15 min, afterwards the organic layer was separated and the aqueous layer was extracted 
with  DCM  (2  x  50  mL).  The  combined  organic  layers  were  washed  with  brine  (1  x  50  mL),  
dried over MgSO4 and evaporated in vacuo. The crude product was purified by 
chromatography (PE/EA 1:1) to give compound 83 (1.54 mg, 8.37 mmol, 88%) as a yellowish 
oil. 
Rf = 0.31 (PE/EA 1:1); [?]??? = + 44.8 (DCM, c = 0.5); 1H-NMR (300 MHz, CDCl3): ?H = 9.59 (s, 
1H), 4.64 (dd, J = 10.6, 3.8 Hz, 1H), 4.34 (dd, J = 5.7, 0.8 Hz, 1H), 4.08 (q, J = 7.1 Hz, 2H), 2.51 
(ddd, J = 13.4, 10.6, 5.7 Hz, 1H), 2.36 (dd, J = 13.3, 3.9 Hz, 1H), 2.20 (td, J = 5.5, 3.9 Hz, 1H), 
1.46 (dd, J = 3.8, 1.0 Hz, 1H), 1.23 (t, J = 7.1 Hz, 3H), 1.26 - 1.19 (m, 1H); 13C-NMR (75 MHz, 
CDCl3): ?C = 203.36 (+), 170.20 (Cq), 85.29 (+), 67.22 (+), 60.85 (-), 30.26 (-), 27.54 (+), 25.21 
(+), 14.31 (+); IR (ATR): ? (cm-1) = 3435 (br), 2984, 1712, 1451, 1411, 1385, 1323, 1298, 1273, 
1177, 1107, 1051, 1035, 976, 926, 870, 849, 796, 749, 702; MS (CI): m/z (%) = 185.0 (15) 
[MH+], 202.1 (100) [MNH4+]; HRMS (ESI): calcd for C9H13O4 [MH+] 185.0808, found 185.0808. 
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(1S,5S,6S)-ethyl 3-(hydroxymethyl)-2-oxabicyclo[3.1.0]hex-3-ene-6-carboxylate (98) 
 
 
 
To a stirred ice-cooled solution of compound 59 (1.09 g, 5.14 mmol) in anhydrous THF 
(20 mL) under a nitrogen atmosphere, a suspension of LAH (118 mg, 3.11 mmol, 0.6 equiv) in 
anhydrous THF (5 mL) was added dropwise within 10 min. The reaction mixture was stirred 
for 1 h at 0 °C. After dropwise addition of water (118 µL) the mixture was stirred for another 
30  min.  Then  15%  NaOH  solution  (118  µL)  was  added  followed  by  water  (354  µL).  The  
mixture was warmed to room temperature, treated with MgSO4 and filtered through a Celite 
pad. The solvent was evaporated under reduced pressure. The crude product was purified by 
column  chromatography  (PE/EA  3:1  to  1:1)  to  obtain  compound  98 (744  mg,  4.04  mmol,  
79%) as a colorless oil. 
Rf = 0.34 (PE/EA 1:1); [?]??? = - 103.3 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H = 5.37 (dt, 
J = 2.6, 0.9 Hz, 1H), 4.84 (dd, J = 5.6, 1.0 Hz, 1H), 4.11 (q, J = 7.1 Hz, 2H), 4.08 (d, J = 1.0 Hz, 
2H), 2.76 (m, 1H), 2.22 (br s, 1H), 1.24 (t, J = 7.1 Hz, 3H), 1.04 (dd, J = 2.6, 1.0 Hz, 1H); 
13C-NMR (75 MHz, CDCl3): ?C = 172.88 (Cq), 159.31 (Cq), 102.83 (+), 67.27 (+), 60.77 (-), 57.37 
(-), 31.99 (+), 22.65 (+), 14.27 (+); IR (ATR): ? (cm-1) = 3438 (br), 2983, 2940, 2874, 1710, 
1650, 1446, 1400, 1379, 1331, 1289, 1268, 1177, 1084, 1041, 1004, 921, 884, 831, 727; MS 
(CI): m/z (%) = 185.1 (10) [MH+], 202.1 (100) [MNH4+]. 
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(1S,5S,6S)-ethyl 3-formyl-2-oxabicyclo[3.1.0]hex-3-ene-6-carboxylate (99) 
 
 
 
Dess-Martin periodinane (257 mg, 0.61 mmol, 1.06 equiv) was added to a solution of alcohol 
98 (105  mg,  0.57  mmol)  in  DCM  (11  mL)  at  room  temperature  and  stirred  for  1.5  h.  After  
completion the reaction was quenched with a mixture of saturated aqueous Na2S2O3 
solution (20 mL) and saturated aqueous NaHCO3 solution (20 mL). The obtained mixture was 
stirred for 15 min, then the organic layer was separated and the aqueous layer was 
extracted with DCM (2 x 15 mL). The combined organic layers were washed with brine 
(15 mL), dried over MgSO4 and evaporated in vacuo. The crude product was purified by 
column chromatography (PE/EA 3:1) to give compound 99 (50 mg, 0.27 mmol, 49%) as a 
yellowish oil. 
Rf = 0.40 (PE/EA 1:1); [?]??? = - 133.0 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H = 9.36 (d, 
J = 0.5 Hz, 1H), 6.46 (d, J = 3.0 Hz, 1H), 4.99 (ddd, J = 5.1, 1.1, 0.5 Hz, 1H), 4.14 (q, J = 7.1 Hz, 
2H), 2.91 (dt, J = 5.1, 3.0 Hz, 1H), 1.24 (t, J =  7.1  Hz,  3H),  1.18  (dd,  J = 2.8, 1.1 Hz, 1H); 
13C-NMR (75 MHz, CDCl3): ?C = 180.43 (+), 171.39 (Cq), 156.99 (Cq), 123.44 (+), 67.84 (+), 
61.32 (-), 31.97 (+), 22.33 (+), 14.24 (+); IR (ATR): ? (cm-1) = 3102, 2986, 1716, 1692, 1599, 
1402, 1376, 1290, 1270, 1182, 1153, 1084, 1042, 996, 913, 827, 759, 731; MS (EI): m/z (%) = 
53.1 (32), 81.1 (30), 97.0 (52), 109.0 (100) [M+?CO2Et], 125.0 (38), 153.0 (61) [M+?CHO], 
182.0 (6) [M+•]; HRMS (EI): calcd for C9H10O4 [M+•] 182.0579, found 182.0583. 
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(1S,3R,5S,6S)-ethyl 3-((benzylimino)methyl)-2-oxabicyclo[3.1.0]hexane-6-carboxylate (102) 
 
O
CO2Et
H
H
H
N
 
 
To a solution of aldehyde 83 (105  mg,  0.57  mmol)  in  anhydrous  DCM  (5  mL)  was  added  
MgSO4 and the mixture was stirred for 15 min at room temperature under a nitrogen 
atmosphere. After addition of benzylamine (63 mg, 0.059 mmol, 1.03 equiv) the reaction 
mixture was refluxed for 1.5 h and then cooled to room temperature. Filtration and 
evaporation of the solvent under reduced pressure afforded crude 102 as a colorless oil. 
Rf = 0.31 (PE/EA 1:1); [?]??? = + 30.3 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H = 7.67 (dt, 
J = 3.5, 1.4 Hz, 1H), 7.37 - 7.20 (m, 5H), 4.97 - 4.88 (m, 1H), 4.59 (s, 2H), 4.27 (dd, J = 5.7, 
0.9 Hz, 1H), 4.08 (q, J = 7.1 Hz, 2H), 2.54 (ddd, J = 13.3, 9.6, 6.1 Hz, 1H), 2.35 (ddd, J = 13.3, 
4.9, 0.5 Hz, 1H), 2.23 (tdd, J = 6.1, 3.9, 0.8 Hz, 1H), 1.67 (dd, J = 3.8, 1.0 Hz, 1H), 1.24 (t, J = 
7.1 Hz, 3H); 13C-NMR (101 MHz, CDCl3): ?C = 170.46 (Cq), 166.61 (+), 138.51 (Cq), 128.66 (+), 
128.05 (+), 127.24 (+), 83.65 (+), 67.23 (+), 64.59 (-), 60.56 (-), 32.05 (-), 29.79 (+), 26.60 (+), 
14.33 (+); IR (ATR): ? (cm-1) = 2979, 2930, 1715, 1495, 1453, 1406, 1386, 1307, 1261, 1175, 
1107, 1028, 969, 908, 851, 802, 731, 698, 648; MS (ESI): m/z (%) = 274.1 (100) [MH+]; HRMS 
(ESI): calcd for C16H20NO3 [MH+] 274.1443, found 274.1437. 
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(1S,5S,6S)-ethyl 3-((benzylimino)methyl)-2-oxabicyclo[3.1.0]hex-3-ene-6-carboxylate (104) 
 
O
CO2Et
H
H
H
N
 
 
To a solution of aldehyde 99 (137  mg,  0.75  mmol)  in  anhydrous  DCM  (8  mL)  was  added  
MgSO4 and the mixture was stirred for 15 min at room temperature under a nitrogen 
atmosphere.  After  addition  of  benzylamine  (90  µL,  0.83  mmol,  1.1  equiv)  the  reaction  
mixture was refluxed for 1.5 h and then cooled to room temperature. Filtration and 
evaporation of the solvent under reduced pressure afforded crude 104 as a colorless oil. 
Rf = 0.40 (PE/EA 1:1);?[?]??? = - 96.2 (DCM, c = 0.5); 1H-NMR (300 MHz, CDCl3): ?H = 7.74 (t, J = 
1.2 Hz, 1H), 7.31 – 7.15 (m, 5H), 5.83 (d, J = 2.8 Hz, 1H), 4.90 (dd, J = 5.4, 0.9 Hz, 1H), 4.66 (s, 
2H), 4.08 (q, J = 7.1 Hz, 2H), 2.80 (dt, J = 5.5, 2.8 Hz, 1H), 1.19 (t, J = 7.1 Hz, 3H), 1.14 (dd, J = 
2.7, 1.1 Hz, 1H); 13C-NMR (75 MHz, CDCl3): ?C = 172.06 (Cq), 156.12 (Cq), 150.79 (+), 138.19 
(Cq), 128.63 (+), 128.42 (+), 127.31 (+), 113.61 (+), 67.53 (+), 65.08 (-), 60.97 (-), 32.20 (+), 
22.82 (+), 14.32 (+); IR (ATR): ? (cm-1) = 3062, 3030, 2979, 1714, 1648, 1594, 1495, 1454, 
1397, 1380, 1343, 1290, 1269, 1178, 1085, 1042, 995, 934, 893, 829, 732, 698; MS (ESI): 
m/z (%) = 272.1 (100) [MH+];  HRMS  (ESI):  calcd  for  C16H18NO3 [MH+] 272.1287, found 
272.1281. 
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(1S,3R,5S,6S)-ethyl 3-(4-tosyl-4,5-dihydrooxazol-5-yl)-2-oxabicyclo[3.1.0]hexane-6-
carboxylate (106) 
 
 
 
Finely powdered NaCN (70 mg, 1.42 mmol, 0.18 equiv) was added in one portion to a stirred 
solution of TosMIC (1.70 g, 8.70 mmol, 1.1 equiv) and aldehyde 83 (1.46 g, 7.91 mmol) in 
anhydrous EtOH (80 mL) at room temperature under a nitrogen atmosphere. After 1 h, the 
solvent was evaporated under reduced pressure. The residue was dissolved in CHCl3 
(100 mL) and washed with saturated aqueous NaHCO3 solution (1 x 100 mL). The aqueous 
layer was extracted with CHCl3 (1 x 40 mL) and the combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo. Purification by column chromatography 
(PE/EA 1:1) afforded a 2:1 diastereomeric mixture of compound 106 (2.10 g, 5.54 mmol, 
70%) as a yellowish foam.  
Major: Rf = 0.29 (PE/EA 1:1); 1H-NMR (400 MHz, CDCl3): ?H = 7.80 (d, J = 8.2 Hz, 2H), 7.37 (d, 
J = 8.2 Hz, 2H), 7.01 (s, 1H), 4.91 (dd, J = 5.8, 4.4 Hz, 1H), 4.86 (dd, J = 5.9, 1.7 Hz, 1H), 4.60 - 
4.52 (m, 1H), 4.17 (d, J = 6.0 Hz, 1H), 4.09 (q, J = 7.1 Hz, 2H), 2.51 - 2.41 (m, 1H), 2.44 (s, 3H), 
2.27 - 2.20 (m, 1H), 1.88 (ddd, J = 13.6, 8.2, 1.2 Hz, 1H), 1.73 (d, J = 3.8, 1H), 1.23 (t, J = 7.1, 
3H); 13C-NMR (75 MHz, CDCl3): ?C = 169.87 (Cq), 159.32 (+), 145.83 (Cq), 132.87 (Cq), 129.97 
(+), 129.63 (+), 86.60 (+), 85.71 (+), 79.54 (+), 67.06 (+), 60.71 (-), 33.52 (+), 30.01 (-), 26.70 
(+), 21.82 (+), 14.29 (+);  
minor: Rf = 0.29 (PE/EA 1:1); 1H-NMR (400 MHz, CDCl3): ?H = 7.79 (d, J = 8.3 Hz, 2H), 7.36 (d, 
J = 8.3 Hz, 2H), 7.00 (s, 1H), 4.99 (dd, J = 6.4, 1.7 Hz, 1H), 4.88 - 4.81 (m, 1H), 4.63 - 4.55 (m, 
1H), 4.15 (d, J = 6.0 Hz, 1H), 4.07 (q, J = 7.1 Hz, 2H), 2.57 - 2.49 (m, 1H), 2.44 (s, 3H), 2.27 - 
2.20 (m, 1H), 2.12 (ddd, J = 13.4, 8.2, 1.0 Hz, 1H), 1.73, (d, J = 3.8, 1H), 1.21 (t, J = 7.1, 3H); 
13C-NMR (75 MHz, CDCl3): ?C = 170.04 (Cq), 159.15 (+), 145.79 (Cq), 133.02 (Cq), 129.97 (+), 
129.53 (+), 87.27 (+), 86.65 (+), 68.76 (+), 67.33 (+), 60.64 (-), 33.15 (+), 30.58 (-), 27.11 (+), 
21.82 (+), 14.29 (+);  
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Data  for  isomeric  mixture:  IR  (ATR):  ? (cm-1) = 2978, 2936, 1716, 1618, 1453, 1408, 1387, 
1306, 1177, 1149, 1108, 1086, 1075, 975, 934, 852, 813, 707, 668; Elemental analysis calcd 
(%) for C16H21NO6S • 1.2 H2O: C 53.91, H 5.88, N 3.49, S 8.00, found C 53.83, H 5.93, N 3.34, 
S 7.92. 
 
(1S,3R,5S,6S)-methyl 3-carbamoyl-2-oxabicyclo[3.1.0]hexane-6-carboxylate (108), 
(1S,3R,5S,6S)-2-oxabicyclo[3.1.0]hexane-3,6-dicarboxamide (109) 
 
 
 
In a sealable pressure tube diester 78 (46 mg, 0.21 mmol) and a saturated solution of NH3 in 
MeOH  (3  mL)  was  heated  to  95  °C  for  17  h.  After  cooling  the  reaction  mixture  was  
concentrated in vacuo. Compound 109 (24 mg, 0.14 mmol, 67%) crystallized as colorless 
crystals from MeOH/CHCl3. The remaining solution was concentrated and purified by column 
chromatography (EA) to give compound 108 (11 mg, 0.06 mmol, 28%) as a colorless oil. 
108: Rf = 0.35 (EA); [?]??? = + 66.1 (DCM, c = 0.5); 1H-NMR (300 MHz, CDCl3): ?H = 6.48 (br s, 
1H), 5.80 (br s, 1H), 4.69 (dd, J = 10.5, 4.2 Hz, 1H), 4.33 (dd, J = 5.7, 1.0 Hz, 1H), 3.64 (s, 3H), 
2.60 (ddd, J = 13.5, 10.5, 5.9 Hz, 1H), 2.45 (dd, J = 13.4, 4.2 Hz, 1H), 2.22 (tdd, J = 5.8, 3.9, 0.6 
Hz, 1H), 1.73 (dd, J = 3.9, 1.1 Hz, 1H); 13C-NMR (75 MHz, CDCl3): ?C = 175.67 (Cq), 170.73 (Cq), 
80.68 (+), 67.23 (+), 51.95 (+), 31.34 (-), 27.93 (+), 26.25 (+); IR (ATR): ? (cm-1) = 3443, 3229, 
2959, 2919, 2855, 1711, 1681, 1439, 1399, 1327, 1303, 1274, 1171, 1114, 1078, 1023, 965, 
927, 902, 869, 858, 726, 687, 622; MS (ESI): m/z (%) = 186.0 (10) [MH+], 202.8 (20) [MNH4+], 
227.0 (100) [MH+MeCN]; HRMS (ESI): calcd for C8H11NNaO4 [MNa+] 208.0580, found 
208.0576. 
109: mp = 210 °C; [?]??? = + 27.6 (MeOH, c = 0.5); 1H-NMR (300 MHz, MeOD): ?H = 4.68 (dd, 
J = 10.5, 4.5 Hz, 1H), 4.24 (dd, J = 5.7, 1.0 Hz, 1H), 2.62 (ddd, J = 13.3, 10.5, 6.1 Hz, 1H), 2.26 
(dd, J = 13.3, 4.5 Hz, 1H), 2.11 (m, 1H), 1.73 (dd, J = 3.8, 1.0 Hz, 1H); 13C-NMR (75 MHz, 
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CDCl3): ?C = 178.75 (Cq), 174.92 (Cq), 82.03 (+), 67.88 (+), 32.74 (-), 30.39 (+), 26.11 (+); 
IR (ATR): ? (cm-1) = 3360, 3306 (br), 2535, 2487, 2443, 2385, 1635, 1611, 1511, 1442, 1174, 
1109, 1079, 1017, 961, 943, 861, 943, 861, 729, 687, 650; MS (ESI): m/z (%) = 171.0 (20) 
[MH+], 188.0 (22) [MNH4+], 212.0 (100) [MH+MeCN], 341.1 (30) [2MH+]; HRMS (ESI): calcd for 
C7H11N2O3 [MH+] 171.0764, found 171.0763. 
 
(1S,3R,5S,6S)-ethyl 3-((tert-butyldimethylsilyloxy)methyl)-2-oxabicyclo[3.1.0]hexane-6-
carboxylate (110)  
 
 
 
To a stirred solution of alcohol 79 (2.53  g,  13.6  mmol)  in  DCM  (45  mL)  under  a  nitrogen  
atmosphere anhydrous NEt3 (2.8 mL, 20 mmol, 1.5 equiv), TBSCl (2.48 g, 16.5 mmol, 
1.2 equiv) and DMAP (83 mg, 0.68 mmol, 0.05 equiv) was added successively. The reaction 
mixture was stirred for 18 h at room temperature and then quenched with a saturated 
aqueous NH4Cl solution (40 mL). The layers were separated and the aqueous layer was 
extracted with DCM (2 x 20 mL). The combined organic phases were dried over MgSO4, 
filtered and concentrated in vacuo. Purification by column chromatography (PE/EA 5:1) 
afforded compound 110 (3.88 g, 12.9 mmol, 95%) as a colorless oil. 
Rf = 0.52 (PE/EA 5:1); [?]????= + 35.0 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H = 4.48 (ddt, 
J = 9.1, 7.0, 4.1 Hz, 1H), 4.13 (d, J = 5.9 Hz, 1H), 4.06 (q, J = 7.1 Hz, 2H), 3.54 (dd, J = 11.0, 
4.0 Hz, 1H), 3.45 (dd, J = 11.0, 4.2 Hz, 1H), 2.33 (ddd, J = 13.0, 9.2, 6.9 Hz, 1H), 2.21 - 2.11 (m, 
1H), 1.91 (ddd, J = 13.0, 6.9, 0.8 Hz, 1H), 1.87 (dd, J = 3.9, 0.9 Hz, 1H), 1.21 (t, J = 7.1 Hz, 3H), 
0.89 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H); 13C-NMR (75 MHz, CDCl3): ?C = 170.74 (+), 86.16 (+), 
67.32 (+), 65.31 (-), 60.22 (-), 32.22 (+), 30.13 (-), 27.42 (+), 25.94 (+), 18.38 (Cq), 14.23 
(+), -5.35 (+), -5.43 (+); IR (ATR): ? (cm-1) = 2955, 2931, 2858, 1720, 1463, 1408, 1309, 1256, 
1176, 1112, 1096, 1054, 979, 839, 778; MS (ESI): m/z (%) = 301.0 (100) [MH+]; HRMS (EI): 
calcd for C15H28SiO4 [M+•] 300.1757, found 300.1760. 
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(1S,3R,5S,6S)-methyl 3-((tert-butyldimethylsilyloxy)methyl)-2-oxabicyclo[3.1.0]hexane-6-
carboxylate (111), (1S,3R,5S,6S)-3-((tert-butyldimethylsilyloxy)methyl)-2-oxabicyclo[3.1.0] 
hexane-6-carboxamide (112) 
 
 
 
In a sealable pressure tube compound 110 (102  mg,  0.34  mmol)  dissolved  in  a  saturated  
solution of NH3 in anhydrous MeOH (7 mL) was heated at 80 °C for 16 h. After cooling, the 
solvent was removed under reduced pressure. The residue was purified by column 
chromatography (PE/EA 2:1, then EA) to give compound 111 (38 mg, 0.13 mmol, 39%) and 
compound 112 (51 mg, 0.19 mmol, 55%) as colorless oils. 
111: Rf = 0.74 (EA); [?]??? = + 28.6 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H = 4.50 (ddt, 
J = 9.0, 7.1, 4.1 Hz, 1H), 4.15 (d, J = 5.9 Hz, 1H), 3.62 (s, 3H), 3.56 (dd, J = 11.1, 3.9 Hz, 1H), 
3.45 (dd, J = 11.1, 4.2 Hz, 1H), 2.34 (ddd, J = 13.0, 9.1, 6.9 Hz, 1H), 2.21 - 2.13 (m, 1H), 1.92 
(ddd, J = 13.3, 7.2, 0.9 Hz, 1H), 1.88 (dd, J = 3.9, 0.9 Hz, 1H), 0.90 (s, J = 2.9 Hz, 9H), 0.06 (s, 
3H), 0.05 (s, 3H); 13C-NMR (75 MHz,  CDCl3): ?C = 171.72 (Cq), 86.82 (+), 67.92 (+), 65.77 (-), 
52.07 (+), 32.63 (+), 30.61 (-), 28.13 (+), 26.49 (+), 18.95 (Cq), -4.77 (+), -4.87 (+); IR (ATR): 
? (cm-1) = 2953, 2935, 2857, 1724, 1472, 1462, 1439, 1393, 1313, 1256, 1198, 1169, 1134, 
1112, 1097, 1056, 980, 837, 778; MS (ESI): m/z (%) = 287.0 (100) [MH+]; HRMS (ESI): calcd for 
C14H27O4Si [MH+] 287.1673, found 287.1681. 
112: Rf = 0.35 (EA); [?]??? = + 31.7 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H = 5.43 (br s, 
2H), 4.51 (ddt, J = 9.0, 7.4, 3.8 Hz, 1H), 4.15 (d, J = 5.8 Hz, 1H), 3.59 (dd, J = 11.1, 3.7 Hz, 1H), 
3.46 (dd, J = 11.1, 4.1 Hz, 1H), 2.42 - 2.29 (m, 1H), 2.27 - 2.19 (m, 1H), 1.91 (ddd, J = 12.9, 7.2, 
0.8 Hz, 1H), 1.68 (dd, J = 3.8, 0.7 Hz, 1H), 0.92 (s, J = 2.9 Hz, 9H), 0.07 (s, 3H), 0.07 (s, 3H); 
13C-NMR (75 MHz, CDCl3): ?C = 172.22 (Cq), 86.48 (+), 67.44 (+), 65.25 (-), 33.83 (+), 30.23 (-), 
27.04 (+), 26.11 (+), 18.56 (Cq), -5.13 (+), -5.24 (+); IR (ATR): ? (cm-1) = 3334 (br), 3194, 2952, 
2928, 2857, 1660, 1617, 1434, 1361, 1254, 1176, 1125, 1092, 979, 837, 778; MS (ESI): m/z 
(%) = 287.0 (100) [MH+]; HRMS (ESI): calcd for C13H26NO3Si [MH+] 272.1676, found 272.1684. 
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(1S,3R,5S,6S)-ethyl 3-((E/Z)-2-formamido-2-tosylvinyl)-2-oxabicyclo[3.1.0]hexane-6-
carboxylate (113) 
 
 
 
A stirred suspension of tBuOK (79 mg, 0.71 mmol, 1.3 equiv) in anhydrous DME (0.5 mL) was 
added to a solution of TosMIC (106 mg, 0.54 mmol, 1.0 equiv) in anhydrous DME (0.7 mL) at 
-35 °C under a nitrogen atmosphere. A solution of aldehyde 83 (100  mg,  0.54  mmol)  in  
anhydrous DME (1 mL) was added dropwise to the mixture at the same temperature. After 
30  min  the  mixture  was  poured  into  ice-water  acidified  by  acetic  acid  (10  mL;  pH  <3)  and  
extracted  with  DCM  (2  x  10  mL).  The  organic  layers  were  washed  with  water  (1  x  10  mL),  
dried  over  MgSO4 and evaporated to dryness. The residue was separated by column 
chromatography (PE/EA 3:1 to 1:1) to give compound 113 (111 mg, 0.29 mmol, 54%) as a 
colorless foam. 
Data for isomeric mixture: Rf = 0.54 (PE/EA 1:3); [?]??? =  +  53.3  (DCM,  c  =  1.0);  1H-NMR 
(400 MHz, CDCl3): ?H = 8.00 (s, 0.7H), 7.81 (s, 1H), 7.70 (d, J = 8.2 Hz, 0.6H), 7.68 (d, J = 8.2 Hz, 
1.4H), 7.46 (d, J = 10.3 Hz, 0.3H), 7.33 (d, J = 8.2 Hz, 0.6H), 7.29 (d, J = 8.2 Hz, 1.4H), 6.71 (d, 
J = 7.1 Hz, 0.7H), 6.61 (d, J = 7.8 Hz, 0.3H), 5.09 - 4.96 (m, 1H), 4.21 (d, J = 5.8 Hz, 1H), 4.08 (q, 
J = 7.1 Hz, 2H), 2.69 - 2.53 (m, 1H), 2.42 (s, 0.9H), 2.39 (s, 2.1H), 2.27 (dd, J = 9.6, 5.4 Hz, 
0.3H), 2.20 (dd, J = 9.7, 5.7 Hz, 0.7H), 1.91 (dd, J = 13.5, 6.5 Hz, 1H), 1.72 (d, J = 3.5 Hz, 1H), 
1.24 (t, J = 7.1 Hz, 3H); 13C-NMR (101 MHz, CDCl3, major isomer labeled with *): ?C = 170.31* 
(Cq), 169.88 (Cq), 163.50 (+), 158.50* (+), 145.97 (Cq), 145.50* (Cq), 138.05* (+), 137.21 (Cq), 
134.53 (+), 134.30* (Cq), 133.68 (Cq), 132.48* (Cq), 130.46 (+), 130.16* (+), 128.66 (+), 
128.24* (+), 80.51* (+), 79.53 (+), 67.39* (+), 67.32 (+), 60.82 (-), 60.70* (-), 35.49 (-), 33.92* 
(-), 32.81 (+), 31.86* (+), 27.05 (+), 26.73* (+), 21.76* (+), 21.76 (+), 14.30* (+), 14.30 (+); IR 
(ATR): ? (cm-1) = 3287 (br), 2981, 1712, 1658, 1597, 1494, 1409, 1321, 1181, 1149, 1100, 
1089, 1067, 970, 850 658, 582; MS (ESI): m/z (%) = 397.1 (100) [MNH4+]; HRMS (ESI): calcd 
for C18H25N2O6S [MNH4+] 397.1428, found 397.1429. 
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(1S,3R,5S,6S)-ethyl 3-((E/Z)-2-isocyano-2-tosylvinyl)-2-oxabicyclo[3.1.0]hexane-6-
carboxylate (114) 
 
 
 
To a stirred solution of 113 (86 mg, 0.24 mmol) in anhydrous DME (3.2 ml) at -5 °C under a 
nitrogen atmosphere NEt3 (114  mg,  1.13  mmol,  4.7  equiv)  was  added  in  one  portion,  
followed by slow addition of POCI3 (54 mg, 0.35 mmol, 1.5 equiv) in anhydrous DME (1 ml) at 
-10  °C.  After  stirring  for  30  min  at  0°C,  the  mixture  was  poured  into  ice-water  (10  mL),  
immediately  extracted  with  DCM  (2  x  10  mL)  and  dried  over  MgSO4.  The  solvent  was  
evaporated under reduced pressure. The residue (110 mg) was separated from polar 
compounds by fast column chromatography (PE/EA 2:1) to give crude 114 (40  mg,  
0.11 mmol, 48%).  
Data for isomeric mixture: Rf = 0.66, 0.65 (PE/EA 1:1); IR (ATR): ? (cm-1) = 2133 (N=C), 1718 
(C=O); MS (ESI): m/z (%) = 362.0 (100) [MH+], 379.0 (65) [MH4+]; HRMS (ESI): calcd for 
C18H20NO5S [MH+] 362.1057, found 362.1054. 
 
(1S,3R,5S,6R)-2-oxabicyclo[3.1.0]hexane-3,6-diylbis(methylene)bis(oxy)bis(tert-butyl-
dimethylsilane) (115) 
 
 
 
Compound 115 was obtained as a colorless oil in 5% yield when crude product of the LAH-
reduction of diester 78 was used in the protecting reaction without separation of dialcohol 
80 from monoalcohol 79. 
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Rf = 0.33 (PE/EA 19:1); [?]????= + 26.4 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H = 4.43 (tt, 
J = 7.9, 4.9 Hz, 1H), 3.72 (dd, J = 6.3, 1.2 Hz, 1H), 3.48 (d, J = 4.9 Hz, 2H), 3.44 (dd, J = 11.1, 
6.2 Hz, 1H), 3.34 (dd, J = 11.1, 6.4 Hz, 1H), 2.23 (ddd, J = 12.7, 8.2, 7.3 Hz, 1H), 1.69 (ddd, J = 
12.7, 7.6, 1.5 Hz, 1H), 1.53 - 1.42 (m, 1H), 1.14 - 1.04 (m, 1H), 0.87 (s, 9H), 0.85 (s, 9H), 0.03 
(s, 3H), 0.03 (s, 3H), 0.01 (s, 6H); 13C-NMR (75 MHz, CDCl3): ?C = 87.79 (+), 66.16 (-), 64.45 (+), 
62.43 (-), 34.54 (+), 31.71 (-), 26.09 (+), 26.04 (+), 21.76 (+), 18.52 (Cq), 18.43 (Cq), -5.08 
(+), -5.13 (+), -5.19 (+), -5.21 (+); IR (ATR): ? (cm-1) = 2954, 2929, 2884, 2857, 1472, 1463, 
1413, 1389, 1361, 1253, 1179, 1132, 1083, 1006, 939, 831, 813, 773, 666; MS (ESI): m/z (%) = 
241.0 (100) [MH+?C6H16OSi], 373.1 (2) [MH+], 390.1 (50) [MNH4+]; HRMS (ESI): calcd for 
C19H41O3Si2 [MH+] 373.2589, found 373.2586. 
 
((1S,3R,5S,6R)-3-((tert-butyldimethylsilyloxy)methyl)-2-oxabicyclo[3.1.0]hexan-6-yl)-
methanol (116) 
 
 
 
To a stirred ice-cooled solution of 110 (3.88 mg, 12.9 mmol) in anhydrous THF (50 mL) under 
a nitrogen atmosphere, a suspension of LAH (412 mg, 10.9 mmol, 0.84 equiv) in anhydrous 
THF (5 mL) was added dropwise within 10 min. The reaction mixture was stirred for 45 min 
at  0 °C.  After  dropwise addition of  water (0.41 mL)  the mixture was stirred for  another 30 
min. Then a 15% aqueous NaOH solution (0.41 mL) was added followed by water (1.24 mL). 
The mixture was warmed to room temperature, treated with MgSO4 and filtered through a 
Celite pad. The solvent was evaporated under reduced pressure. The crude product was 
purified by column chromatography (PE/EA 3:1, then 1:1) to obtain compound 116 (3.17 g, 
12.3 mmol, 95%) as a colorless oil. 
Rf = 0.30 (PE/EA 1:1); [?]??? = + 44.6 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H = 4.43 (tt, 
J = 7.9, 4.9 Hz, 1H), 3.73 (dd, J = 6.3, 1.1 Hz, 1H), 3.46 (d, J = 4.9 Hz, 2H), 3.37 - 3.21 (m, 2H), 
2.23 (ddd, J = 12.8, 8.3, 7.2 Hz, 1H), 2.21 (br s, 1H), 1.68 (ddd, J = 12.8, 7.6, 1.5 Hz, 1H), 1.51 - 
1.43 (m, 1H), 1.21 - 1.13 (m, 1H), 0.85 (s, 9H), 0.01 (s, 6H); 13C-NMR (75 MHz, CDCl3): ?C = 
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87.94 (+), 66.01 (-), 64.33 (+), 62.32 (-), 34.78 (+), 31.54 (-), 26.01 (+), 21.98 (+), 18.45 
(Cq), -5.25 (+), -5.27 (+); IR (ATR): ? (cm-1) = 3386 (br), 2953, 2929, 2858, 1463, 1410, 1254, 
1130, 1095, 1023, 837, 777, 669; MS (ESI): m/z (%) = 241.0 (78) [MH+?H2O], 259.0 (55) 
[MH+], 276.1 (20) [MNH4+], 300.0 (100) [MH+MeCN], 481.2 (35) [2MH+?2H2O], 499.2 (85) 
[2MH+?H2O], 517.2 (50) [2MH+]; HRMS (ESI): calcd for C13H27O3Si [MH+] 259.1724, found 
259.1731. 
 
(((1S,3R,5S,6R)-6-(benzyloxymethyl)-2-oxabicyclo[3.1.0]hexan-3-yl)methoxy)(tert-butyl)-
dimethylsilane (117) 
 
 
 
To a solution of alcohol 116 (1.00 g, 3.87 mmol) in anhydrous DMF (25 mL), NaH (309 mg, 60 
wt% in mineral oil, 7.74 mmol, 2.0 equiv) was added in one portion at 0 °C under a nitrogen 
atmosphere. The resulting suspension was stirred at 0 °C for 10 min, then benzyl bromide 
(919  µL,  7.74  mmol,  2.0  equiv)  was  added  dropwise  at  0  °C.  The  mixture  was  allowed  to  
warm to room temperature and stirred for 2 h. MeOH (5 mL) was added carefully to quench 
the reaction. The solvent was evaporated under reduced pressure. The residue was diluted 
in DCM and washed with saturated aqueous NH4Cl solution (20 mL). The aqueous phase was 
extracted with DCM (3 x 20 mL). The organic layers were combined, dried over MgSO4 and 
concentrated in vacuo. The resulting residue was purified by column chromatography 
(PE/EA 9:1) to obtain compound 117 (1.14 g, 3.28 mmol, 85%) as a colorless oil. 
Rf = 0.22 (PE/EA 9:1), 0.53 (PE/EA 3:1); [?]??? = + 22.5 (DCM, c = 1.0); 1H-NMR (300 MHz, 
CDCl3): ?H = 7.38 - 7.22 (m, 5H), 4.46 (ddd, J = 9.8, 8.1, 4.9 Hz, 3H), 3.75 (dd, J = 6.2, 1.1 Hz, 
1H), 3.50 (d, J = 5.0 Hz, 2H), 3.35 (dd, J = 10.6, 6.6 Hz, 1H), 3.09 (dd, J = 10.6, 7.6 Hz, 1H), 2.27 
(ddd, J = 12.8, 8.3, 7.2 Hz, 1H), 1.74 (ddd, J = 12.8, 7.5, 1.5 Hz, 1H), 1.61 - 1.45 (m, 1H), 1.23 
(dddd, J = 7.7, 6.7, 4.0, 1.2 Hz, 1H), 0.90 (s, J = 2.9 Hz, 9H), 0.06 (d, J = 1.0 Hz, 6H); 13C-NMR 
(75 MHz, CDCl3): ?C = 138.50 (Cq), 128.49 (+), 127.75 (+), 127.68 (+), 87.80 (+), 72.50 (-), 69.61 
(-), 66.20 (-), 64.62 (+), 31.99 (+), 31.66 (-), 26.10 (+), 22.45 (+), 18.54 (Cq), -5.18 (+); IR (ATR): 
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? (cm-1) = 3038, 2932, 2858, 1461, 1380, 1254, 1182, 1132, 1091, 1009, 840, 778, 738, 697; 
MS (ESI): m/z (%) = 241.1 (100) [M+?C7H7O], 349.1 (15) [MH+], 366.1 (65) [MNH4+], 714.5 (20) 
[2MNH4+]; HRMS (ESI): calcd for C20H33O3Si [MH+] 349.2193, found 349.2197. 
 
((1S,3R,5S,6R)-6-(benzyloxymethyl)-2-oxabicyclo[3.1.0]hexan-3-yl)methanol (118) 
 
 
 
To a solution of compound 117 (3.03 mg, 8.69 mmol) in anhydrous THF (60 mL) a solution of 
TBAF•3H2O (4.11 mg, 13.0 mmol, 1.5 equiv) in anhydrous THF (30 mL) was added and stirred 
for 13 h at room temperature. After evaporating the solvent the crude product was purified 
by column chromatography (EA) to give 118 (1.94 mg, 8.28 mmol, 95%) as a colorless oil. 
Rf = 0.42 (EA); [?]??? = + 47.2 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H = 7.39 - 7.23 (m, 
5H), 4.59 - 4.49 (m, 1H), 4.48 (d, J = 2.2 Hz, 2H), 3.78 (dd, J = 6.2, 1.1 Hz, 1H), 3.56 (ddd, J = 
11.4, 5.4, 3.2 Hz, 1H), 3.42 - 3.31 (m, 1H), 3.26 (dd, J = 10.5, 7.0 Hz, 1H), 3.16 (dd, J = 10.5, 
7.1 Hz, 1H), 2.26 (ddd, J = 12.8, 8.1, 7.3 Hz, 1H), 2.07 (br s, 1H), 1.69 (ddd, J = 12.8, 8.0, 
1.6 Hz, 1H), 1.55 (dddd, J = 7.6, 6.0, 4.0, 1.6 Hz, 1H), 1.20 (tdd, J =  7.1,  4.0,  1.2  Hz,  1H);  
13C-NMR (75 MHz, CDCl3): ?C = 138.35 (Cq), 128.51 (+), 127.78 (+), 127.74 (+), 88.08 (+), 72.67 
(-), 69.47 (-), 65.36 (-), 64.71 (+), 32.57 (+), 31.17 (-), 22.51 (+); IR (ATR): ? (cm-1) = 3421 (br), 
3027, 2924, 2862, 1497, 1454, 1414, 1360, 1180, 1087, 1071, 1028, 987, 844, 810, 739, 698, 
614; MS (ESI): m/z (%) = 235.0 (5) [MH+], 469.0 (25) [2MH+], 486.1 (75) [2MH4+], 491.1 (100) 
[2MNa+]; HRMS (ESI): calcd for C14H18NaO3 [MNa+] 257.1148, found 257.1153. 
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(1S,3R,5S,6R)-6-(benzyloxymethyl)-2-oxabicyclo[3.1.0]hexane-3-carbaldehyde (119) 
 
 
 
To a stirred solution of alcohol 118 (4.35 g, 18.6 mmol) in DCM (150 mL) was added in one 
portion Dess-Martin periodinane (8.66 g, 20.4 mmol, 1.1 equiv) at room temperature. After 
2 h saturated aqueous NaHCO3 (60 mL) and saturated aqueous Na2S2O3 (60 mL) were added. 
The mixture was stirred for another 15 min. After completion the reaction was quenched 
with a mixture of saturated aqueous Na2S2O3 solution (60 mL) and saturated aqueous 
NaHCO3 solution  (60  mL).  The  mixture  was  stirred  for  15  min,  then  the  organic  layer  was  
separated and the aqueous layer was extracted with DCM (2 x 50 mL). The combined organic 
layers  were  washed  with  brine  (1  x  50  mL),  dried  over  MgSO4 and evaporated in vacuo. 
Purification by column chromatography (PE/EA 1:1) afforded compound 119 (3.87 g, 
16.7 mmol, 90%) as a colorless oil. 
Rf = 0.31 (PE/EA 1:1); [?]??? = + 57.5 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H = 9.57 (d, 
J = 0.8 Hz, 1H), 7.39 - 7.21 (m, 5H), 4.58 (ddd, J = 10.2, 3.9, 0.7 Hz, 1H), 4.47 (d, J = 1.1 Hz, 
2H), 3.95 (dd, J = 5.9, 1.3 Hz, 1H), 3.30 (dd, J = 10.5, 6.7 Hz, 1H), 3.17 (dd, J = 10.5, 7.1 Hz, 
1H), 2.40 (ddd, J = 13.0, 10.3, 5.9 Hz, 1H), 2.26 (ddd, J = 13.0, 4.0, 0.6 Hz, 1H), 1.53 (tdd, J = 
5.8, 4.0, 0.6 Hz, 1H), 0.97 (tdd, J = 6.9, 3.9, 1.3 Hz, 1H); 13C-NMR (75 MHz, CDCl3): ?C = 204.38 
(+), 138.19 (Cq), 128.54 (+), 127.81 (+), 127.77 (+), 86.02 (+), 72.77 (-), 69.06 (-), 64.86 (+), 
31.08 (-), 25.84 (+), 20.30 (+); IR (ATR): ? (cm-1) = 3031, 2942, 2860, 1730, 1497, 1455, 1422, 
1362, 1091, 1076, 1030, 988, 738, 699; MS (EI): m/z (%) = 91.1 (100) [C7H7+], 231.1 (<1) 
[M•?H+]; HRMS (ESI): calcd for C14H20NO3 [MNH4+] 250.1438, found 250.1439. 
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5-((1S,3R,5S,6R)-6-(benzyloxymethyl)-2-oxabicyclo[3.1.0]hexan-3-yl)-4-tosyl-4,5-dihydro-
oxazole (120) 
 
 
 
Finely powdered NaCN (28 mg, 0.57 mmol, 0.22 equiv) was added in one portion to a stirred 
solution of TosMIC (555 mg, 2.84 mmol, 1.1 equiv) and aldehyde 119 (600 mg, 2.58 mmol) in 
anhydrous EtOH (25 mL) at room temperature under a nitrogen atmosphere. The reaction 
mixture was stirred for 2 h. The solvent was evaporated under reduced pressure. The 
residue was dissolved in CHCl3 (30 mL) and washed with saturated aqueous NaHCO3 solution 
(30 mL). The aqueous layer was extracted with CHCl3 (2 x 15 mL) and the combined organic 
layers were dried over MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography (PE/EA 1:1) afforded a 3:2 diastereomeric mixture of compound 120 
(854 mg, 2.00 mmol, 77%) as yellowish foam.  
Major: Rf = 0.41 (PE/EA 1:1); 1H-NMR (300 MHz, CDCl3): ?H = 7.81 (d, J = 8.3 Hz, 2H), 7.39 - 
7.33 (m, 2H), 7.34 - 7.20 (m, 5H), 7.00 - 6.96 (m, 1H), 4.94 - 4.91 (m, 1H), 4.92 - 4.89 (m, 1H), 
4.62 - 4.52 (m, 1H), 4.51 - 4.45 (m, 2H), 3.79 (dd, J = 6.2, 0.9 Hz, 1H), 3.31 (dd, J = 10.5, 6.5 
Hz, 1H), 3.11 (dd, J = 10.5, 7.3 Hz, 1H), 2.44 (s, 3H), 2.40 - 2.20 (m, 1H), 1.81 (ddd, J = 13.3, 
8.8, 1.3 Hz, 1H), 1.65 - 1.53 (m, 1H), 1.30 - 1.18 (m, 1H); 13C-NMR (75 MHz, CDCl3): ?C = 
159.28 (+), 145.62 (Cq), 138.15 (Cq), 133.09 (Cq), 129.89 (+), 129.60 (+), 128.47 (+), 127.75 (+), 
127.71 (+), 86.80 (+), 86.36 (+), 79.63 (+), 72.70 (-), 69.00 (-), 64.69 (+), 33.03 (+), 30.85 (-), 
22.12 (+), 21.79 (+);  
minor: Rf = 0.41 (PE/EA 1:1); 1H-NMR (300 MHz, CDCl3): ?H = 7.80 (d, J = 8.3 Hz, 2H), 7.39 - 
7.33 (m, 2H), 7.34 - 7.20 (m, 5H), 7.00 - 6.96 (m, 1H), 4.98 (dd, J = 6.2, 1.7 Hz, 1H), 4.84 (dd, 
J = 6.2, 3.4 Hz, 1H), 4.58 - 4.50 (m, 1H), 4.47 - 4.42 (m, 2H), 3.76 (dd, J = 6.3, 0.8 Hz, 1H), 3.26 
(dd, J = 10.5, 6.8 Hz, 1H), 3.14 (dd, J = 10.5, 7.2 Hz, 1H), 2.44 (s, 3H), 2.43 - 2.33 (m, 1H), 2.01 
(ddd, J = 13.0, 8.4, 1.6 Hz, 1H), 1.65 - 1.53 (m, 1H), 1.30 - 1.18 (m, 1H); 13C-NMR (75 MHz, 
CDCl3): ?C = 159.35 (+), 145.62 (Cq), 138.19 (Cq), 133.09 (Cq), 129.89 (+), 129.52 (+), 128.45 
(+), 127.75 (+), 127.71 (+), 87.66 (+), 87.31 (+), 79.13 (+), 72.63 (-), 69.04 (-), 64.92 (+), 32.83 
(+), 31.19 (-), 22.12 (+), 21.79 (+);  
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Data  for  isomeric  mixture:  IR  (ATR):  ? (cm-1) = 3033, 2948, 2861, 1616, 1597, 1486, 1455, 
1362, 1319, 1304, 1292, 1148, 1108, 1086, 1071, 1028, 939, 848, 813, 739, 700, 664, 651, 
587, 533. 
 
5-((1S,3R,5S,6R)-6-(benzyloxymethyl)-2-oxabicyclo[3.1.0]hexan-3-yl)-1H-imidazole (121a), 
5-((1S,3S,5S,6R)-6-(benzyloxymethyl)-2-oxabicyclo[3.1.0]hexan-3-yl)-1H-imidazole (121b) 
 
 
In a sealable pressure tube oxazoline 120 (1.70 g, 3.98 mmol) and a saturated solution of 
NH3 in anhydrous MeOH (40 mL, 70 equiv) was heated at 95 °C for 16 h. Within this time the 
solution turned red. After cooling, the solvent was removed under reduced pressure. The 
residue was purified by column chromatography (DCM/saturated NH3 in MeOH 9:1) to give 
an epimeric mixture of compound 121a and 121b (726 mg, 2.69 mmol, 68%) as a colorless 
oil. 
121A: Rf = 0.22 (DCM/saturated NH3 in MeOH 9:1); 1H-NMR (300 MHz, CDCl3): ?H = 8.28 (br s, 
1H), 7.48 (s, 1H), 7.38 - 7.22 (m, 5H), 6.83 (s, 1H), 5.42 (t, J = 7.5 Hz, 1H), 4.47 (d, J = 1.7 Hz, 
2H), 3.86 (dd, J = 6.2, 1.2 Hz, 1H), 3.29 - 3.15 (m, 2H), 2.64 - 2.51 (m, 1H), 2.15 (ddd, J = 12.8, 
7.0, 1.4 Hz, 1H), 1.66 - 1.57 (m, 1H), 1.45 - 1.34 (m, 1H); 13C-NMR (75 MHz, CDCl3): ?C = 
139.57 (Cq), 138.27 (Cq), 135.36 (+), 128.54 (+), 127.87 (+), 127.80 (+), 116.10 (+), 81.53 (+), 
72.69 (-), 69.71 (-), 64.45 (+), 35.21 (-), 30.89 (+), 22.67 (+).  
121b: Rf = 0.22 (DCM/saturated NH3 in MeOH 9:1); 1H-NMR (300 MHz, CDCl3): ?H = 8.28 (br s, 
1H), 7.55 (s, 1H), 7.38 - 7.22 (m, 5H), 6.90 (s, 1H), 4.76 (t, J = 8.2 Hz, 1H), 4.50 (d, J = 2.6 Hz, 
2H), 3.90 - 3.78 (m, 1H), 3.42 - 3.31 (m, 1H), 3.23 - 3.11 (m, 1H), 2.38 - 2.23 (m, 2H), 1.59 - 
1.48 (m, 1H), 1.19 - 1.05 (m, 1H); 13C-NMR (75 MHz, CDCl3): ?C = 138.22 (Cq), 137.81 (Cq), 
135.62 (+), 128.54 (+), 127.86 (+), 127.80 (+), 115.90 (+), 74.14 (+), 72.72 (-), 69.90 (-), 62.56 
(+), 34.54 (-), 21.40 (+), 20.80 (+). 
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Data for isomeric mixture: IR (ATR): ? (cm-1) = 3090 (br), 2936, 2858, 1716, 1670, 1496, 1453, 
1362, 1313, 1273, 1087, 1071, 1027, 839, 738, 698, 626; MS (ESI): m/z (%) = 271.0 (100) 
[MH+], 312.1 (30) [MH+MeCN], 541.2 (40) [2MH+]; HRMS (ESI): calcd for C16H19N2O2 [MH+] 
271.1441, found 271.1446; 
 
ethyl 5-((1S,3R,5S,6R)-6-(benzyloxymethyl)-2-oxabicyclo[3.1.0]hexan-3-yl)-1H-imidazole-1-
carboxylate (131a), ethyl 5-((1S,3S,5S,6R)-6-(benzyloxymethyl)-2-oxabicyclo[3.1.0]hexan-3-
yl)-1H-imidazole-1-carboxylate (131b) 
 
 
 
A solution of an epimeric mixture of imidazole 121 (1.10 mg, 4.06 mmol), ethyl 
chloroformate (733 µL, 7.72 mmol, 1.9 equiv), anhydrous pyridine (623 µL, 7.72 mmol, 1.9 
equiv) and DMAP (79 mg, 0.65 mmol, 0.16 equiv) in benzene (80 mL) was stirred for 10 min 
at 50 °C. After addition of water (5 mL), the solvent was evaporated. A saturated aqueous 
NH4Cl  solution  (50  mL)  was  added  und  extracted  with  DCM  (3  x  25  mL).  The  extract  was  
washed with brine, dried over MgSO4, filtered and concentrated in vacuo. The residual oil 
was purified by column chromatography (PE/EA 1:1) to give an epimeric mixture of 
compound 131a and 131b (1.01 g, 2.95 mmol, 73%) as a colorless oil. 
131a: Rf = 0.26 (PE/EA 1:1); 1H-NMR (300 MHz, CDCl3): [?]??? = - 15.2 (DCM, c = 1.0); ?H = 8.06 
(d, J = 1.3 Hz, 1H), 7.37 - 7.27 (m, 5H), 7.28 (t, J = 1.2 Hz, 1H), 5.38 (ddd, J = 8.4, 6.7, 0.9 Hz, 
1H), 4.48 (d, J = 3.8 Hz, 2H), 4.45 (q, J = 7.1 Hz, 2H), 3.88 (dd, J = 6.1, 1.2 Hz, 1H), 3.33 (dd, J = 
10.5, 6.7 Hz, 1H), 3.13 (dd, J = 10.6, 7.4 Hz, 1H), 2.61 (ddd, J = 12.8, 8.6, 6.9 Hz, 1H), 2.15 
(ddd, J = 12.8, 6.7, 1.4 Hz, 1H), 1.67 - 1.57 (m, 1H), 1.47 - 1.39 (m, 1H), 1.42 (t, J = 7.1 Hz, 3H); 
13C-NMR (75 MHz, CDCl3): ?C = 148.63 (Cq), 145.81 (Cq), 138.32 (Cq), 137.17 (+), 128.41 (+), 
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127.70 (+), 127.26 (+), 113.26 (+), 81.75 (+), 72.52 (-), 69.50 (-), 64.68 (+), 64.45 (-), 43.88 (-), 
30.63 (+), 22.66 (+), 14.21 (+);  
131b: Rf = 0.24 (PE/EA 1:1), 0.54 (EA); 1H-NMR (300 MHz, CDCl3): ?H = 8.07 (d, J = 1.3 Hz, 1H), 
7.35 - 7.26 (m, 5H), 7.33 - 7.31 (m, 1H), 4.72 (dd, J = 8.8, 7.4 Hz, 1H), 4.49 (d, J = 3.1 Hz, 2H), 
4.43 (q, J = 7.1 Hz, 2H), 3.91 (dd, J = 5.5, 1.6 Hz, 1H), 3.38 (dd, J = 10.5, 6.2 Hz, 1H), 3.13 (dd, 
J = 10.5, 7.5 Hz, 2H), 2.35 (dd, J = 12.3, 7.3 Hz, 1H), 2.24 (ddd, J = 12.4, 9.0, 5.0 Hz, 1H), 1.59 - 
1.50 (m, 2H), 1.40 (t, J = 7.1 Hz, 3H); 13C-NMR (75 MHz, CDCl3): ?C = 148.58 (Cq), 143.45 (Cq), 
138.34 (Cq), 137.26 (+), 128.44 (+), 127.72 (+), 127.67 (+), 113.85 (+), 74.88 (+), 72.58 (-), 
69.71 (-), 64.49 (-), 62.91 (+), 34.52 (-), 22.14 (+), 20.86 (+), 14.21 (+); 
Data  for  isomeric  mixture:  IR  (ATR):  ? (cm-1) = 3032, 2937, 2859, 1759, 1482, 1454, 1409, 
1388, 1336, 1252, 1207, 1093, 1069, 1019, 843, 769, 740, 699, 607; MS (ESI): m/z (%) = 342.9 
(100) [MH+]; HRMS (ESI): calcd for C19H23N2O4 [MH+] 343.1652, found 343.1656. 
 
ethyl 5-((1S,3R,5S,6R)-6-(hydroxymethyl)-2-oxabicyclo[3.1.0]hexan-3-yl)-1H-imidazole-1-
carboxylate (132a) ethyl 5-((1S,3S,5S,6R)-6-(hydroxymethyl)-2-oxabicyclo[3.1.0]hexan-3-
yl)-1H-imidazole-1-carboxylate (132b) 
 
 
 
A epimeric mixture of compound 131 (134 mg, 0.39 mmol), Pd(OH)2/C (20%, 95 mg) and 
cyclohexene (1.6 mL,  16 mmol,  40 equiv)  in  anhydrous EtOH (15 mL)  was refluxed for  1 h.  
After filtration through a Celite pad the solvent was evaporated. The residue was purified by 
column chromatography (EA, then EA/MeOH 19:1) to afford an epimeric mixture of alcohol 
132a and 132b (72 mg, 0.29 mmol, 73%) as a colorless foam.  
132a: Rf = 0.38 (EA/MeOH 19:1); [?]??? = - 4.6 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H = 
8.06 (d, J = 1.3 Hz, 1H), 7.29 (m, 1H), 5.38 (ddd, J = 8.5, 6.6, 0.9 Hz, 1H), 4.45 (q, J = 7.1 Hz, 
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2H), 3.90 (dd, J = 6.2, 1.3 Hz, 1H), 3.40 (dd, J = 11.6, 7.4 Hz, 1H), 3.33 (dd, J = 11.6, 7.3 Hz, 
1H), 2.61 (ddd, J = 12.8, 8.6, 6.9 Hz, 1H), 2.16 (ddd, J = 12.8, 6.7, 1.5 Hz, 1H), 1.75 (br s, 1H), 
1.62 (tdd, J = 6.8, 4.0, 1.5 Hz, 1H), 1.50 - 1.43 (m, 1H), 1.42 (t, J = 7.1 Hz, 3H); 13C-NMR (75 
MHz, CDCl3): ?C = 148.69 (Cq), 145.65 (Cq), 137.31 (+), 113.54 (+), 81.81 (+), 64.60 (-), 64.51 
(+), 62.61 (-), 34.83 (-), 33.45 (+), 22.44 (+), 14.30 (+); IR (ATR): ? (cm-1) = 3373 (br), 2982, 
2943, 2876, 1758, 1489, 1409, 1336, 1253, 1176, 1103, 1068, 1018, 847, 768, 606; MS (ESI): 
m/z (%) = 252.9 (40) [MH+], 294.0 (15) [MH+MeCN], 505.1 (100) [2MH+]; HRMS (ESI): calcd 
for C12H17N2O4 [MH+] 253.1183, found 253.1190. 
132b: Rf = 0.36 (EA/MeOH 19:1); [?]??? = + 10.5 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H 
= 8.05 (d, J = 1.2 Hz, 1H), 7.32 - 7.29 (m, 1H), 4.70 (dd, J = 8.6, 7.5 Hz, 1H), 4.42 (q, J = 7.1 Hz, 
2H), 3.91 (dd, J = 5.5, 1.6 Hz, 1H), 3.41 (dd, J = 11.5, 6.8 Hz, 1H), 3.32 (dd, J = 11.5, 7.1 Hz, 
1H), 2.32 (dd, J = 12.4, 7.2 Hz, 1H), 2.21 (ddd, J = 12.4, 9.0, 5.0 Hz, 1H), 1.58 - 1.47 (m, 2H), 
1.38 (t, J = 7.1 Hz, 3H); 13C-NMR (75 MHz, CDCl3): ?C = 148.66 (Cq), 143.43 (Cq), 137.38 (+), 
113.98 (+), 75.10 (+), 64.64 (-), 62.86 (-), 62.42 (+), 34.59 (-), 24.90 (+), 20.54 (+), 14.30 (+); 
IR (ATR): ? (cm-1) = 3349 (br), 2939, 2869, 1760, 1487, 1409, 1342, 1254, 1123, 1018, 852, 
768, 607; MS (ESI): m/z (%) = 252.8 (100) [MH+], 505.1 (30) [2MH+]; HRMS (ESI): calcd for 
C12H17N2O4 [MH+] 253.1183, found 253.1188. 
 
ethyl 5-((1S,3R,5S,6R)-6-((1,3-dioxoisoindolin-2-yl)methyl)-2-oxabicyclo[3.1.0]hexan-3-yl)-
1H-imidazole-1-carboxylate (133), ethyl 5-((2R,4S,5R)-5-(1,3-dioxoisoindolin-2-yl)-4-
vinyltetrahydrofuran-2-yl)-1H-imidazole-1-carboxylate (135a), ethyl 5-((2R,4S,5S)-5-(1,3-
dioxoisoindolin-2-yl)-4-vinyltetrahydrofuran-2-yl)-1H-imidazole-1-carboxylate (135b) 
 
 
 
DIAD  (211  mg,  0.98  mmol,  1.5  equiv)  was  added  to  a  solution  PPh3 (257 mg, 0.98 mmol, 
1.5 equiv) in anhydrous THF (7 mL) at room temperature under a nitrogen atmosphere. After 
stirring for 10 min phthalimide (144 mg, 0.98 mmol, 1.5 equiv) was added and stirred for 
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another 10 min. After addition of alcohol 132a (165 mg, 0.65 mmol) in THF the reaction 
mixture was stirred overnight. The solvent was evaporated under reduced pressure. The 
residue was purified by column chromatography (PE/EA 5:1 to EA) to obtain 135a (126 mg, 
0.33 mmol, 51%), 135b (25  mg,  0.07  mmol,  10%)  and  133 (72  mg,  0.19  mmol,  29%)  as  
colorless oils.  
135a: Rf = 0.37 (PE/EA 1:1); [?]??? = - 23.6 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H = 8.10 
(d, J = 1.2 Hz, 1H), 7.85 (dd, J = 5.5, 3.0 Hz, 2H), 7.72 (dd, J = 5.5, 3.0 Hz, 2H), 7.40 (dd, J = 1.3, 
0.7 Hz, 1H), 5.93 (d, J = 7.5 Hz, 1H), 5.86 (ddd, J = 17.1, 10.3, 8.0 Hz, 1H), 5.50 (dd, J = 10.6, 
4.9 Hz, 1H), 5.13 (dt, J = 17.1, 1.2 Hz, 1H), 5.10 - 5.04 (m, 1H), 4.44 (q, J = 7.1 Hz, 2H), 4.01 - 
3.85 (m, 1H), 2.65 (ddd, J = 12.2, 7.2, 5.0 Hz, 1H), 2.24 (dt, J = 12.2, 11.3 Hz, 1H), 1.41 (t, J = 
7.1 Hz, 3H); 13C-NMR (75 MHz, CDCl3): ?C = 167.92 (Cq), 148.63 (Cq), 143.33 (Cq), 137.37 (+), 
136.39 (+), 134.37 (+), 132.02 (Cq), 123.60 (+), 117.58 (-), 114.40 (+), 85.06 (+), 76.33 (+), 
64.59 (-), 46.68 (+), 39.34 (-), 14.27 (+); IR (ATR): ? (cm-1) = 2985, 2927, 2853, 1760, 1716, 
1468, 1410, 1367, 1332, 1252, 1210, 1084, 1019 977, 919, 891, 845, 769, 736, 721, 655, 611, 
531; MS (ESI): m/z (%) = 381.9 (100) [MH+], 422.9 (45) [MH+MeCN], 763.2 (90) [2MH+]; HRMS 
(ESI): calcd for C20H20N3O5 [MH+] 382.1375, found 382.1365. 
135b: Rf = 0.33 (PE/EA 1:1); [?]??? = + 73.6 (DCM, c = 0.5); 1H-NMR (300 MHz, CDCl3): ?H = 
8.09 (d, J = 1.3 Hz, 1H), 7.83 (dd, J = 5.5, 3.0 Hz, 2H), 7.72 (dd, J = 5.5, 3.0 Hz, 2H), 7.61 - 7.53 
(m, 1H), 6.21 (d, J = 8.6 Hz, 1H), 5.69 (ddd, J = 17.5, 10.2, 7.5 Hz, 1H), 5.20 (dt, J = 17.2, 1.3 
Hz, 1H), 5.11 - 5.04 (m, 1H), 5.06 - 5.00 (m, 1H), 4.46 (q, J = 7.1 Hz, 2H), 3.56 - 3.41 (m, 1H), 
2.93 - 2.77 (m, 1H), 2.51 - 2.40 (m, 1H), 1.42 (t, J = 7.1 Hz, 3H).; 13C-NMR (75 MHz, CDCl3): ?C 
= 167.77 (Cq), 148.78 (Cq), 143.44 (Cq), 136.78 (+), 134.30 (+), 133.84 (+), 131.98 (Cq), 123.61 
(+), 118.82 (-), 114.31 (+), 82.69 (+), 77.63 (+), 64.53 (-), 47.93 (+), 36.93 (-), 14.33 (+); 
IR (ATR): ? (cm-1) = 2985, 2955, 2925, 1762, 1720, 1468, 1410, 1364, 1326, 1258, 1228, 1113, 
1090, 1018, 901, 838, 792, 770, 722, 604, 530; MS (ESI): m/z (%) = 381.9 (100) [MH+], 763.2 
(10) [2MH+]; HRMS (ESI): calcd for C20H20N3O5 [MH+] 382.1397, found 382.1403. 
133: Rf = 0.27 (PE/EA 1:1);?[?]??? = - 12.4 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H = 8.03 
(d, J = 1.2 Hz, 1H), 7.83 (dd, J = 5.5, 3.0 Hz, 2H), 7.70 (dd, J = 5.5, 3.0 Hz, 2H), 7.24 (t, J = 1.0 
Hz, 1H), 5.36 (t, J = 7.7 Hz, 1H), 4.43 (q, J = 7.1 Hz, 2H), 4.05 (dd, J = 6.2, 0.9 Hz, 1H), 3.51 (dd, 
J = 14.3, 7.1 Hz, 1H), 3.38 (dd, J = 14.3, 8.2 Hz, 1H), 2.59 (ddd, J = 12.9, 8.4, 7.1 Hz, 1H), 2.07 
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(ddd, J = 12.7, 7.2, 1.6 Hz, 1H), 1.76 (ddd, J = 7.0, 3.9, 1.5 Hz, 1H), 1.57 - 1.48 (m, 1H), 1.40 (t, 
J = 7.1 Hz, 3H), 1.30 - 1.20 (m, 1H); 13C-NMR (75 MHz, CDCl3): ?C = 168.45 (Cq), 148.65 (Cq), 
145.26 (Cq), 137.27 (+), 134.06 (Cq), 132.31 (+), 123.37 (+), 113.43 (+), 82.36 (+), 65.09 (+), 
64.54 (-), 38.00 (-), 35.03 (-), 30.67 (+), 23.63 (+), 14.28 (+); IR (ATR): ? (cm-1) = 2977, 2931, 
1760, 1711, 1467, 1433, 1409, 1391, 1357, 1336, 1253, 1211, 1137, 1102, 1019, 950, 846, 
769, 721, 614, 530; MS (ESI): m/z (%) = 381.9 (100) [MH+], 763.3 (75) [2MH+]; HRMS (ESI): 
calcd for C20H20N3O5 [MH+] 382.1397, found 382.1396. 
 
ethyl 5-((1S,3S,5S,6R)-6-((1,3-dioxoisoindolin-2-yl)methyl)-2-oxabicyclo[3.1.0]hexan-3-yl)-
1H-imidazole-1-carboxylate (137) 
 
 
 
DIAD  (54  mg,  0.25  mmol,  1.5  equiv)  was  added  to  a  solution  PPh3 (65.5 mg, 0.25 mmol, 
1.5  equiv)  in  anhydrous  THF  (1.3  mL)  at  room  temperature  under  a  nitrogen  atmosphere.  
After stirring for 10 min phthalimide (37 mg, 0.25 mmol, 1.5 equiv) was added and stirred for 
another 10 min. After addition of alcohol 132b (42 mg, 0.17 mmol) the reaction mixture was 
stirred for 18 h. The solvent was evaporated under reduced pressure. The residue was 
purified by column chromatography (PE/EA 3:1 to 1:1) to obtain compound 137 (17 mg, 
0.04 mmol, 27%) as a colorless oil.  
Rf = 0.43 (PE/EA 1:3); [?]??? = + 17.1 (DCM, c = 0.2); 1H-NMR (400 MHz, CDCl3): ?H = 8.07 (d, 
J = 1.3 Hz, 1H), 7.90 - 7.82 (m, 2H), 7.76 - 7.67 (m, 2H), 7.30 (s, 1H), 4.68 (t, J = 8.0 Hz, 1H), 
4.45 (q, J = 7.1 Hz, 2H), 4.11 (dd, J = 5.7, 1.2 Hz, 1H), 3.54 (dd, J = 14.2, 6.9 Hz, 1H), 3.42 (dd, 
J = 14.3, 7.8 Hz, 1H), 2.36 - 2.19 (m, 2H), 1.73 - 1.62 (m, 1H), 1.48 - 1.38 (m, 1H), 1.41 (t, J = 
7.1 Hz, 3H); 13C-NMR (101 MHz, CDCl3): ?C = 168.50 (Cq), 148.68 (Cq), 143.44 (Cq), 137.38 (+), 
134.12 (+), 132.33 (Cq), 123.43 (+), 113.93 (+), 75.15 (+), 64.59 (-), 63.38 (+), 38.09 (-), 34.48 
(-), 21.89 (+), 21.56 (+), 14.30 (+); IR (ATR): ? (cm-1) = 2978, 2936, 2873, 1758, 1707, 1467, 
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1391, 1336, 1251, 1139, 1087, 1017, 944, 850, 769, 721, 611, 541, 501; MS (ESI): m/z (%) = 
381.9 (100) [MH+], 763.3 (10) [2MH+]; HRMS (ESI): calcd for C20H20N3O5 [MH+] 382.1397, 
found 382.1405. 
 
2-(((1S,3R,5S,6R)-3-((tert-butyldimethylsilyloxy)methyl)-2-oxabicyclo[3.1.0]hexan-6-yl)-
methyl)isoindoline-1,3-dione (138), (R)-tert-butyldimethyl((4-vinyl-2,3-dihydrofuran-2-
yl)methoxy)silane (153), 2-((2R,3S,5R)-5-((tert-butyldimethylsilyloxy)methyl)-3-vinyltetra-
hydrofuran-2-yl)isoindoline-1,3-dione (154a), 2-((2S,3S,5R)-5-((tert-butyldimethylsilyloxy)-
methyl)-3-vinyltetrahydrofuran-2-yl)isoindoline-1,3-dione (154b) 
 
 
 
DIAD (1.58 g, 8.72 mmol, 1.5 eq) was added dropwise to a solution of alcohol 116 (1.50 g, 
5.82 mmol), PPh3 (2.29 g, 8.72 mmol, 1.5 equiv) and phthalimide (1.28 mg, 8.72 mmol, 
1.5 equiv) in anhydrous THF (116 mL) at 50 °C. After stirring at 50 °C for 1 h the mixture was 
cooled to room temperature quenched with water (50 mL). The phases were separated and 
the  organic  layer  was  extracted  with  DCM  (3  x  25  mL).  The  combined  organic  layers  were  
dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by column 
chromatography (PE/EA 9:1, then 5:1) to obtain compound 153 (100 mg, 0.42 mmol, 7%) as 
a  colorless  oil  and  compound  154b (115 mg, 0.30 mmol, 5%), compound 154a (1.04 g, 
2.67 mmol, 46%) and compound 138 (665 mg, 1.72 mmol, 29%) as colorless solids.  
153: Rf = 0.77 (PE/EA 5:1), 0.59 (PE/EA 9:1); [?]??? = - 125.8 (DCM, c = 1.0); 1H-NMR 
(300 MHz, CDCl3): ?H = 6.46 (ddd, J = 18.0, 11.0, 0.6 Hz, 1H), 6.41 (m, 1H), 4.85 (dd, J = 10.7, 
1.1 Hz, 1H), 4.85 - 4.76 (m, 1H), 4.70 (dddd, J = 10.5, 7.3, 5.9, 4.9 Hz, 1H), 3.73 (dd, J = 10.9, 
112   
Experimental 
 
5.9 Hz, 1H), 3.65 (dd, J = 10.9, 4.8 Hz, 1H), 2.73 (dddd, J = 14.4, 10.4, 1.8, 0.7 Hz, 1H), 2.48 
(dddd, J = 14.6, 7.3, 1.7, 0.6 Hz, 1H), 0.89 (s, 9H), 0.07 (s, 3H), 0.07 (s, 3H); 13C-NMR (75 MHz, 
CDCl3): ?C = 144.97 (+), 129.08 (+), 116.31 (Cq), 109.70 (-), 83.00 (+), 65.64 (-), 30.71 (-), 26.01 
(+), 18.50 (Cq), -5.14 (+), -5.19 (+); IR (ATR): ? (cm-1) = 2955, 2929, 2857, 1641, 1472, 1463, 
1253, 1105, 1006, 980, 834, 776, 667; 
154b: Rf = 0.40 (PE/EA 5:1); [?]??? = + 95.5 (DCM, c = 0.5); 1H-NMR (300 MHz, CDCl3): ?H = 
7.83 (dd, J = 5.6, 3.0 Hz, 2H), 7.72 (dd, J = 5.6, 3.0 Hz, 2H), 6.13 (d, J = 8.4 Hz, 1H), 5.62 (ddd, 
J = 17.5, 10.2, 7.5 Hz, 1H), 5.15 (dt, J = 17.1, 1.4 Hz, 1H), 4.99 (ddd, J = 10.2, 1.5, 1.0 Hz, 1H), 
4.18 (ddt, J = 10.7, 6.5, 5.2 Hz, 1H), 3.97 (dd, J = 10.5, 6.6 Hz, 1H), 3.82 (dd, J = 10.5, 4.9 Hz, 
1H), 3.41 - 3.26 (m, 1H), 2.39 (dt, J = 12.1, 11.2 Hz, 1H), 2.13 (ddd, J = 11.7, 7.6, 5.5 Hz, 1H), 
0.89 (s, 9H), 0.07 (s, 3H), 0.06 (s, 3H); 13C-NMR (75 MHz, CDCl3): ?C = 167.89 (Cq), 134.26 (+), 
134.12 (+), 131.99 (Cq), 123.50 (+), 118.46 (-), 83.27 (+), 82.56 (+), 65.93 (-), 47.39 (+), 34.02 
(-), 26.14 (+), 18.62 (Cq), -5.04 (+), -5.11 (+); IR (ATR): ? (cm-1) = 2956, 2928, 2857, 1787, 
1772, 1720, 1470, 1416, 1370, 1351, 1327, 1255, 1117, 1101, 1059, 1005, 924, 891, 838, 777, 
720; MS (ESI): m/z (%) = 388.0 (100) [MH+], 729.4 (15) [2MH+]; HRMS (ESI): calcd for 
C21H30NO4Si [MH+] 388.1939, found 388.1941; 
154a: Rf = 0.38 (PE/EA 5:1); [?]??? = - 41.5 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H = 7.84 
(dd, J = 5.6, 3.0 Hz, 2H), 7.72 (dd, J = 5.6, 3.0 Hz, 2H), 5.79 (ddd, J = 17.1, 10.2, 8.0 Hz, 1H), 
5.74 (d, J = 7.6 Hz, 1H), 5.09 (dt, J = 17.7, 1.4 Hz, 1H), 5.04 (ddd, J = 7.9, 1.4, 0.9 Hz, 1H), 4.53 
(dq, J = 5.2, 4.1 Hz, 6H), 3.87 - 3.73 (m, 7H), 3.73 (dd, J = 11.0, 4.2 Hz, 10H), 3.67 (dd, J = 11.0, 
4.4 Hz, 1H), 2.35 (ddd, J = 12.6, 7.6, 5.3 Hz, 1H), 1.89 (ddd, J = 12.2, 11.1, 10.1 Hz, 1H), 0.90 
(s, 9H), 0.07 (s, 3H), 0.06 (s, 3H); 13C-NMR (75 MHz, CDCl3): ?C = 167.95 (Cq), 136.90 (+), 
134.31 (+), 132.06 (Cq), 123.57 (+), 117.25 (-), 85.23 (+), 80.85 (+), 65.07 (-), 46.15 (+), 35.26 
(-), 26.08 (+), 18.51 (Cq), -5.10 (+), -5.21 (+); IR (ATR): ? (cm-1) = 2954, 2929, 2857, 1775, 
1717, 1470, 1405, 1368, 1328, 1253, 1084, 996, 921, 872, 836, 777, 718, 665, 530; MS (ESI): 
m/z (%) = 388.0 (70) [MH+], 405.0 (70) [MNH4+], 775.4 (20) [2MH+], 792.4 (100) [2MNH4+]; 
HRMS (ESI): calcd for C21H30NO4Si [MH+] 388.1939, found 388.1942; 
138: mp = 63 - 65 °C; Rf = 0.25 (PE/EA 5:1); [?]??? = + 28.9 (DCM, c = 1.0); 1H-NMR (300 MHz, 
CDCl3): ?H = 7.79 (dd, J = 5.5, 3.0 Hz, 2H), 7.67 (dd, J = 5.4, 3.1 Hz, 2H), 4.46 - 4.34 (m, 1H), 
3.89 (dd, J = 6.2, 0.6 Hz, 1H), 3.47 (dd, J = 14.3, 6.9 Hz, 1H), 3.41 (d, J = 4.9 Hz, 2H), 3.28 (dd, 
J = 14.3, 8.4 Hz, 1H), 2.20 (ddd, J = 12.7, 8.1, 7.3 Hz, 1H), 1.70 - 1.53 (m, 2H), 1.36 - 1.25 (m, 
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1H), 0.82 (s, 9H), -0.02 (s, 6H); 13C-NMR (75 MHz, CDCl3): ?C = 168.28 (Cq), 133.94 (+), 132.23 
(Cq), 123.22 (+), 87.79 (+), 65.97 (-), 64.86 (+), 37.87 (-), 31.45 (-), 31.13 (+), 25.97 (+), 23.09 
(+), 18.42 (Cq), -5.30 (+), -5.31 (+); IR (ATR): ? (cm-1) = 2955, 2929, 2856, 1772, 1712, 1468, 
1433, 1391, 1356, 1330, 1253, 1188, 1137, 1088, 1007, 990, 950, 836, 777, 720, 529; 
MS (ESI): m/z (%) = 388.1 (50) [MH+], 405.0 (100) [MNH4+]; HRMS (ESI): calcd for C21H30NO4Si 
[MH+] 388.1939, found 388.1940. 
 
2-(((1S,3R,5S,6R)-3-(hydroxymethyl)-2-oxabicyclo[3.1.0]hexan-6-yl)methyl)isoindoline-1,3-
dione (139) 
 
 
 
To a solution of phthalimide 138 (150 mg, 0.65 mmol) in anhydrous THF (5 mL) a solution of 
TBAF•3H2O (305 mg, 0.97 mmol, 1.5 equiv) in anhydrous THF (1.5 mL) was added dropwise 
and stirred for 1.5 h at 0 °C. The mixture was allowed to warm to room temperature and the 
solvent was evaporated under reduced pressure. The resulting residue was purified by 
column chromatography (EA/MeOH 9:1) to afford compound 139 (124 mg, 0.45 mmol, 70%) 
as a colorless oil.  
mp = 85 °C; Rf = 0.44 (EA); [?]??? = + 17.8 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H = 7.81 
(dd, J = 5.5, 3.0 Hz, 2H), 7.69 (dd, J = 5.4, 3.1 Hz, 2H), 4.54 - 4.40 (m, 1H), 3.91 (dd, J = 6.3, 
0.6 Hz, 1H), 3.55 - 3.42 (m, 1H), 3.48 (dd, J = 14.3, 7.0 Hz, 2H), 3.36 - 3.23 (m, 1H), 3.30 (dd, 
J = 14.3, 8.3 Hz, 2H), 2.21 (dt, J = 12.9, 7.6 Hz, 1H), 2.11 (t, J = 6.2 Hz, 1H), 1.69 - 1.56 (m, 1H), 
1.63 (br s, 1H), 1.27 (tdd, J = 7.9, 3.6, 0.8 Hz, 1H). 13C-NMR (75 MHz, CDCl3): ?C = 168.38 (Cq), 
134.05 (+), 132.18 (Cq), 123.33 (+), 88.23 (+), 65.15 (-), 64.86 (+), 37.83 (-), 31.76 (+), 31.04 
(-), 23.30 (+); IR (ATR): ? (cm-1) = 3459 (br), 2937, 2876, 1770, 1703, 1467, 1434, 1392, 1356, 
1188, 1138, 1076, 951, 860, 794, 720, 614, 530; MS (ESI): m/z (%) = 274.0 (2) [MH+], 291.0 (7) 
[MNH4+], 547.1 (100) [2MH+]; HRMS (ESI): calcd for C15H16NO4 [MH+] 274.1074, found 
274.1074. 
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(1S,3R,5S,6R)-6-((1,3-dioxoisoindolin-2-yl)methyl)-2-oxabicyclo[3.1.0]hexane-3-
carbaldehyde (140) 
 
 
 
To stirred suspension of alcohol 139 (42  mg,  0.15  mmol)  and  NaHCO3 (26 mg, 0.31 mmol, 
2.0 equiv) in DCM (3 mL) was added Dess-Martin periodinane (108 mg, 0.25 mmol, 
1.7  equiv)  and  stirred  for  5  h  at  room  temperature.  The  mixture  was  quenched  with  a  
mixture of saturated aqueous Na2S2O3 solution (2 mL) and saturated aqueous NaHCO3 
solution (2 mL) and stirred for another 15 min. The phases were separated and the aqueous 
layer was extracted with DCM (2 x 5 mL). The combined organic layers were dried over 
MgSO4, filtered and concentrated under reduced pressure. Purification by column 
chromatography (PE/EA 1:3) provided compound 140 (33 mg, 0.12 mmol, 79%) as a colorless 
solid.  
mp = 107 - 110 °C; Rf = 0.43 (PE/EA 1:3); [?]??? = + 46.3 (DCM, c = 0.5); 1H-NMR (300 MHz, 
CDCl3): ?H = 9.53 (d, J = 0.8 Hz, 1H), 7.85 (dd, J = 5.5, 3.0 Hz, 2H), 7.73 (dd, J = 5.4, 3.1 Hz, 2H), 
4.59 (ddd, J = 10.2, 4.1, 0.4 Hz, 1H), 4.13 (dd, J = 5.9, 1.1 Hz, 1H), 3.50 (dd, J = 14.4, 7.2 Hz, 
1H), 3.40 (dd, J = 14.4, 7.9 Hz, 1H), 2.41 (ddd, J = 13.1, 10.3, 6.1 Hz, 1H), 2.21 (dd, J = 13.1, 
4.2 Hz, 1H), 1.69 (td, J = 5.9, 4.0 Hz, 1H), 1.16 - 1.02 (m, 1H); 13C-NMR (75 MHz, CDCl3): ?C = 
203.86 (+), 168.34 (Cq), 134.18 (+), 132.18 (Cq), 123.47 (+), 86.43(+), 65.24 (+), 37.60 (-), 
31.04 (-), 25.73 (+), 21.38 (+); IR (ATR): ? (cm-1) = 2935, 1770, 1708, 1467, 1434, 1393, 1358, 
1331, 1194, 1139, 1108, 1080, 948, 856, 793, 720, 530; MS (APCI): m/z (%) = 253.9 (30) 
[M+?H2O], 271.9 (100) [MH+], 285.9 (25) [MNH4+];  HRMS  (EI):  calcd  for  C15H13NO4 [M+•] 
271.0845, found 271.0844. 
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2-(((1S,3R,5S,6R)-3-(4-tosyl-4,5-dihydrooxazol-5-yl)-2-oxabicyclo[3.1.0]hexan-6-yl)methyl)-
isoindoline-1,3-dione (141) 
 
 
 
Finely powdered NaCN (3 mg, 0.06 mmol, 0.18 equiv) was added in one portion to a stirred 
solution of TosMIC (72 mg, 0.37 mmol, 1.1 equiv) and aldehyde 140 (91 mg, 0.34 mmol) in 
anhydrous EtOH (3 mL) and anhydrous DCM (1 mL). The reaction mixture was stirred for 1 h 
at room temperature. The solvent was evaporated under reduced pressure. The residue was 
dissolved in CHCl3 (5  mL)  and washed with saturated aqueous NaHCO3 solution (1 x  5 mL).  
The aqueous layer was extracted with CHCl3 (2 x 5 mL) and the combined organic layers were 
dried over MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography (PE/EA 1:1) afforded compound 141 (127  mg,  0.27  mmol,  81%)  as  a  
yellowish foam.  
Data for isomeric mixture: Rf = 0.25 (PE/EA 1:1); 1H-NMR (300 MHz, CDCl3): ?H = 7.93 - 7.65 
(m, 6H), 7.38 (d, J = 8.6 Hz, 1.2H), 7.35 (d, J = 8.6 Hz, 0.8H), 6.96 (s, 1H), 4.97 - 4.89 (m, 1H), 
4.87 - 4.78 (m, 1H), 4.62 (ddd, J = 9.1, 7.6, 3.4 Hz, 0.6H), 4.53 (td, J = 8.4, 3.2 Hz, 0.4H), 3.98 
(dd, J = 6.4, 0.7 Hz, 0.6H), 3.92 (dd, J = 6.4, 0.8 Hz, 0.4H), 3.55 - 3.41 (m, 1H), 3.41 - 3.30 (m, 
1H), 2.45 (s, 1.8H), 2.44 (s, 1.2H), 2.42 - 2.24 (m, 1H), 1.96 (ddd, J = 13.1, 8.5, 1.6 Hz, 0.4H), 
1.80 - 1.64 (m, 1.6H), 1.43 - 1.30 (m, 1H); 13C-NMR (75 MHz, CDCl3): ?C =  168.43  (Cq) and 
168.40 (Cq), 159.45 (+) and 159.37 (+), 145.74 (Cq) and 145.71 (Cq), 134.16 (+), 133.14 (Cq) 
and 133.08 (Cq), 132.25 (Cq) and 132.22 (Cq), 130.01 (+) and 129.95 (+), 129.71 (+) and 129.59 
(+), 123.47 (+) and 123.45 (+), 87.87 (+) and 87.40 (+), 87.34 (+) and 86.32 (+), 79.43 (+) and 
78.99 (+), 65.15 (+) and 65.11 (+), 37.66 (-) and 37.59 (-), 32.66 (+) and 31.68 (+), 31.18 (-) 
and 30.71 (-), 23.22 (+) and 22.58 (+), 21.87 (+); IR (ATR): ? (cm-1) = 2927, 2873, 1770, 1710, 
1617, 1434, 1393, 1357, 1321, 1187, 1148, 1109, 1085, 951, 914, 859, 813, 721, 648, 588, 
531; MS (ESI): m/z (%) = 467.1 (100) [MH+], 484.1 (90) [MNH4+]; HRMS (ESI): calcd for 
C24H23N2O6S [MH+] 467.1271, found 467.1264. 
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(1S,3R,5S,6S)-methyl 3-(oxazol-5-yl)-2-oxabicyclo[3.1.0]hexane-6-carboxylate (142) 
 
 
 
To a solution of oxazoline 106 (396  mg,  1.04  mmol)  in  anhydrous  MeOH  (10  mL),  K2CO3 
(289 mg, 2.09 mmol, 2 equiv) was added under a nitrogen atmosphere. The reaction mixture 
was refluxed for 30 min, quenched with water (15 mL) and extracted with DCM (3 x 15 mL). 
The combined organic layers were dried over MgSO4, filtrated and concentrated in vacuo. 
Purification by column chromatography (PE/EA 1:1) afforded compound 142 (67  mg,  
0.32 mmol, 31%) as a colorless solid.  
mp = 61 °C; Rf = 0.36 (PE/EA 1:3); [?]??? = + 30.6 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H 
= 7.84 (s, 1H), 6.97 (s, 1H), 5.47 (dd, J = 9.4, 6.1 Hz, 1H), 4.30 (dd, J = 5.9, 0.6 Hz, 1H), 3.65 (s, 
3H), 2.72 (ddd, J = 13.4, 9.5, 6.6 Hz, 1H), 2.37 - 2.30 (m, 1H), 2.26 (ddd, J = 13.5, 6.1, 0.7 Hz, 
1H), 1.98 (dd, J = 3.9, 0.9 Hz, 1H); 13C-NMR (75 MHz, CDCl3): ?C = 170.80 (Cq), 151.63 (Cq), 
151.51 (+), 124.18 (+), 77.16 (+), 67.36 (+), 51.89 (+), 33.00 (-), 31.18 (+), 27.25 (+); IR (ATR): ? 
(cm-1) = 3435 (br), 3129, 2954, 1716, 1507, 1440, 1394, 1311, 1274, 1198, 1171, 1107, 1070, 
963, 860, 715; MS (EI): m/z (%) = 95.0 (100), 180.1 (39) [M+?CHO], 209.1 (<1) [M+•]; HRMS 
(EI): calcd for C10H11NO4 [M+•] 209.0688, found 209.0694. 
 
(1S,3R,5S,6R)-3-(oxazol-5-yl)-2-oxabicyclo[3.1.0]hexan-6-yl)methanol (143) 
 
 
 
To a stirred ice-cooled solution of oxazole 142 (65 mg, 0.31 mmol) in anhydrous THF (3 mL) 
under  a  nitrogen  atmosphere,  LAH  (9.3  mg,  0.25  mmol,  0.8  equiv)  was  added  in  small  
portions within 5 min. The reaction mixture was stirred for 30 min at 0 °C. After addition of 
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water  (10  µL)  the  mixture  was  stirred  for  another  30  min.  Then  a  15%  aqueous  NaOH  
solution  (10  µL)  was  added  followed  by  water  (30  µL).  The  mixture  was  warmed  to  room  
temperature, treated with MgSO4 and filtered through a Celite pad. The solvent was 
evaporated under reduced pressure. The crude product was purified by column 
chromatography (EA) to obtain compound 143 (40 mg, 0.22 mmol, 71%) as a colorless solid. 
mp = 95 °C; Rf = 0.19 (EA); [?]??? = + 25.8 (DCM, c = 1.0); 1H-NMR (400 MHz, CDCl3): ?H = 7.81 
(s, 1H), 6.93 (s, 1H), 5.41 (dd, J = 8.4, 6.9 Hz, 1H), 3.90 (dd, J = 6.2, 1.2 Hz, 1H), 3.39 (dd, J = 
11.6, 7.2 Hz, 1H), 3.33 (dd, J = 11.5, 7.1 Hz, 1H), 2.59 (ddd, J = 13.0, 8.7, 6.9 Hz, 1H), 2.13 
(ddd, J = 13.0, 6.7, 1.4 Hz, 1H), 2.11 (br s, 1H), 1.69 - 1.62 (m, 1H), 1.40 (tdd, J = 7.1, 4.0, 
1.2 Hz, 1H); 13C-NMR (75 MHz, CDCl3): ?C = 152.18 (Cq), 151.31 (+), 123.62 (+), 78.11 (+), 
64.70 (+), 62.12 (-), 33.85 (-), 33.45 (+), 22.08 (+); IR (ATR): ? (cm-1) = 3369 (br), 3125, 2945, 
2881, 1508, 1461, 1414, 1353, 1262, 1176, 1106, 1026, 990, 966, 910, 885, 846, 645; MS (CI): 
m/z (%) = 182.1 (99) [MH+], 199.1 (100) [MNH4+]; HRMS (LSI): calcd for C9H12NO3 [MH+] 
182.0817, found 182.0816. 
 
2-(((1S,3R,5S,6R)-3-(oxazol-5-yl)-2-oxabicyclo[3.1.0]hexan-6-yl)methyl)isoindoline-1,3-
dione (144) 
 
 
 
DIAD (96 mg, 0.45 mmol, 1.5 equiv) was added dropwise to a solution of oxazole 143 (54 mg, 
0.30 mmol), PPh3 (117 mg, 0.45 mmol, 1.5 equiv) and phthalimide (66 mg, 0.45 mmol, 1.5 
equiv) in anhydrous THF (6 mL) at 0 °C under a nitrogen atmosphere. After stirring at 0 °C for 
30  min  the  mixture  was  allowed  to  warm  to  room  temperature  and  the  solvent  was  
evaporated under reduced pressure. The residue was purified by column chromatography 
(PE/EA 3:1 to EA) to obtain compound 144 (51 mg, 0.17 mmol, 55%) as a colorless solid. 
mp = 83 °C; Rf = 0.51 (EA); [?]??? = + 18.9 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H = 7.84 
(dd, J = 5.5, 3.1 Hz, 2H), 7.79 (s, 1H), 7.72 (dd, J = 5.5, 3.1 Hz, 2H), 6.92 (s, 1H), 5.45 - 5.37 (m, 
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1H), 4.08 (dd, J = 6.3, 1.0 Hz, 1H), 3.56 (dd, J = 14.4, 6.9 Hz, 1H), 3.36 (dd, J = 14.4, 8.4 Hz, 
1H), 2.59 (ddd, J = 13.1, 8.6, 7.1 Hz, 1H), 2.09 (ddd, J = 13.1, 7.2, 1.4 Hz, 1H), 1.84 - 1.75 (m, 
1H), 1.59 - 1.51 (m, 1H); 13C-NMR (75 MHz, CDCl3): ?C = 168.33 (Cq), 151.59 (Cq), 151.30 (+), 
134.08 (+), 132.18 (Cq), 123.87 (+), 123.36 (+), 78.48 (+), 65.23 (+), 37.73 (-), 33.92 (-), 30.69 
(+), 23.24 (+); IR (ATR): ? (cm-1) = 3141, 3938, 1769, 1708, 1509, 1467, 1433, 1392, 1357, 
1329, 1260, 1225, 1197, 1136, 1101, 1071, 1026, 950, 851, 798, 720, 645, 531; MS (EI): m/z 
(%) = 77.1 (8), 95.1 (100), 104.1 (6), 130.1 (6), 160.1 (18), 310.1 (1) [M+•]; HRMS (EI): calcd for 
C17H14N2O4 [M+•] 310.0954, found 310.0956. 
 
methyl-N'-cyano-N-(((1S,3R,5S,6R)-3-(oxazol-5-yl)-2-oxabicyclo[3.1.0]hexan-6-yl)methyl) -
carbamimidothioate (145) 
 
 
 
A solution of aminooxazole 57a (19  mg,  0.11  mmol)  and  dimethyl  
N-cyanodithioiminocarbonate (34 mg, 0.22 mmol, 2 equiv) in EtOH was stirred at room 
temperature for 18 h. The solvent was evaporated under reduced pressure. The crude 
product was purified by column chromatography (DCM then DCM/MeOH 9:1) to afford 
compound 145 (29 mg, 0.11 mmol, quantitative) as a colorless oil. 
Rf = 0.51 (PE/EA 9:1); [?]??? = + 14.3 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H = 7.84 (s, 
1H), 7.16 (s, 0.5H), 6.96 (s, 1H), 6.53 (s, 0.5H), 5.43 (dd, J = 8.4, 7.2 Hz, 1H), 3.96 (dd, J = 6.3, 
0.9 Hz, 1H), 3.45 - 2.86 (m, signal broadening due to rotamers, 2H), 2.73 - 2.32 (m, signal 
broadening due to rotamers, 3H), 2.62 (ddd, J = 13.0, 8.6, 7.0 Hz, 1H), 2.15 (dd, J = 13.0, 
6.9 Hz, 1H), 1.77 - 1.68 (m, 1H), 1.50 - 1.37 (m, 1H); 13C-NMR (75 MHz, CDCl3): ?C = 151.67 
(Cq), 151.44 (+), 123.99 (+), 78.34 (+), 64.99 (+), 44.01 (signal broadening due to rotamers, -), 
33.82 (-), 30.09 (+), 23.30 (+), 14.64 (signal broadening due to rotamers, +), C=N and C N 
signals  too  weak  to  be  observed;  IR  (ATR):  ? (cm-1) = 3263 (br), 3126, 3011, 2939, 2174, 
1716, 1554, 1511, 1430, 1357, 1285, 1182, 1104, 938, 846, 645; MS (ESI): m/z (%) = 279.0 
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(30) [MH+], 296.0 (40) [MNH4+], 557.1 (100) [2MH+]; HRMS (EI): calcd for C12H14N4O2S [M+•] 
278.0837, found 278.0833. 
 
2-(((1S,3R,5S,6R)-3-((tert-butyldimethylsilyloxy)methyl)-2-oxabicyclo[3.1.0]hexan-6-
yl)methyl)isoindoline-1,3-dione (138), (R)-tert-butyldimethyl((4-vinyl-2,3-dihydrofuran-2-
yl)methoxy)silane (153) 
 
 
 
A solution of alcohol 116 (40 mg, 0.15 mmol), EDC (49 mg, 0.31 mmol, 2 equiv) and CuCl2 
(22  mg,  0.17  mmol,  1.08  equiv)  in  anhydrous  MeCN  (3  mL)  was  stirred  at  80  °C  under  a  
nitrogen atmosphere for  0.5 h.  The reaction mixture was quenched with water (3 mL)  and 
the  mixture  was  extracted  with  EA  (3  x  3  mL)  and  DCM  (2  x  3  mL).  The  organic  layer  was  
dried  over  MgSO4 and concentrated in vacuo to afford 22 mg (0.09 mmol, 62%) of 
analytically pure compound 153. 
For analytical data see page 111. 
 
 
tert-butyl(((2R,4S)-5-(((1S,3R,5S,6R)-3-((tert-butyldimethylsilyloxy)methyl)-2-oxabicyclo-
[3.1.0]hexan-6-yl)methoxy)-4-vinyltetrahydrofuran-2-yl)methoxy)dimethylsilane (165) 
 
 
 
To alcohol 116 (45  mg,  0.17  mmol)  dissolved  in  benzene  (1.5  ml),  Cu(OTf)2 (11 mg, 
0.03 mmol, 0.18 equiv) was added. The heterogeneous mixture was stirred for 1 h at room 
temperature. The reaction mixture was treated with water and extracted with EA (3 x 5 mL). 
The organic  layers  were dried over MgSO4, filtered and concentrated in vacuo. Purification 
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by column chromatography (PE/EA 19:1) yielded compound 165 (40 mg, 0.08 mmol, 94%) as 
a colorless oil. 
Major: Rf = 0.36 (PE/EA 9:1); 1H-NMR (300 MHz, CDCl3): ?H = 5.77 (ddd, J = 17.2, 10.2, 8.3 Hz, 
1H), 5.13 - 4.97 (m, 2H), 4.81 (d, J = 2.5 Hz, 1H), 4.50 - 4.39 (m, 1H), 4.18 - 4.07 (m, 1H), 3.79 - 
3.70 (m, 1H), 3.67 (dd, J = 4.8, 0.7 Hz, 2H), 3.56 - 3.45 (m, 2H), 3.42 (dd, J = 10.9, 7.2 Hz, 1H), 
3.12 (dd, J = 10.8, 7.2 Hz, 1H), 2.85 - 2.71 (m, 1H), 2.34 - 2.11 (m, 2H), 1.77 - 1.60 (m, 2H), 
1.60 - 1.41 (m, 1H), 1.21 - 1.06 (m, 1H), 0.89 (s, 9H), 0.88 (s, 9H), 0.06 (s, 6H), 0.04 (s, 6H);  
13C-NMR (101 MHz, CDCl3): ?C = 139.00 (+), 115.31 (-), 108.19 (+), 87.78 (+), 78.91 (+), 67.08 
(-), 66.38 (-), 65.46 (-), 64.57 (+), 49.82 (+), 33.13 (-), 31.99 (+), 31.84 (-), 26.08 (+), 22.51 (+), 
18.53 (Cq), -5.16 (+); minor: Rf = 0.36 (PE/EA 9:1); 1H-NMR (300 MHz, CDCl3): ?H = 5.85 (ddd, 
J = 17.3, 10.2, 8.3 Hz, 1H), 5.14 - 4.98 (m, 2H), 4.87 (d, J = 4.6 Hz, 1H), 4.50 - 4.39 (m, 1H), 
4.18 - 4.07 (m, 1H), 3.79 - 3.70 (m, 1H), 3.56 - 3.45 (m, 2H), 3.69 - 3.62 (m, 2H), 3.35 (dd, J = 
10.9, 7.0 Hz, 1H), 3.18 (dd, J = 10.7, 6.7 Hz, 1H), 2.81 - 2.67 (m, 1H), 2.32 - 2.12 (m, 2H),  2.11 
- 1.96 (m, 1H), 1.77 - 1.60 (m, 1H), 1.60 - 1.41 (m, 1H), 1.21 - 1.06 (m, 1H), 0.89 (s, 9H), 0.89 
(s, 9H), 0.06 (s, 6H), 0.05 (s, 6H); 13C-NMR (101 MHz, CDCl3): ?C = 136.17 (+), 116.28 (-), 
103.85 (+), 87.72 (+), 80.58 (+), 68.09 (-), 66.30 (-), 66.01 (-), 64.85 (+), 49.32 (+), 33.20 (-), 
31.72 (-), 31.68 (+), 26.11 (+), 21.94 (+), 18.55 (Cq), -5.11 (+);  
Data for isomeric mixture: [?]??? = + 4.2 (DCM, c = 1.0); IR (ATR): ? (cm-1) = 2953, 2928, 2857, 
1472, 1463, 1389, 1361, 1254, 1136, 1096, 1038, 1006, 836, 776, 667; MS (ESI): m/z (%) = 
499.3 (5) [MH+], 516.3 (100) [MNH4+], 521.2 (70) [MNa+]; HRMS (ESI): calcd for C26H54NO5Si2 
[MNH4+] 516.3535, found 516.3525. 
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(1S,5S,6S)-ethyl 3-((tert-butyldimethylsilyloxy)methyl)-2-oxabicyclo[3.1.0]hex-3-ene-6-
carboxylate (166) 
 
 
 
To a stirred solution of alcohol 98 (683 mg, 3.71 mmol) in DCM (12 mL), anhydrous NEt3 
(771 µL, 5.56 mmol, 1.5 equiv) and TBSCl (683 mg, 4.53 mmol, 1.2 equiv) was added in one 
portion, followed by DMAP (23 mg, 0.19 mmol, 0.05 equiv). The mixture was stirred 4 h at 
room temperature. The reaction mixture was poured into saturated aqueous NH4Cl solution 
(15 mL) and extracted with DCM (2 x 15 mL). The combined organic phases were dried over 
MgSO4 and evaporated to dryness. The residue was separated by column chromatography 
(PE/EA 5:1) to give compound 166 (1.10 g, 3.69 mmol, 99%) as a colorless oil. 
Rf = 0.52 (PE/EA 5:1);?[?]??? = - 93.4 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H = 5.33 (dt, 
J = 2.2, 1.0 Hz, 1H), 4.85 (dd, J = 5.6, 1.0 Hz, 1H), 4.16 (q, J = 14.0 Hz, 2H), 4.12 (q, J = 7.1 Hz, 
2H), 2.76 (dt, J = 5.4, 2.6 Hz, 1H), 1.25 (t, J = 7.1 Hz, 3H), 1.04 (dd, J = 2.6, 1.0 Hz, 1H), 0.89 (s, 
J = 3.0 Hz, 9H), 0.07 (s, 3H), 0.07 (s, 3H); 13C-NMR (101 MHz, CDCl3): ?C = 172.88 (Cq), 159.88 
(Cq), 102.09 (+), 67.47 (+), 60.68 (-), 58.39 (-), 32.06 (+), 25.94 (+), 22.78 (+), 18.48 (Cq), 14.41 
(+), -5.23 (+); IR (ATR): ? (cm-1) = 2955, 2931, 2887, 2858, 1716, 1652, 1606, 1464, 1399, 
1378, 1306, 1289, 1256, 1174, 1157, 1116, 1084, 1045, 1003, 939, 888, 835, 779, 726; 
MS (ESI): m/z (%) = 299.1 (95) [MH+], 321.1 (100) [MNa+], 619.3 (25) [2MNa+]; HRMS (ESI): 
calcd for C15H27O4Si [MH+] 299.1673, found 299.1676. 
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((1S,5R,6R)-3-((tert-butyldimethylsilyloxy)methyl)-2-oxabicyclo[3.1.0]hex-3-en-6-yl)-
methanol (167) 
 
 
 
To a stirred ice-cooled solution of  ester  166 (1.10 g,  3.69 mmol)  in  anhydrous THF (15 mL)  
under  a  nitrogen  atmosphere,  a  suspension  of  LAH  (119  mg,  3.31  mmol,  0.85  equiv)  in  
anhydrous THF (4 mL) was added dropwise within 10 min. The reaction mixture was stirred 
for 1 h at 0 °C. After dropwise addition of water (120 µL) the mixture was stirred for another 
30 min. Then a 15% aqueous NaOH solution (120 µL) was added followed by water (360 µL). 
The mixture was warmed to room temperature, treated with MgSO4 and filtered through a 
Celite pad. The solvent was evaporated under reduced pressure. The crude product was 
purified by column chromatography (PE/EA 3:1) to obtain compound 167 (835  mg,  
3.26 mmol, 88%) as a colorless oil. 
Rf = 0.18 (PE/EA 3:1);?[?]??? = - 57.7 (CHCl3, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H = 5.22 (dt, 
J = 2.3, 1.1 Hz, 1H), 4.37 (dd, J = 6.0, 1.3 Hz, 1H), 4.20 - 4.04 (m, 2H), 3.54 (dd, J = 11.6, 7.2 Hz, 
1H), 3.40 (dd, J = 11.5, 7.8 Hz, 1H), 2.07 (dt, J = 5.7, 2.7 Hz, 1H), 1.54 (s, J = 14.3 Hz, 1H), 0.89 
(s, 9H), 0.67 (tdd, J = 7.7, 2.9, 1.3 Hz, 1H), 0.07 (d, J = 0.8 Hz, 6H); 13C-NMR (75 MHz, CDCl3): 
?C = 158.12 (Cq), 102.46 (+), 64.07 (+), 62.76 (-), 58.64 (-), 25.99 (+), 25.48 (+), 22.86 (+), 18.53 
(Cq), -5.17 (+); IR (ATR): ? (cm-1) = 3352 (br), 2953, 2929, 2885, 2857, 1657, 1472, 1463, 1403, 
1255, 1218, 1160, 1118, 1084, 1018, 959, 939, 836, 816, 778, 740, 667; MS (ESI): m/z (%) = 
257.0 (35) [MH+], 513.1 (100) [2MH+]; HRMS (ESI): calcd for C13H25O3Si [MH+] 257.1567, 
found 257.1568. 
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tert-butyldimethyl((5-vinylfuran-2-yl)methoxy)silane (168), 2-(((1S,5R,6R)-3-((tert-butyl-
dimethylsilyloxy)methyl)-2-oxabicyclo[3.1.0]hex-3-en-6-yl)methyl)isoindoline-1,3-dione 
(169) 
 
 
 
DIAD  (115  µg,  0.59  mmol,  1.5  equiv)  was  added  dropwise  to  a  solution  of  alcohol  167 
(100 mg, 0.39 mmol), PPh3 (153 mg, 0.59 mmol, 1.5 equiv) and phthalimide (86 mg, 
0.59 mmol, 1.5 equiv) in anhydrous THF (7 mL) at 0 °C under a nitrogen atmosphere. After 
stirring for 2 h at 0 °C the mixture was allowed to come to room temperature. The solvent 
was evaporated under reduced pressure. The residue was purified by column 
chromatography (PE/EA 19:1, then 5:1) to obtain compound 168 (50 mg, 0.21 mmol, 54%) as 
a colorless oil and compound 169 (57 mg, 0.15 mmol, 38%) as a colorless solid. 
168: Rf = 0.57 (PE/EA 19:1); 1H-NMR (300 MHz, CDCl3): ?H = 6.46 (dd, J = 17.5, 11.3 Hz, 1H), 
6.21 (d, J = 3.2 Hz, 1H), 6.18 (d, J = 3.2 Hz, 1H), 5.64 (dd, J = 17.5, 1.2 Hz, 1H), 5.12 (dd, J = 
11.3, 1.4 Hz, 1H), 4.64 (s, 2H), 0.91 (s, 9H), 0.10 (s, 6H). 13C-NMR (75 MHz, CDCl3): ?C = 154.07 
(Cq), 152.85 (Cq), 125.21 (+), 112.02 (-), 108.98 (+), 108.89 (+), 58.45 (-), 26.03 (+), 18.58 (Cq), 
-5.04 (+); IR (ATR): ? (cm-1) = 2956, 2929, 2885, 2858, 1687, 1642, 1526, 1472, 1463, 1370, 
1254, 1190, 1077, 1036, 1017, 1006, 980, 939, 988, 833,775, 723, 671, 650; MS (EI): m/z (%) 
= 75.1 (19), 107.1 (100) [M+?C6H15OSi], 181.1 (93) [M+?C4H9], 238.2 (5) [M+]; 
169:  mp  =  79  °C; Rf = 0.27 (PE/EA 5:1); [?]??? = - 47.7 (DCM, c = 1.0); 1H-NMR (300 MHz, 
CDCl3): ?H = 7.86 (dd, J = 5.4, 3.1 Hz, 2H), 7.72 (dd, J = 5.4, 3.1 Hz, 2H), 5.16 (dt, J = 2.3, 1.1 Hz, 
1H), 4.53 (dd, J = 6.0, 1.2 Hz, 1H), 4.08 (m, 2H), 3.58 (dd, J = 14.4, 7.6 Hz, 1H), 3.48 (dd, J = 
14.4, 7.9 Hz, 2H), 2.20 (ddd, J = 5.6, 2.7, 2.6 Hz, 1H), 0.87 (s, 9H), 0.81 (tdd, J = 7.7, 2.8, 1.2, 
1H), 0.04 (d, 3H), 0.04 (d, 3H); 13C-NMR (75 MHz, CDCl3): ?C = 168.52 (Cq), 158.25 (Cq), 134.12 
(+), 132.32 (Cq), 123.43 (+), 102.21 (+), 64.56 (+), 58.57 (-), 37.99 (-), 26.50 (+), 25.98 (+), 
20.08 (+), 18.50 (Cq), -5.21 (+); IR (ATR): ? (cm-1) = 2953, 2929, 2857, 1772, 1714, 1468, 1433, 
1387, 1355, 1268, 1175, 1136, 1115, 1084, 1016, 962, 944, 838, 780, 719, 619, 529; MS (EI): 
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m/z (%) = 73.1 (62), 107.0 (18), 160 (26) [C6H9NO2], 181.0 (100), 225.1 (83) [M+?C6H9NO2], 
253.0 (25), 328.0 (26) [M+?C4H9], 385.1 (<1) [M+]; HRMS (EI): calcd for C11H35N3O4Si [M+•] 
385.1709, found 385.1707. 
 
(R)-tert-butyldimethyl((4-vinyl-2,3-dihydrofuran-2-yl)methoxy)silane (153), (((1S,3R,5S,6R)-
6-(azidomethyl)-2-oxabicyclo[3.1.0]hexan-3-yl)methoxy)(tert-butyl)dimethylsilane (175), 
(((2R,4S,5R)-5-azido-4-vinyltetrahydrofuran-2-yl)methoxy)(tert-butyl)dimethylsilane 
(176a), (((2R,4S,5S)-5-azido-4-vinyltetrahydrofuran-2-yl)methoxy)(tert-butyl)dimethyl-
silane (176b) 
 
 
 
Method A: To a solution of alcohol 116 (86 mg, 0.33 mmol) and PPh3 (175 mg, 0.67 mmol, 
2.0 equiv) in anhydrous THF (3.5 mL), DIAD (143 mg, 0.67 mmol, 2.0 equiv) and DPPA 
(187 mg, 0.67 mmol, 2.0 equiv) were added dropwise at 0 °C under a nitrogen atmosphere. 
The reaction mixture was stirred for 0.5 h at the same temperature. The mixture was 
allowed to warm to room temperature and the solvent was evaporated under reduced 
pressure. The resulting residue was purified by column chromatography (PE/EA 19:1 to 5:1) 
to afford compound 153 (4.0 mg, 0.02 mmol, 5%), compound 176a (35 mg, 0.12 mmol, 37%), 
compound 176b (18 mg, 0.06 mmol, 19%) and compound 175 (19 mg, 0.07 mmol, 21%) as 
colorless oils.  
Method B: Alcohol 116 (84  mg,  0.33  mmol)  was  dissolved  in  a  9:1  mixture  of  anhydrous  
toluene and anhydrous DMF (1.4 mL) under a nitrogen atmosphere. DPPA (183 mg, 
0.65 mmol, 2.0 equiv) and DBU (99 mg, 0.66 mmol, 2.0 equiv) was added. The reaction was 
stirred  for  1  h  at  50  °C.  The  reaction  mixture  was  concentrated  in vacuo and purified by 
column chromatography (PE/EA 50:1, then 19:1) to afford compound 153 (4.0 mg, 
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0.02 mmol, 5%), compound 176a (31 mg, 0.10 mmol, 32%), compound 176b (27 mg, 
0.09 mmol, 27%) and compound 175 (11 mg, 0.04 mmol, 12%) as colorless oils.  
153: for analytical data see page 111. 
176a: Rf = 0.50 (PE/EA 19:1); [?]??? = - 80.0 (DCM, c = 0.5); 1H-NMR (300 MHz, CDCl3): ?H = 
5.77 (ddd, J = 17.2, 10.2, 8.1 Hz, 1H), 5.19 - 5.09 (m, 1H), 5.16 (d, J = 4.3, 1H) 5.12 - 5.04 (m, 
1H), 4.28 (ddt, J = 8.6, 6.7, 4.4 Hz, 1H), 3.73 (dd, J = 11.1, 4.4 Hz, 1H), 3.68 (dd, J = 11.1, 
4.6 Hz, 1H), 2.72 (qd, J = 8.0, 4.1 Hz, 1H), 2.20 (ddd, J = 12.7, 7.9, 6.7 Hz, 1H), 1.71 (dt, J = 
12.6, 8.2 Hz, 1H), 0.90 (s, 9H), 0.07 (s, 6H).13C-NMR (75 MHz, CDCl3): ?C = 137.39 (+), 116.73 
(-), 96.83 (+), 80.58 (+), 64.91 (-), 50.12 (+), 33.02 (-), 26.06 (+), 18.52 (Cq), -5.14 (+), -5.17 (+); 
IR (ATR): ? (cm-1) = 2953, 2929, 2857, 2103, 1472, 1462, 1254, 1233, 1139, 1096, 1073, 837, 
779; MS (ESI): m/z (%) = 256.2 [MH+?N2] (100); HRMS (ESI): calcd for C13H26NO2Si [MH+?N2] 
256.1727, found 256.1730. 
176b: Rf = 0.38 (PE/EA 19:1); [?]??? = + 161.4 (DCM, c = 0.5); 1H-NMR (400 MHz, CDCl3): ?H = 
5.75 (ddd, J = 17.4, 10.4, 7.6 Hz, 1H), 5.38 (d, J = 5.3 Hz, 1H), 5.19 - 5.15 (m, 1H), 5.15 - 5.11 
(m, 1H), 4.22 (td, J = 10.7, 5.7 Hz, 1H), 3.75 (dd, J = 10.7, 5.6 Hz, 1H), 3.68 (dd, J = 10.7, 
4.9 Hz, 1H), 2.89 (td, J = 12.5, 7.1 Hz, 1H), 2.15 - 2.01 (m, 1H), 1.74 (td, J = 12.4, 10.1 Hz, 1H), 
0.91 (s, 9H), 0.09 (s, 6H); 13C-NMR (75 MHz, CDCl3): ?C = 134.51 (+), 117.83 (-), 94.22 (+), 
81.96 (+), 66.47 (-), 48.99 (+), 31.88 (-), 26.03 (+), 18.52 (Cq), -5.21 (+), -5.23 (-); IR (ATR): 
? (cm-1) = 2953, 2929, 2857, 2111, 1472, 1463, 1250, 1130, 1085, 1060, 1030,994, 920,837, 
777, 679; MS (ESI): m/z (%) = 241.2 (100) [MH+?N3H], 256.2 (32) [MH+?N2], 306.2 (13) 
[MNa+]; HRMS (ESI): calcd for C13H26NO2Si [MH+?N2] 256.1727, found 256.1733. 
175: Rf = 0.55 (PE/EA 5:1); [?]??? = + 44.1 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H = 4.48 
(ddd, J = 8.7, 8.2, 4.5 Hz, 1H), 3.77 (dd, J = 6.3, 1.1 Hz, 1H), 3.54 (dd, J = 10.9, 4.3 Hz, 1H), 3.48 
(dd, J = 10.9, 4.7 Hz, 1H), 3.14 (dd, J = 13.2, 7.0 Hz, 1H), 2.87 (dd, J = 13.2, 8.1 Hz, 1H), 2.28 
(ddd, J = 12.8, 8.4, 7.2 Hz, 1H), 1.80 (ddd, J = 12.9, 7.5, 1.5 Hz, 1H), 1.62 - 1.49 (m, 1H), 1.36 - 
1.18 (m, 1H), 0.90 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H); 13C-NMR (75 MHz, CDCl3): ?C = 87.78 (+), 
65.73 (-), 64.39 (+), 51.22 (-), 31.18 (-), 30.42 (+), 26.09 (+), 23.17 (+), 18.55 (Cq), -5.17 (+), -
5.22 (+); IR (ATR): ? (cm-1) = 2952, 2929, 2857, 2089, 1472, 1462, 1253, 1173, 1128, 1094, 
1060, 1007, 990, 886, 834, 776, 670; MS (ESI): m/z (%) = 283.1 (50) [M+], 292.1 (82), 301.1 
(58) [MNH4+], 315.1 (72), 333.0 (62), 456.1 (100); HRMS (ESI): calcd for C13H26N3O2Si 
284.1789 [MH+], found 284.1794. 
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diisopropyl 1-((2R,3S,5R)-5-((tert-butyldimethylsilyloxy)methyl)-3-vinyltetrahydrofuran-2-
yl)hydrazine-1,2-dicarboxylate (184a), diisopropyl 1-((2S,3S,5R)-5-((tert-butyldimethylsilyl-
oxy)methyl)-3-vinyltetrahydrofuran-2-yl)hydrazine-1,2-dicarboxylate (184b), diisopropyl 1-
(((1S,3R,5S,6R)-3-((tert-butyldimethylsilyloxy)methyl)-2-oxabicyclo[3.1.0]hexan-6-yl)-
methyl)hydrazine-1,2-dicarboxylate (185) 
 
 
To a solution of alcohol 116 (79 mg, 0.31 mmol) and PPh3 (240 mg, 0.92 mmol, 3.0 equiv) in 
anhydrous THF (6 mL) at 0 °C under a nitrogen atmosphere was added DIAD (197 mg, 
0.92 mmol, 3.0 equiv). The reaction mixture was stirred for 3 h at 0 °C, then warmed to room 
temperature and further stirred for 17 h. The solvent was removed under reduced pressure. 
Purification by column chromatography (PE/EA 9:1) afforded compound 153 (7  mg,  
0.03 mmol, 9%), an epimeric mixture of compounds 184a and 184b (75 mg, 0.17 mmol, 54%, 
dr = 7:3) and 185 (44 mg, 0.10 mmol, 32%) as colorless oils. 
153: for analytical data see page 111. 
184a: Rf = 0.26 (PE/EA 5:1); [?]??? = - 4.8 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H = 6.30 
(s, 0.7H), 6.15 (s, 0.3H), 5.87 (ddd, J = 17.0, 10.3, 6.6 Hz, 1H), 5.68 (br s, 1H), 5.26 - 5.11 (m, 
1H), 5.13 - 5.06 (m, 1H), 4.95 (sept, J = 6.3 Hz, 2H), 4.18 (td, J = 9.7, 4.5 Hz, 1H), 3.62 (d, J = 
3.1 Hz, 2H), 2.95 (br s, 1H), 2.13 (ddd, J = 12.7, 7.3, 5.9 Hz, 1H), 1.76 (m, 1H), 1.36 - 1.14 (m, 
12H), 0.89 (s, 9H), 0.06 (s, 3H) 0.05 (s, 3H); 13C-NMR (75 MHz, CDCl3): ?C = 156.32 (Cq), 155.27 
(Cq), 136.34 (+), 116.78 (-), 91.12 (+), 79.56 (+), 70.68 (+), 69.86 (+), 65.70 (-), 44.83 (+), 33.53 
(-), 26.05 (+), 22.10 (+), 22.02 (+), 18.48 (Cq), -5.14 (+), -5.22 (+); IR (ATR): ? (cm-1) = 3289 (br), 
2979, 2930, 2858, 1721, 1470, 1407, 1373, 1291, 1252, 1233, 1181, 1106, 1038, 1005, 990, 
915, 834, 776, 667; MS (ESI): m/z (%) = 445.1 (100) [MH+], 889.6 (75) [2MH+]; HRMS (ESI): 
calcd for C21H44N2O6Si [MH4+] 462.2994, found 462.3004. 
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184b: Rf = 0.25 (PE/EA 5:1); analytically pure sample could not be separated from 184a. 
185: Rf = 0.17 (PE/EA 5:1); [?]??? = - 15.4 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H = 6.50 
(br s, 3/4H), 6.27 (br s, 1/4H), 4.94 (sept, J = 6.5 Hz, 2H), 4.54 - 4.38 (m, 1H), 3.79 (d, J = 
5.9 Hz, 1H), 3.49 (d, J = 4.9 Hz, 2H), 3.18 (br s, 2H), 2.33 - 2.16 (m, 1H), 1.70 (dd, J = 12.2, 
8.3 Hz, 1H), 1.54 - 1.42 (m, 1H), 1.31 - 1.14 (m, 12 H), 1.23 - 1.13 (m, 1H), 0.88 (s, 9H), 0.04 (s, 
6H).13C-NMR (75 MHz, CDCl3): ?C = 155.87 (2Cq), 88.02 (+), 70.19 (+), 69.80 (+), 66.02 (-), 
64.85 (+), 49.53 (-), 31.56 (-), 30.53 (+), 26.09 (+), 22.62 (+), 22.19 (+), 22.11 (+), 18.54 
(Cq), -5.17 (+), -5.20 (+); IR (ATR): ? (cm-1) = 3289 (br), 2977, 2927, 2858, 1708, 1508, 1469, 
1405, 1385, 1253, 1223, 1179, 1107, 1033, 1013, 938, 835, 776, 668; MS (ESI): m/z (%) = 
445.1 (100) [MH+], 462.1 (50) [MNH4+], 889.6 (60) [2MH+]; HRMS (ESI): calcd for C21H41N2O6Si 
[MH+] 445.2728, found 445.2741. 
 
bis(((1S,3R,5S,6R)-3-((tert-butyldimethylsilyloxy)methyl)-2-oxabicyclo[3.1.0]hexan-6-yl)-
methyl) oxalate (190) 
 
 
 
A solution of oxalyl chloride (39 mg, 0.31 mmol, 1.5 equiv) in anhydrous DCM (0.5 ml) was 
added dropwise to a stirred solution of alcohol 116 (53 mg, 0.21 mmol) in anhydrous DCM 
(2 ml), containing NEt3 (62 mg, 0.62 mmol, 3.0 equiv) at 0 °C. After 0.5 h the reaction mixture 
was quenched with water (3 mL) and extracted with EA (3 x 3 mL). The combined organic 
layers were dried over MgSO4, filtered and the solvent evaporated under reduced pressure. 
The residue was purified by column chromatography (PE/EA 9:1) to give compound 190 
(50 mg, 0.18 mmol, 86%) as a colorless oil.  
Rf = 0.31 (PE/EA 3:1); [?]??? = + 24.2 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H = 4.48 
(ddd, J = 12.9, 8.4, 4.7 Hz, 2H), 4.06 (dd, J = 11.8, 7.7 Hz, 2H), 3.97 (dd, J = 11.8, 7.9 Hz, 2H), 
3.86 (dd, J = 6.3, 0.9 Hz, 2H), 3.49 (dd, J = 4.7, 1.1 Hz, 4H), 2.28 (ddd, J = 12.9, 8.4, 7.2 Hz, 2H), 
1.77 (ddd, J = 12.9, 7.5, 1.3 Hz, 2H), 1.69 - 1.58 (m, 2H), 1.39 (tdd, J = 7.8, 3.9, 1.0 Hz, 2H), 
128   
Experimental 
 
0.88 (s, 18H), 0.04 (s, 12H); 13C-NMR (75 MHz, CDCl3): ?C = 157.94 (Cq), 87.81 (+), 66.73 (-), 
65.90 (-), 64.55 (+), 31.23 (-), 30.12 (+), 26.08 (+), 23.08 (+), 18.54 (Cq), -5.18 (+), -5.22 (+); 
IR (ATR): ? (cm-1) = 2952, 2929, 2857, 1768, 1743, 1472, 1463, 1414, 1389, 1361, 1313, 1253, 
1161, 1135, 1096, 1005, 939, 916, 835, 776, 670; MS (ESI): m/z (%) = 588.3 (40) [MNH4+], 
593.3 (100) [MNa+]; HRMS (ESI): calcd for C28H50NaNO8Si2 [MNa+] 593.2936, found 593.2919. 
 
((1S,3R,5S,6R)-3-((tert-butyldimethylsilyloxy)methyl)-2-oxabicyclo[3.1.0]hexan-6-yl)-
methyl 2,2-dichloroacetate (191) 
 
 
 
Dichloroacetyl chloride (36.5 mg, 0.25 mmol, 2.2 equiv) in anhydrous DCM (0.5 ml) was 
added dropwise to a stirred solution of alcohol 116 (29.1 mg, 0.11 mmol) in anhydrous DCM 
(1.4 ml) containing NEt3 (25 mg, 0.25 mmol, 2.2 equiv) at room temperature under a 
nitrogen atmosphere. Further NEt3 (13 mg, 0.13 mmol, 1.1 equiv) was added after 30 min 
and  the  reaction  was  stirred  for  additional  1  h.  The  reaction  mixture  was  concentrated  in 
vacuo and purified by column chromatography (PE/EA 5:1) to afford compound 191 (39 mg, 
0.11 mmol, 94%) as a colorless oil. 
Rf = 0.42 (PE/EA 5:1); [?]??? = + 18.0 (DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): ?H = 5.94 (s, 
1H), 4.49 (ddt, J = 8.7, 7.6, 4.4 Hz, 1H), 4.03 (dd, J = 10.4, 6.5 Hz, 1H), 3.97 (dd, J = 10.4, 
6.5 Hz, 1H), 3.85 (dd, J = 6.3, 1.0 Hz, 1H), 3.54 (dd, J = 11.0, 4.2 Hz, 1H), 3.47 (dd, J = 11.0, 
4.7 Hz, 1H), 2.28 (ddd, J = 12.9, 8.5, 7.2 Hz, 1H), 1.80 (ddd, J = 12.9, 7.4, 1.4 Hz, 1H), 1.68 - 
1.56 (m, 1H), 1.40 (tdd, J = 7.8, 3.9, 1.1 Hz, 1H), 0.89 (s, 9H), 0.05 (s, 3H), 0.05 (s, 3H); 13C-
NMR (75 MHz, CDCl3): ?C = 164.82 (Cq), 87.73 (+), 67.23 (-), 65.70 (-), 64.44 (+), 64.40 (+), 
31.00 (-), 29.81 (+), 26.09 (+), 22.93 (+), 18.55 (Cq), -5.17 (+), -5.23 (+); IR (ATR): ? (cm-1) = 
2954, 2929, 2886, 2857, 1765, 1749, 1472, 1463, 1300, 1279, 1255, 1163, 1137, 1097, 1006, 
962, 838, 816, 778, 670; MS (ESI): m/z (%) = 241.2 (95), 280.3 (100), 369.1 [MH+] (30), 386.1 
[MNH4+] (98); HRMS (ESI): calcd for C15H27Cl2O4Si [MH+] 369.1050, found 369.1040. 
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(2R,5aS,8aS,8bS)-2-((tert-butyldimethylsilyloxy)methyl)-7-phenyl-5,5a,8a,8b-tetrahydro-
2H-furo[2,3-e]isoindole-6,8(3H,7H)-dione (206a) and (2R,5aR,8aR,8bR)-2-((tert-butyl-
dimethylsilyloxy)methyl)-7-phenyl-5,5a,8a,8b-tetrahydro-2H-furo[2,3-e]isoindole-
6,8(3H,7H)-dione (206b) 
 
 
 
To a solution of diene ent-153 (68  mg,  0.28  mmol)  in  DCM  (1  mL)  was  added  N-phenyl 
maleimide  (54  mg,  0.31  mmol,  1.1  equiv)  and  stirred  at  room  temperature  for  16  h.  The  
solvent was evaporated under reduced pressure. The crude product was purified by column 
chromatography (PE/EA acetate 2:1) to afford both 206a and 206b as a colorless solid. 
Crystallizations from ether/n-pentane gave a crystalline solid of compound 206a (82  mg,  
0.20 mmol, 70%) and compound 206b (15 mg, 0.04 mmol, 13%). 
206a: mp = 142 °C; Rf = 0.48 (PE/EA 1:1); [?]??? = + 47.7 (DCM, c = 1.0); 1H-NMR (300 MHz, 
CDCl3): ?H = 7.52 - 7.29 (m, 3H), 7.20 (dt, J = 3.5, 2.1 Hz, 2H), 5.85 - 5.64 (m, 1H), 4.72 - 4.54 
(m, 1H), 4.24 (qd, J = 7.2, 4.3 Hz, 1H), 3.74 (qd, J = 10.7, 4.0 Hz, 2H), 3.62 (t, J = 8.6 Hz, 1H), 
3.22 (ddd, J = 8.6, 6.7, 1.6 Hz, 1H), 2.87 (ddd, J = 15.3, 7.3, 1.7 Hz, 1H), 2.73 - 2.45 (m, 2H), 
2.29 - 2.05 (m, 1H), 0.96 - 0.75 (m, 9H), 0.05 (s, 3H), 0.05 (s, 3H); 13C-NMR (75 MHz, CDCl3): ?C 
= 178.68 (Cq), 174.89 (Cq), 143.87 (Cq), 132.08 (Cq), 129.20 (+), 128.65 (+), 126.49 (+), 115.65 
(+), 80.71 (+), 76.16 (+), 65.37 (-), 43.80 (+), 39.45 (+), 31.98 (-), 25.96 (+), 24.79 (-), 18.36 
(Cq), -5.21 (+), -5.33 (+); IR (ATR): ? (cm-1) = 2950, 2928, 2855, 1706, 1499, 1472, 1386, 1254, 
1205, 1185, 1098, 1074, 1008, 973, 878, 835, 775, 756, 692, 624, 570; MS (ESI): m/z (%) = 
414.0 (100) [MH+], 431.0 (53) [MNH4+], 827.4 (20) [2MH+]; HRMS (ESI): calcd for C23H32NO4Si 
[MH+] 414.2095, found 414.2105. 
206b: Rf = 0.39 (PE/EA 1:1); [?]??? = + 5.1 (DCM, c = 0.5); 1H-NMR (300 MHz, CDCl3): ?H = 7.48 
- 7.31 (m, 3H), 7.24 - 7.16 (m, 2H), 5.81 - 5.71 (m, 1H), 4.50 - 4.42 (m, 1H), 4.20 - 4.09 (m, 
1H), 3.83 (dd, J = 10.2, 4.8 Hz, 1H), 3.68 (t, J = 8.8 Hz, 1H), 3.50 (dd, J = 10.2, 6.9 Hz, 1H), 3.28 
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- 3.19 (m, 1H), 2.91 (ddd, J = 15.6, 7.3, 1.7 Hz, 1H), 2.77 - 2.65 (m, 1H), 2.34 (m, 1H), 2.26 - 
2.14 (m, 1H), 0.86 (s, 9H), 0.03 (s, 3H), 0.03 (s, 3H); 13C-NMR (75 MHz, CDCl3): ?C = 178.39 
(Cq), 173.72 (Cq), 142.15 (Cq), 132.17 (Cq), 129.21 (+), 128.61 (+), 126.51 (+), 116.63 (+), 80.48 
(+), 75.39 (+), 65.50 (-), 43.66 (+), 40.16 (+), 33.52 (-), 26.03 (+), 24.35 (-), 18.46 (Cq), -5.21 (+), 
-5.26(+); IR (ATR): ? (cm-1) = 2954, 2929, 2856, 1712, 1499, 1471, 1380, 1253, 1181, 1098, 
837, 778, 754, 692; MS (ESI): m/z (%) = 414.0 (100) [MH+], 431.0 (30) [MNH4+], 827.4 (5) 
[2MH+], 844.6 (25) [2MNH4+];  HRMS  (ESI):  calcd  for  C23H32NO4Si [MH+] 414.2095, found 
414.2099. 
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Pharmacological methods 
Materials 
Histamine dihydrochloride was purchased from Alfa Aesar GmbH & Co. KG (Karlsruhe, 
Germany). [3H]N?-methylhistamine and [3H]histamine were from PerkinElmer Life Sciences 
(Boston, MA). Guanosine diphosphate (GDP) was from Sigma-Aldrich Chemie GmbH 
(Munich, Germany), unlabeled GTP?S was from Roche (Mannheim, Germany). [35S]GTP?S 
was from PerkinElmer Life Sciences (Boston, MA) or Hartmann Analytic GmbH 
(Braunschweig, Germany). GF/C filters were from Whatman (Gaithersburg, USA). For liquid 
scintillation counting was used: PerkinElmer MicroBeta2 2450 MicroplateCounter 
(Massachusetts, USA), Brandel Harvester MWXRT-96TI, Brandel (Gaithersburg, USA). 
Scintillation  cocktail  RotiszintTM  eco  plus  was  from  Carl  Roth  GmbH  &  Co  KG  (Karlsruhe,  
Germany). 
[35S]GTP?S binding assay220,221 
[35S]GTP?S binding assays were performed as previously described for the H3R222,223 and 
H4R.224 H3R assays: Sf9 insect cell membranes coexpressing the hH3R, mammalian G?i2 and 
??1?2 were employed, H4R assays: Sf9 insect cell membranes coexpressing the hH4R, 
mammalian G?i2 and G?1?2 were employed.  
The respective membranes were thawed, sedimented by a 10 min centrifugation at 4 °C and 
13000 g. Membranes were resuspended in binding buffer (12.5 mM MgCl2 , 1 mM EDTA, and 
75 mM Tris/HCl, pH 7.4). Each assay tube contained Sf9 membranes expressing the 
respective  HR  subtype  (15  –  30  ?g  protein/tube),  1  ?M  GDP,  0.05%  (w/v)  bovine  serum  
albumin, 0.2 nM [35S]GTP?S and the investigated ligands (dissolved in millipore water or in a 
mixture (v/v) of 80% millipore water and 20% DMSO) at various concentrations in binding 
buffer  (total  volume  250  ?L).  All  H4R  assays  additionally  contained  100  mM  NaCl.  For  the  
determination of KB values (antagonist mode of the [35S]GTP?S binding assay) histamine was 
added to the reaction mixtures (final concentrations: H3/4R: 100 nM). Incubations were 
conducted  for  90  min  at  25  °C  and  shaking  at  250  rpm.  Bound  [35S]GTP?S was separated 
from free [35S]GTP?S by filtration through GF/C filters, followed by three washes with 2 ml of 
binding buffer (4 °C) using a Brandel Harvester. Filter-bound radioactivity was determined 
after an equilibration phase of at least 12 h by liquid scintillation counting. The experimental 
conditions chosen ensured that no more than 10% of the total amount of [35S]GTP?S added 
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was bound to filters. Non-specific binding was determined in the presence of 10 ?M 
unlabeled GTP?S. 
Radioligand binding assay225,226 
For the binding experiments the Sf9 insect cell membranes described above were employed. 
The respective membranes were thawed and sedimented by centrifugation at 4 °C and 
13000 g for 10 min. Membranes were resuspended in binding buffer (12.5 mM MgCl2, 1 mM 
EDTA and 75 mM Tris/HCl, pH 7.4). Each well (total volume 250 µL) contained 50 µg (hH3R) 
or 120 µg (hH4R) of membrane protein. Competition binding experiments were performed in 
the presence 3 nM [3H]N?-methylhistamine (hH3R) or 15 nM [3H]histamine (hH3R and hH4R) 
and increasing concentrations of unlabeled ligands. Incubations were conducted for 60 min 
at 25 °C and shaking at 250 rpm. Bound radioligand was separated from free radioligand by 
filtration through 0.3% polyethyleneimine-pretreated (PEI) GF/C filters, followed by three 
washes  with  2  mL  of  cold  binding  buffer  (4  °C)  using  a  Brandel  Harvester.  Filter-bound  
radioactivity was determined after an equilibration phase of at least 12 h by liquid 
scintillation counting. 
Data analysis and pharmacological parameters 
All data are presented as mean of N independent experiments ± SEM. Agonist potencies 
were given as EC50 values (molar concentration of the agonist causing 50% of the maximal 
response). Maximal responses (intrinsic activities) were expressed as ?-values. The ?-value 
of histamine was set to 1.00; ?-values of other compounds were referred to this value. 
IC50 values were converted to Ki and KB values using the Cheng-Prussoff equation.227            
pKi values were analyzed by nonlinear regression and best fit to one-site (monophasic) 
competition isotherms. pEC50 and pKB values from the functional  [35S]GTP?S were analyzed 
by nonlinear regression and best fit to sigmoidal dose-response curves (GraphPad Prism 5.0 
software, San Diego, CA). 
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F. Appendix 
HPLC purity data 
Table 10. HPLC purity data of the synthezised target compounds.[a] 
no. tR (min) k’ purity (%) no. tR (min) k’ purity (%) 
55a 3.30 0.42    98 55b 3.31 0.42    94 
55c 3.29 0.41 > 99 55d 3.30 0.42 > 99 
   54a[b] 4.20      8.34 
0.80 
2.58 > 99     54b
[b] 4.20    8.35 
0.80 
2.58 > 99 
   54c[b] 4.22      8.26 
0.81 
2.55 > 99     54d
[b] 4.22    8.29 
0.81 
2.56 > 99 
57a 4.34 0.86    93 57b 4.23 0.82    91 
   56a[b] 4.27    11.38 
0.83 
3.88 > 99    56b
[b] 4.16   11.33 
0.79 
3.86    95 
[a] Eurosphere-100 C18, 250 × 4.0 mm, 5 ?m; Knauer, Berlin, Germany; t0 =  2.33  min;  gradient  mode:  MeCN  (0.1%  
TFA)/water (0.1% TFA): 0 min: 10/90, 20 min: 90/10, 30 min: 90/10; [b] two tR values due two partial protonation of the 
cyanoguanidines. 
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NMR Spectra 
 
1H- and 13C-NMR spectra of the synthezised compounds.  
NMR frequencies and used solvents are stated for the respective spectra.  
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1-(((1S,3R,5S,6R)-3-(1H-imidazol-5-yl)-2-oxabicyclo[3.1.0]hexan-6-yl)methyl)-2-cyano-3-
methylguanidine (54a) 
1H-NMR (300 MHz, MeOD)
 
13C-NMR (75 MHz, MeOD) 
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1-(((1S,3S,5S,6R)-3-(1H-imidazol-5-yl)-2-oxabicyclo[3.1.0]hexan-6-yl)methyl)-2-cyano-3-
methylguanidine (54c) 
1H-NMR (600 MHz, MeOD) 
13C-NMR (150 MHz, MeOD)
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((1S,3R,5S,6R)-3-(1H-imidazol-5-yl)-2-oxabicyclo[3.1.0]hexan-6-yl)methanamine (55a) 
1H-NMR (300 MHz, MeOD) 
13C-NMR (75 MHz, MeOD)
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((1S,3R,5S,6R)-3-(1H-imidazol-5-yl)-2-oxabicyclo[3.1.0]hexan-6-yl)methanamine • 2 TFA 
(55a•2TFA) 
1H-NMR (600 MHz, MeOD) 
13C-NMR (150 MHz, MeOD)
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((1S,3S,5S,6R)-3-(1H-imidazol-5-yl)-2-oxabicyclo[3.1.0]hexan-6-yl)methanamine • 2 TFA 
(55c• 2 TFA) 
1H-NMR (600 MHz, MeOD) 
13C-NMR (150 MHz, MeOD)
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2-cyano-1-methyl-3-(((1S,3R,5S,6R)-3-(oxazol-5-yl)-2-oxabicyclo[3.1.0]hexan-6-yl)methyl) 
guanidine (56a) 
1H-NMR (400 MHz, CDCl3) 
13C-NMR (100 MHz, CDCl3)
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((1S,3R,5S,6R)-3-(oxazol-5-yl)-2-oxabicyclo[3.1.0]hexan-6-yl)methanamine (57a) 
 
1H-NMR (400 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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(1S,3R,5S,6S)-ethyl 3-(hydroxymethyl)-2-oxabicyclo[3.1.0]hexane-6-carboxylate (79) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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(1S,3R,5S,6S)-ethyl 3-formyl-2-oxabicyclo[3.1.0]hexane-6-carboxylate (83) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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(1S,5S,6S)-ethyl 3-(hydroxymethyl)-2-oxabicyclo[3.1.0]hex-3-ene-6-carboxylate (98) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3)
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(1S,5S,6S)-ethyl 3-formyl-2-oxabicyclo[3.1.0]hex-3-ene-6-carboxylate (99) 
 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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(1S,3R,5S,6S)-ethyl 3-((benzylimino)methyl)-2-oxabicyclo[3.1.0]hexane-6-carboxylate (102) 
+ benzylamine 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (100 MHz, CDCl3)
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(1S,5S,6S)-ethyl 3-((benzylimino)methyl)-2-oxabicyclo[3.1.0]hex-3-ene-6-carboxylate (104) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3)
 
O
CO2Et
H
H
H
N
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(1S,3R,5S,6S)-ethyl 3-(4-tosyl-4,5-dihydrooxazol-5-yl)-2-oxabicyclo[3.1.0]hexane-6-
carboxylate (106) 
1H-NMR (400 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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(1S,3R,5S,6S)-methyl 3-carbamoyl-2-oxabicyclo[3.1.0]hexane-6-carboxylate (108) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3)
 
OH2NOC
CO2Me
H
H
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(1S,3R,5S,6S)-2-oxabicyclo[3.1.0]hexane-3,6-dicarboxamide (109) 
1H-NMR (300 MHz, MeOD) 
13C-NMR (75 MHz, CDCl3)
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(1S,3R,5S,6S)-ethyl 3-((tert-butyldimethylsilyloxy)methyl)-2-oxabicyclo[3.1.0]hexane-6-
carboxylate (110) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (100 MHz, CDCl3) 
 
O
CO2Et
H
H
TBSO
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(1S,3R,5S,6S)-methyl 3-((tert-butyldimethylsilyloxy)methyl)-2-oxabicyclo[3.1.0]hexane-6-
carboxylate (111) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3)
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(1S,3R,5S,6S)-3-((tert-butyldimethylsilyloxy)methyl)-2-oxabicyclo[3.1.0]hexane-6-
carboxamide (112) 
1H-NMR (300 MHz, CDCl3) 
 
13C-NMR (75 MHz, CDCl3)
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(1S,3R,5S,6S)-ethyl 3-((E/Z)-2-formamido-2-tosylvinyl)-2-oxabicyclo[3.1.0]hexane-6-
carboxylate (113) 
1H-NMR (400 MHz, CDCl3) 
13C-NMR (100 MHz, CDCl3)
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(1S,3R,5S,6R)-2-oxabicyclo[3.1.0]hexane-3,6-diylbis(methylene)bis(oxy)bis(tert-butyl-
dimethylsilane) (115) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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((1S,3R,5S,6R)-3-((tert-butyldimethylsilyloxy)methyl)-2-oxabicyclo[3.1.0]hexan-6-yl)-
methanol (116) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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(((1S,3R,5S,6R)-6-(benzyloxymethyl)-2-oxabicyclo[3.1.0]hexan-3-yl)methoxy)(tert-butyl)-
dimethylsilane (117) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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(1S,3R,5S,6R)-6-(benzyloxymethyl)-2-oxabicyclo[3.1.0]hexan-3-yl)methanol (118) 
 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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(1S,3R,5S,6R)-6-(benzyloxymethyl)-2-oxabicyclo[3.1.0]hexane-3-carbaldehyde (119) 
 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (100 MHz, CDCl3) 
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5-((1S,3R,5S,6R)-6-(benzyloxymethyl)-2-oxabicyclo[3.1.0]hexan-3-yl)-4-tosyl-4,5-
dihydrooxazole (120)  
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3)
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5-((1S,5S,6R)-6-(benzyloxymethyl)-2-oxabicyclo[3.1.0]hexan-3-yl)-1H-imidazole (121) 
 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3)
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ethyl 5-((1S,5S,6R)-6-(benzyloxymethyl)-2-oxabicyclo[3.1.0]hexan-3-yl)-1H-imidazole-1-
carboxylate (131) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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ethyl 5-((1S,3R,5S,6R)-6-(hydroxymethyl)-2-oxabicyclo[3.1.0]hexan-3-yl)-1H-imidazole-1-
carboxylate (132a) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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ethyl 5-((1S,3S,5S,6R)-6-(hydroxymethyl)-2-oxabicyclo[3.1.0]hexan-3-yl)-1H-imidazole-1-
carboxylate (132b) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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ethyl 5-((1S,3R,5S,6R)-6-((1,3-dioxoisoindolin-2-yl)methyl)-2-oxabicyclo[3.1.0]hexan-3-yl)-
1H-imidazole-1-carboxylate (133) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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ethyl 5-((2R,4S,5R)-5-(1,3-dioxoisoindolin-2-yl)-4-vinyltetrahydrofuran-2-yl)-1H-imidazole-
1-carboxylate (135a) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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ethyl 5-((2R,4S,5S)-5-(1,3-dioxoisoindolin-2-yl)-4-vinyltetrahydrofuran-2-yl)-1H-imidazole-
1-carboxylate (135b) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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ethyl 5-((1S,3S,5S,6R)-6-((1,3-dioxoisoindolin-2-yl)methyl)-2-oxabicyclo[3.1.0]hexan-3-yl)-
1H-imidazole-1-carboxylate (137) 
1H-NMR (400 MHz, CDCl3) 
13C-NMR (100 MHz, CDCl3)
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2-(((1S,3R,5S,6R)-3-((tert-butyldimethylsilyloxy)methyl)-2-oxabicyclo[3.1.0]hexan-6-
yl)methyl)isoindoline-1,3-dione (138) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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2-(((1S,3R,5S,6R)-3-(hydroxymethyl)-2-oxabicyclo[3.1.0]hexan-6-yl)methyl)isoindoline-1,3-
dione (139) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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(1S,3R,5S,6R)-6-((1,3-dioxoisoindolin-2-yl)methyl)-2-oxabicyclo[3.1.0]hexane-3-
carbaldehyde (140) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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2-(((1S,3R,5S,6R)-3-(4-tosyl-4,5-dihydrooxazol-5-yl)-2-oxabicyclo[3.1.0]hexan-6-
yl)methyl)isoindoline-1,3-dione (141) 
1H-NMR (400 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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(1S,3R,5S,6S)-methyl 3-(oxazol-5-yl)-2-oxabicyclo[3.1.0]hexane-6-carboxylate (142) 
 
1H-NMR (300 MHz, CDCl3)
 
13C-NMR (75 MHz, CDCl3) 
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((1S,3R,5S,6R)-3-(oxazol-5-yl)-2-oxabicyclo[3.1.0]hexan-6-yl)methanol (143) 
 
1H-NMR (400 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3)
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2-(((1S,3R,5S,6R)-3-(oxazol-5-yl)-2-oxabicyclo[3.1.0]hexan-6-yl)methyl)isoindoline-1,3-
dione (144) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3)
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methyl N'-cyano-N-(((1S,3R,5S,6R)-3-(oxazol-5-yl)-2-oxabicyclo[3.1.0]hexan-6-
yl)methyl)carbamimidothioate (145) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3)
 
  
Appendix 
177 
 
(R)-tert-butyldimethyl((4-vinyl-2,3-dihydrofuran-2-yl)methoxy)silane (153) 
 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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2-((2R,3S,5R)-5-((tert-butyldimethylsilyloxy)methyl)-3-vinyltetrahydrofuran-2-yl)-
isoindoline-1,3-dione (154a) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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2-((2S,3S,5R)-5-((tert-butyldimethylsilyloxy)methyl)-3-vinyltetrahydrofuran-2-yl)-
isoindoline-1,3-dione (154b) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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tert-butyl(((2R,4S)-5-(((1S,3R,5S,6R)-3-((tert-butyldimethylsilyloxy)methyl)-2-oxabicyclo-
[3.1.0]hexan-6-yl)methoxy)-4-vinyltetrahydrofuran-2-yl)methoxy)dimethylsilane (165) 
1H-NMR (300 MHz, CDCl3) 
    
13C-NMR (100 MHz, CDCl3)
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(1S,5S,6S)-ethyl 3-((tert-butyldimethylsilyloxy)methyl)-2-oxabicyclo[3.1.0]hex-3-ene-6-
carboxylate (166) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (100 MHz, CDCl3) 
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((1S,5R,6R)-3-((tert-butyldimethylsilyloxy)methyl)-2-oxabicyclo[3.1.0]hex-3-en-6-yl)-
methanol (167) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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tert-butyldimethyl((5-vinylfuran-2-yl)methoxy)silane (168) 
 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
 
184   
Appendix 
 
2-(((1S,5R,6R)-3-((tert-butyldimethylsilyloxy)methyl)-2-oxabicyclo[3.1.0]hex-3-en-6-yl)-
methyl)isoindoline-1,3-dione (169) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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(((1S,3R,5S,6R)-6-(azidomethyl)-2-oxabicyclo[3.1.0]hexan-3-yl)methoxy)(tert-
butyl)dimethylsilane (175) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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(((2R,4S,5R)-5-azido-4-vinyltetrahydrofuran-2-yl)methoxy)(tert-butyl)dimethylsilane (176a) 
 
1H-NMR (400 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
 
  
Appendix 
187 
 
(((2R,4S,5S)-5-azido-4-vinyltetrahydrofuran-2-yl)methoxy)(tert-butyl)dimethylsilane (176b) 
 
1H-NMR (400 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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diisopropyl 1-((2R,3S,5R)-5-((tert-butyldimethylsilyloxy)methyl)-3-vinyltetrahydrofuran-2-
yl)hydrazine-1,2-dicarboxylate (184a) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3)
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diisopropyl 1-(((1S,3R,5S,6R)-3-((tert-butyldimethylsilyloxy)methyl)-2-oxabicyclo[3.1.0]-
hexan-6-yl)methyl)hydrazine-1,2-dicarboxylate (185) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3)
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bis(((1S,3R,5S,6R)-3-((tert-butyldimethylsilyloxy)methyl)-2-oxabicyclo[3.1.0]hexan-6-
yl)methyl) oxalate (190) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3)
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((1S,3R,5S,6R)-3-((tert-butyldimethylsilyloxy)methyl)-2-oxabicyclo[3.1.0]hexan-6-yl)methyl 
2,2-dichloroacetate (191)                                                                                                                    
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3)
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(2R,5aS,8aS,8bS)-2-((tert-butyldimethylsilyloxy)methyl)-7-phenyl-5,5a,8a,8b-tetrahydro-
2H-furo[2,3-e]isoindole-6,8(3H,7H)-dione (206a) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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(2R,5aR,8aR,8bR)-2-((tert-butyldimethylsilyloxy)methyl)-7-phenyl-5,5a,8a,8b-tetrahydro-
2H-furo[2,3-e]isoindole-6,8(3H,7H)-dione (206b) 
1H-NMR (300 MHz, CDCl3) 
13C-NMR (75 MHz, CDCl3) 
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